var title_f32_49_33552="Periosteal osteosarcoma";
var content_f32_49_33552=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Periosteal osteosarcoma involving femoral diaphysis in 14-year-old boy who presented with painful thigh mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 247px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD3AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD11z29qy9QIANab/0rKvjycc4oA4zXn2I4rwf4qzZigTP3pP5CvbvEjkK2a8A+J8u7ULePPQFv5UAcTU9pj7QmfWoKmtc+egHrQB2uhAtcRD1r1PwzAJnGTz/SvLNJLRsCpwa9X8F5Lx5JwaAPRNOgKbSoGB3resyq8N1PSs+xjwmCTV2MKHxuOfpQBe4bgcDPNXrJDkZHWqUagsCM4962tPiBOTQAapcpp9iZMAu3CA9zXEXE8kkpklckk8mtfxVdCbUI4ATtQZ/Gub1BiSkacsetAHS6PfmbbG3zIOma0pDk49Olc7oQ2qPbrW+2DzQBNczeTpl0QTnymxXErKMYzzXT6gS1pIg/iUiuCWfacZ796AN2KQZAHc4614z+1M24eFwOwuf/AGlXqkd0ouI1BU+4715X+1IuIPCjY5b7Vk/9+aAPBK9I/Z1UN8ZPDwIyCbj/ANJ5K83r0r9nL/ks3h363H/pPLQB9sqoQhQOB2pxwc4BJFP2ncScZpQpwcCgCJ88fXNPX37H0p2wFSaYzeWMZwM0AKWU4IP4mnsw2gA/nVU3EeQAy4HWnxyK+MNx6UADZ288/SoJ8BeV6VZDA4AJwOOlV71tsbMvY0Aee+KlkeUiNcAnkiuPDN5xbyiQOBk9Pau11+7eOQgRgg8ZFc29yhnYhSB/d9T3oA1NDBM6FlI4wOa9Cs13Rqc9sVxmhSRyTRAw9s4ArvbZVaNdv0oAULg5z0qyq5IxxTG2ocMeOpFNNwgRipzj0oAtxqAwY9egzUqDr3/rWYdUgQjcRkCtC3kWZVeNlINAEmRx/KmucH0zUxXG7j8qjaIEqSBxwKAK5+7mviD9o/8A5LP4h+lt/wCk0VfcTISw4wPSvh79pHj40eIv+3b/ANJoqAPM66Xwr/x4X3BP76H/ANBlrmq9H+EPhiTxNDrkcc4hWzSO6ciJ5WKgSDCqoJJ57UAU1JwCc1KvXBrpPEXhC80h7IRE3a3gdoVjhdZflOG3REb19sjkc1nWmh6jNe21q1ncQy3Mqwx/aIzEpYnAGWAFAH1F+zAMfD6c+t7J/Ja9au38u2kf0UmvOvgJpbaP4MmtHnSaRLuQOVRlAYYBHzAZwR1HB7V32sHbp07blUBSSTQB5veuJLlmkP3mJzQqCQxooJJ6e9UTOPNLBSQe1XrG5jW7iZwzIpzgUAZXxKwsdpD2RcYrsvAGnqdItSTgBdxHrXmvj29+06hAw+6zZ/WvYPBMXl6JbHBGUAxQBzXxPYW+msoIBPGPasD4c23m2kakAJJMN2e4FW/jJIUEKnqaq+Dplh8NRzBiHR+MUAausBf7TuduOXwMHtVSOGN/lJIYVBJcrI7M5JdjkVP5EnkiWSRFGOFHWgCd7eNAMFeRnr0qucA88j1qIzBuVB4OOTTGmGw7cccUASFA7gD5QefSrVjZxNp15dHf5sMqKpB4wQc8VmQT5+8OnSktdVu7EyfZbhow/wB7b3oA9F0C2gs9YuIodwBt45DubPJrpK8Ti1++ivfOFzIZJMeYSeWAOQDXpWtalqC+H4NT0kRPsUSyxtzuXHIFAHQuQEYk4AHJoryzxD8RrO+8LTrbmS3vnO3Z6D60UASyvgjtkVj6k5Bbn2rSnbGKxdVc4NAHB+Jn4cCvnz4gymTxAyk/cQCve/EDkhwetfO/i6bzvEV43ZW2/kKAMap7T/Xrxk5qCprXBnTPrQB2emHODXsHw1Qzw8jJQ7f8K8d0rlEFe2/B2Myvdx4Hyqr0Aein5EXAHSpITuYED6027BV8EcjFSWwG7rxQBq2iFiM/WtZXEMRxxkVTsQBAMjk0y8l5Cg0AcvrJf+0i/b19aoKwacs3Wt7VkjaxkkzkowA+tc5brmQscmgDZ06QJLjPWtqF9w5Nc2rFVyOvrV2C8BA5G70oA2sBnIPIxXK6hoSrO7ib90TkDHP0rXF6M88VRvLvzJFRG+9QBFo9hbR3COyBtvrySa8s/a7K+T4PCgDAu+n/AGxr1SW4S2nhVeSCM14z+1NdNcnwyW6L9qwP+/VAHgtek/s5ZHxm8PYxn/SOv/XvLXm1el/s3jPxo8Og+tx/6Ty0AfcQwxIIIp6AKOv0pFQgk5yP1qTao47mgCGYmNSSBtHPFebeJfFZS+WC3IwDhsnoa9I1KIvbPGD8zLgfWvnbxVpd5puvSzzKwG8FXPSgD1jSpJbi1Vhj5hk1flkMKgSuq8ZGBjiua8H6tHLaqMkPgck1u6zZm9tWO8qAOooAvWV+u4Ay5HqAKlvrlfKYA5zXmyTT6WHVbkOF6B+tbdvdS39nl32MepWgCprh8yRiVAbpx6VzgU7+mTkcHtW7fHYu5hvZTwe5FZsLbpGBBBz2GCRQBuaFEEkUy54P+RXoMKrHDnPUZrzyzhKxhx2OeByM100F+Y7bD4HGODQBYuLlzJsBJBNTpGjJu2kex71m28vmNvfJA45rXCqYQVzyM5oA5XxI5gtpCjBCDkc9KqfD7xMZr02kzjnhSO9Y/wAS9YjgxErDewzkVX+FuiT3OqJfEMI1Jwe1AHuatgc+nSgjJFSQRnA3cHFLIuTxQBXZck56Cvhj9pL/AJLT4i/7dv8A0mir7qkBDAADB6k9q+Fv2lP+S1eIv+3b/wBJoqAPMq9K+D3id/DMOuutt9oW8SK2cCZoWVSHOVZeQeK81rqvBZjWG4M4zELm3Lj1XEmf0zQB3viHxje6rc2UtspsfsassLpMzzfMcndKfmb2z0HFUDrN9fTW41W6ur+3jfcYpLhiD64Jzg+9aXgmyg1PxoIrSa1t4P3skLXKjbhRlVG84DHoCTweua7PxcLhtS0L7VpMd87XICyXl3bmS44/1DeQQqx99xwcnrQB7n8CdRTU/AizxRTRILiRAkty1wQBj+Igce1dD4z1L7FYyRKqs0qY+Y8AE+nrVX4YLMvhdRcJJG/nPiN2hbYOMKDF8pA6DPOOtY3xMnKXkKZ4KDigDkjcHkAZFWrW4JV9mAuOTWI0vLcnjrU8c6paOMne3H4UAZPiFzJqVjGCG3N/XpXv3h6Jk0iBW4O0DivnS8bf4jskU4+Zf519DaBc4tDb4YvGMljQB5d8Z5MT2ysctgk1Q8OPKdBgjXiIk5P41V+Ll8s2qIvJKkjml0K8xoFtAF9SD+NAHZSJoltpLXEbP9uAChHPX3ArmnvN7n5ue3NV9RjksYYZp/uyglSTWZ55b7vGaANlLlicYyKk84oMgZPesuKQoBg/iae0/O9iT7UAXp7orHtAANQkMI1VhyRk4qG3/fSb5Pudq1NMthdTTN1VFP6UAc68xViM969f+H10LvwY6vg+X5iHPp1rxeeT964HTNd74R1F7H4da/PzlMhcDuRQB5DrcoN7cBMY3nH50VlTzFpGZu/NFAHu103SsTUm5YHpWveNhawNZbCE559aAPPfE0myRzXzpqj+ZqV257ysf1r6F8SvkSE/wqW/IV85zNvmkb+8xNADKmtBmdfWoataeuZwc4xQB1mkDIXH0r3L4HAnV7pcE/uOa8M0jAIzXvXwJXOqXrjtEBQB312dsxOcZNPt8lgCOT6d6Ze4aTJzwasafGHkDBugzigDbgBEIwc1nas3kWxlc4A71sWcPmYyfkA5rz3xhrX2y/kt4mPkRHYMdyO9AD73UhJZiBOhbexqtbSZGOmKyw+ABng1bglG1jnigDTkkCx89BVOWTKk5x3qs1xuJ3np0qJZg5Az9aAJJryQL8rHiq9hdySXLFm6CqeoXHlhttVtInVpnLH0oA27hysm8nJz1zXk/wC0bKZF8OZ7faP/AGlXqcpDoB3ryz9owAQ+GivQi45/79UAeLV6Z+zd/wAlp8OY9bj/ANJ5a8zr0r9nIkfGbw7tznNx0/695KAPuwfdHalB+bGM0wEHHJyOKeM84IzQArKjHtntXGfEXSI7zRpWKAuozxXaYJwDj64qlrVqtxp80ZzhlxQB82eD9SkttYltVIKBtoXOa9ZOtxi0WJlO/GDj+deYHRf7L8YM8gZE8zPHQ1300S+Z5irwy9MUAcXqzzyXz4DeWzdCf611Oh3Kx2xTcPcY6VV1VWCORtzgc46Cq+kM7zjeFKH5e9AFrXLspsydzdFAHUVWt3EiI3VyTXSyaRFPbbjGd3XjqKgg0swnZGhGf88UAV4BIvLjbHt4A70STNBFtTO49C3OfWuhh0s/ZssSpZfu+9crrsJtZDGFZg35ZoA1NEvvMYQNw4OSa39SvktbCSRmOFU8iuB0id1m3HKnPzZPOK2tVn8zSpUaTJIPagDyK7vZde8UeWrMyl8DPfmvpvwdpS6botvEEUOF5IGK8I+Gnh9ZvFDSSjKox+b8a+kLQBUVV6AACgCSMOFO8jk8Y7ClbOOTg4p7H5fbHamg547fyoAjAO3Dda+E/wBpX/ktniP/ALdv/SaKvvBGVhkHI5FfCH7S/Pxt8R5/6dv/AEmioA8wrr/AUVpMt1HqFxJbWxmiDTIm8p8kuDj0z19q5Cus8DXgsFubg28FwUmiIjnXcmdsuCR3x1oA64+FdXXVIdPjtTPLMnmRND8ySR/3wf7o7k9O+K19R8GS6fqei2a31rI2pRBxM2Y4UO9l2liOg29cVz1v4l1eHV21SHUrmPUDlfPVsNgjBH0xxitnU/G2p65JpX9uMuowWC7RDOSVl5JJfBzk5xxjgCgD6w+C2kpovgeK0jknkAnkYtNbmEkkjOBk5Hoe9YXxTkb+2lCngIM1p/AfU01XwHHNFZw2aCeRRFEzso59WJP61g/FSZRr7LuOQg49KAOTkmxg4HSniTNsMjDFutUJJCqcHj+dPLFo0VRkscD1zQBXsglx41slc/KZFz+dfQ6q9oHmQjyypP5V8k23jjSrTxaZ7a21XVorKTNxNYQB40APJBJ+YcHngema+qI/EGma74Mh1XTLkSWV5AJInxgkHsR2I6EUAeCfESd5taeR/wCIk1c0hj/ZFrg5PJ69KzPiLIBqke3P3BSaPdMunwqDzzxQBoeJdSmvpIQx/dQxiMCoIZCqKo9OtWv3c1oUZcOWyBVaQBCwxtwaALUL7m/eH5R1FNEoaTDNhc9Kp7yQQTz7d6XDNzzjrmgDWN4PNVE4RRxXbfD6BX0XV7uUfKsZCk+uDXnEBDsgGck46V6fcyf2X4CuBblVR0CY7knrQB5bcNmXgjivUfCGktd/DDU4mHNyJGX3wOP5V5GzhiS3X+Ve8+C7G807wWRc3CyQtbmSJMcoCpOM0AfMFxGRcshHIOKKupiXXNpXIaX+tFAHslwNy5Fc/r2QoXHauguHOMZz9K5rXpieOKAPMfGlx5Gm6jKf4YHx9cYr5/r2b4oXJj0K5HQyFU/WvGaACrumj96eAapVr6ZGNgPrQB0Ok5yOK+gfgLEc6jPjHygfpXgmmJgrX0X8EYvL8O3s5/iYj+lAHT3sZ3EgcZ6Va01cPg1Wlf52JH/161dHh3yIccE0AampyjTtAuJjwQhOa8Tcl3Z2+8SSfxr0/wCJl4YNEWFTgyOF49K80QB48nqaAIHJ4BJqeOXC4J7VVkOH2nGM9abKwx8vH9aALrOFh3Zqh9qCng9eKqy3REbKTkDpWPLc8nB5znBoA1ru4DrgH8Kq2l0sNzz/ABCst7zn0qldXpUghjwcigD0O2uVaMbhkevpXnH7QxDaX4UdSDk3Y/Lya2tP1XzIhgnHU1yvxsl8zQ/DGTyJLv8AlDQB5NXpn7N3/JafDn1uP/SeWvM69N/ZrGfjX4cHvcf+k0tAH3NjLc1MAR93ilEWw8DPFP2k9AM+9ADD0x3qGYMYyCeKt+WQo4GarXOQjnHGOKAPDviCRb64r89e/epbTURNa7EbG4Yxmuf+LN80OrM+1mVRyQelcvpXimGKLa5AGDgHrQB6gLN7wtmTjIrV03SSh2vwx6GvP/D3jK0MoiLrg4Oc969S0TUYry5jWIl1IB47fWgDcht0Cou45UYNBstjk7dx9O1alvGMDcVyeoqeCJXkHA2kcUAURFuVRt6dfasbU9IW4QtkZ3DkjmutktyHGR0HUVka3OlhZyTyDITLfpQBwGoWUVi7bCDgnIxXMeIr7FnIVYIem31rE8YfEiCS8aKMYVT1/wAa4678UHUowvJbNAHrfwgmEt6zDHAycnnNe2QuSRjp7Gvnn4RzTwX6+YoUEcL/AFr6DtAGjAUHmgC2Gz260qsyrg0IhwOvFSGLIOBn2oAY/wA6/TvXwh+0v/yW3xH/ANu3/pNFX3qsZCHd37elfBf7TQx8b/Eg/wCvb/0mioA8vroPDf8Ax43n/XaL/wBBlrn66Dw5/wAeN5gf8tov/QZaANVThRU8fGAKrjgeoFSxn5hjpQB9gfszOW+HYU9rh/51l/Flh/wksmeCEFTfsuz7vBs8XXbMTmqfxacjxRNn+6P5UAcXIxx6Cp3lAjQNhgVZWBJHBGDyORweoqnI2VBz2pxfcFGOgoAreB4bLR/FFnZadbx2ljG5kaJGYhj3LFiS3Axz24roPhr4n0I3Wt+E9Jv47lV1a5utOW2UtEtoyLITu6AB2Kgetc/4Wbb43gYD7r5rubXwVo+i/Ey+8WaNNBDa39m0c9qeDHcM6FmUf3WAP0P1oA4v4kAR6zsU7iqDNUtDnP2bB7U74iTpJr0xiOV7Gs7QZwAwbnI7UAdJ5pGCp9+tWVja6tyVPzjrWWHJI446fSrmkXBW7SMnAY4z60AJtVAWPUdqUzNKqqDgD09Kzmuy17NH6MR+tTs4jiyDzQBMtyYpVaM/MOcGt2/1W4k8OLEzkhnyefSuQZmPfGT1rVgL3OmHbkhDzQA/w1aPqmt2lso3B5ACB6Z5r6M8QNHpfhO9KALHBasqgcY+XAry34LaKX1eS/kX5YVIX6mu5+Lt2LTwHqJ3YMgEY98mgD5q0Zg3iC2LHIMoP60VT0aQjWLZiejjmigD2+6bha5jWzjr1rpLvAwfSuW8QsAmScHGaAPCfi5c5hghH8UmfyH/ANevMa7X4oXHm6pBGDwqsf1riqAFre04fIn0rCTG4Z6V0enjge1AHQad1HpX0x8K4BbeBEY9ZTn9a+aLHquK+p/C0P2XwZp8WOWUcfhQBK3MrE9M10WiRgMD361zURDSBfU11ekoFjYj6UAcT8UJy1zaQ9hlv6VxoDBBtFdF8QZfN8QIg5CIKxEGVYnpQBmSkoSWGR9KrSyYXitG6HyE8YPFZcikFumM0AU7mQEHjp2rDvjhs/litm5U7TkHiufv3YNjp6UAUbu7dCT1X0NZc+pqQQ3Bqe7c87hwawb/ABzQBpW+siCTAYFW/SpvincrdeF/C8isG/eXYPPtDXIzruPpV/xPbvF4V0GViSsk1yBn2EX+NAHKV6f+zR/yW3w39bn/ANJpa8wr1D9mf/kt3hvPrcf+k0tAH3gvoTx6VKoUE55GeMU0LgjH1pzkA+npQAkjp6niua8S6vBaWj5cYNN8R6mLZWKtnAycGvK/EOuPqsbQ5A+bIK9TQBzvjG8tNTmm3uAfr+teSeIrBgP9HJBPII4rovEulahC8kkW5upX3Fce9zfbts4bgY+YZoAt+H9OuEuo3aUkA5NfU3w4t4BYRsH/AHpAy2Rk18zaAtzNMmyJiCevtX0L4OafT7CN5F2IV4464oA9XWOHfgSDJGPr71LFJAgyW5HHFeMeMfiTBpKySomZ0GCR2FeaTfHeY/LArk7vvNQB9fJJDKx+bkjGK4v4kyRppk6FzkqQMdq8w8B/Em+1b+Hcuc5Ndd4pe71DTWmQ8sMBcZGPegD5h8R6KsmoSMJDndz9a0vDFla26brhlG0854waua9a3K3kkbp8ysTnFYsWlX13J5eGXPYc0AeneHfEVlbzIsTr8rYBxg17t4P1NL3T1kc4VuMmvm7wx4SmhnjlnXdgglT6etep2+onR7XYjYGOAfSgD2e2aJvuuGPSrqoMZzxXmnhTxA95IjMygnGQK9GtZVlQHsKAJ2QEcivgL9p8Bfjl4lA6f6N/6TRV+gBIr8//ANqD/kunib623/pNFQB5ZXQeHCRY3eP+e0X/AKDLXP10Hhv/AI8bzjP76L/0GWgDTPJqaLqOcVEvH1NSpjcMCgD6i/ZZl/4kl5H6Pmovi24Piy4UckKtVP2WZwI76MnsD+tSfFR2PjO89Btxx7UAck7btq4xS3AAlCgnpTZG5B46cVBK5aQHvigA8JH/AIrSM4JwScV6B4t02WPRxqTOwdpCCBwAO1ed+D5G/wCExTZ94kgGvYvHlwq+FjbyYMoAagDwTWZHmu2LenU96bo5IuMA4zTb4h7o9hVjw/bGa5Zuy0AbwwSOwFSD5HV14PBzTo0UXDKwyMdadMu1WHftQBzkUpGqzs/XPNam4Mq4PArK1JNk4kUckc1bttzQLuzyM5oAmIJP0rvfhvoz6jpd8+CQGCr9TXBqpPA9q+h/hJpX2DwpC0qYedvN5/SgDX8IaZHo1mLbgSSDeQetcR+0NfCDw3Z2wPzyylsewH/169UeFGmSUrmRAQD9a+e/2idQ8/xBb2ivlYIunoTQB5Pp8u3UImB4DCiqtsSLtduM5z1ooA9/1FtuCa4vxPPmJhnoK6fV7jCEe1edeKL3Mb80AeE+Op/O8QS4Odiha56tDX5PN1i7f1fFZ9AEtuMzIPeum05eB71zlkMziup04cCgDf0eAy3lvGBnfIB+tfVQX7PpVlCOAkYNfOHgO1+1eJLCPGR5gJ/CvpHVm2lUH8KAUAUrYE3X05rrbYlLTNctpw3TtzXUdLcCgDyLxlOX8T3GP4cAflVJZD5QHrT/ABYCfE10TxzmqQkOO5xQBNJ8w4qg6nc2anafC1DJIokPfIoAoXQwhrl9RP7zjsa6m7cEEZrltVwrE+tAGJfNg+1YV64PBHPatq+b5faufvD8xFAFFxmT8a7H4k2Rtfhz4FcjBmkv2/8ARFchH806j1NerftA2gs/h38MYsYJgvHP4+RQB4XXp/7M/wDyW7w3/wBvP/pNLXmFen/s0f8AJbfDefW4/wDSaWgD7w80qQCM5PamXUhWNmAOetPOASO9V7nDREDnigDzLxrcyTOyKRuByRnrXIWGnlZ2lk6Dqff0rvNc0oNMWkOW69OBVW204RLhhnuDigDIuPDwu4/u/N2GOKxr34fRkM5jXtnjqa9K007ZAmPr/wDXrbu7dDAu1RyMmgDybQPCdvazrgKu4jJIr0xNNiksBDtGFBCkDpWS8KRXecAA9Af6VtwXQSEgkZ9PWgDxT4i+DfMaRmDGN29K8yPwrlWPzstjOQo54r6kvrYai3lFQQD81WU0WNLIW4RQo6EDrQB5d8MvCf2Mwhl2xjsepNe4w6bFFZbAibcAdOcVy8NoNNkUxjcB0H9a3LbVt0LBzyDgigDita8L2cl+zLEoLHJ7UzSvBttFvZYxjHGR0NdLdSrJMDjI9u9a9iiLErEcnsaAOPOjxxNgrhx/F2xWR4lsY5INxwZc4wOOK7XWXVZVUDGTj61km2E8RV1G4/dz2NAHH+HnaxuUEgJyckgda9j0S582zRjxnpXDDRQ7ow+Ujug5rsNLjaC3AJGzHPHIoA3GdiMKcHvn0r4L/abO744eJT/17f8ApNFX3V5gGecjtXwn+0vz8bPEf/bt/wCk0VAHmFdD4bOLG8/67Rf+gy1z1dL4Rt5bqC4ht43llkuIVREXLMSsuAAKANDGF5qWIYGfWtyDwjrtxrFzpMWmynUbVSZ4NygxgYySScdx371DregaloEkKataNbPKpaMF1bcB1+6TQB7X+zDJtv7pM4zH/WtH4tMB4yusZBwv8q5/9mqYx+IWQDhozWt8VJBJ40vCDkDaP0oA5l3yOmPlqFD0OetSdVPFV+exFAD/AATKE8aRE8Df1r1vx2Y/7KJB3grwcda8a8Jk/wDCXR/73SvVfFDN9g8oyZUjIB7UAeL6g2Lk449q2PD4ENsZCPmc96i1rSILewtr6TUY/Ou9xhtRExY7X2Nlugx196tx7IrdUXpjrQBZE377JNSTSFjxjBqism4j8qkDEqfSgCtqNuZLcbRzk1Laj/RYVPY1NklRu6VVViswAzgGgDf8P6cdS1OCCIZLOAa+nrKAW1nBAoAEaBcD2FfPPwsu44vF9sJsFXbA9jX0ZQAHjrXyN8WNTGo+MtSlU/IspQc9hxX1N4nvhpvh/ULvODFCxH1xxXxZrFy1xeTTMcs7EkmgCrA2JlOM80VFE5ElFAHteuzYDV5Z4qudqPz0zmvRfEEmFbpnrXkvjGbbbTsT0U0AeRXL+ZcSv/eYn9aioooAtaf/AK6up08YCg1zulR7mLe9dRYpwKAPTvg1a+f4qiOMhFJr2nVn33EzH1xXmvwHtQ2oXM5XhVAzXo94QzZ9SaALeix/OTjtXSScIB7Vj6KmVU468Vsy9CO4FAHjnjBNmvSt/eGcVkjG09TXTeObfGoRy+uRXC6r4j0zSdQhs9SuFt3liaVWb7uB2PuecfSgBniXVrbQ9Llvro5VflRAeZH7KKxvB8+rXemtd60yg3DmSCPbhkQ9j7elZGlwy+PfELarfxsmhWTbbaBv+WpHr6+p/AV3F0uGG3igCjctkdx61z2pnO6uin+ZM9+9c9qY5OKAObvCUOD0NYV4Tlq27/p1rDuT+dADdKi87UoIx/E4H617b+1tbfY/Dvw5twMeXbXQx+EFeVeAbQXni3TYMffnQfrXsv7bCCOPwQg6Kl2v/oigD5fr079mr/ktnhz/ALeP/SaWvMa9N/Zs/wCS1eHPrcf+k0tAH3aWIyP61C5yDxgeuac+QOPzqN2+UjH60AZWqRAgccnqSaxJogIyWx3ro72PdHg9MfpWVLHuBBAwOmaAM+0WVimAcHriunjBEIDYJAwaq2FuEQsfvH0q9xgcdqAMq909pX3L3pIrFgUB4+tawxnjt0o+o6dqAK1vbqh2kDnpip9jbvlOMCnKeeTzjr7Uq9ckgGgAlgSaIhwDnuaypdI2/wCrJxnOBW10ADYLdTxxR6Z60AYtpppjfMnJ+vGK1gMJgAf4UZG4gdu9DtigDD1SIszEnPPXFQ2yEPt9u1bMyq+VIGDzmqscAB4GPXPWgCW0iXaO+a0I8oNo6dqr2/AwT9KmOQ/POetAD1fqOenX0r4b/aS/5LT4i/7dv/SaKvuPr3FfDn7SH/JaPEP/AG7f+k0VAHmdelfCDxFZ6Bb6t9t0tL0XM1sokEzRSQgeaTtYDPPcd8V5rW/4cOLG7/67Rf8AoMtAHs+s+MrO6+JGrato99daTaXuUFysYlJBxlnRuxx90e1YPjzVrPU5rMW13/aFxCrie/MHk/aMkbRs7bQCPfNcZvY805WYd6APZ/2dpNviqFQRypFdJ8Usf8JjeYIBG3P5VxXwIlWPxZZ7jwciuw+KhA8YXn/Aen0oA5gtgHbzVdW5yRyDTlJ59MVEnK575oAd4LjMni0D617DrenxSWBM4ICpncK8m+HRB8ZLuGRyK951e38+wMbBcFDxQB85+I7+SaezsykQgsy/lMoIbDNuOTnnmtG12TNbo2SjMobBwcE9qxPFCiHV5Fz0Y9Kv2EjfZ4pEYqynIIPIPrQB6J/wjekLqQtxHeYGrtpRPnDJyMrJ06j071xRbYZEJHykrn6HFI+q6gsm4X1zuMnnbvMOfM6b/wDe9+tVGkZ5CzsSzElie5NAFuJzlM+tQuT57HA4NBf5RtpmfnbnrQBqeHLs2viGxmBxiZTX1Xp9ylzbqyEEgDcPQ4r5DsWYajb46hxXvfwz1W8udRvY5QWt2IH+6QKAJfjpqYsfBUsCvtkuHCj6Dk18n3Em5jx3r3f9pXUs3NjYq33E3sPcmvAnbJ680AORsEetFRKfmFFAHqviCY7XOeteQeO7jFnPg9RivTfEE3DYNeO+O5sxbfVqAOIooooA19IwVHbmuqsF4X0Nczo8Z2L2zXWach+XigD3v4I2wi0W7uCOpOK6UybplznvVD4XQfZvBW7HLKT+dXAMy5xwKAOn0ZcIG7Vokbs471R0pSluma0EAJ5PFAHCeNbXeh28sp3D3r5W8bW994o8e3lvpNvJcmDbbjYPlXb1JPQDOa+sPF94BeeXHglRk4rjLXTrWxikSygjgR2LsEGNxPJJ9TQByfgfRtR0TQks9Uu47gr/AKuNF4hHdd38Vad5ENhJHStWZcGqV0uUPtQBgyABcYxisPUV+96Gt+4UgnHf1rE1FcZz3oA5DUcDNc9dHBzmuh1UbS1c5dc55FAHefAi1+2/EbSV25AmDEfSvR/23DmTwd9Lz/2hXL/su2nnfEGFzz5UbNn8K6X9tg5fwd9Lz/2hQB8w16b+zYcfGrw4f+vj/wBJpa8yr039mz/ktXhz/t4/9JpaAPugsPwqJj3NP43+/emMOSSPyoAqXT4T6elZsxUnDH5u1X7s7V+lYd2xMylWYKrZ+tAG9b8RjBz9Kn4KjINVbQnyx24qypOM0AI7DHIPXjFOYdgcUDPJ604AnqOaAI2HzdcYp2Mtz6U4bd2Oc0u35v8APFACggYGeMUdx/SlA6H070Z55HHtQA0k55PPsKjJDcggqeQRT1OGbIIA7nvTSvbH4DtQBG4yarEEMR396tMmAQP51UZcOxPNAFqDnjqTzipup5BBqGA9Mmpzgj3oAacknsB1r4f/AGkf+S0eIcf9O3/pNFX3AcHntivh/wDaQ/5LR4hx6W3/AKTRUAeZ1v8Ahz/jxu/+u0X/AKDLWBW/4d/48bv/AK7Rf+gy0AaikhSB0NO7c8f1pB0pUJNAHpHwYmEfi3TyR/HXoPxaGPF9yD12jn8K8u+GbtH4k05kOD5g/nXqnxaiZPFDs3LNGpoA44OTGR7VWj4XJqZOQV/Ws2fUWtdf0LSzDF9l1BJi0rDD+YM7VVvXIUYPB3UAa/w3JPjFdoz1/nX0B4mFwujYt0G512kgdM1816FeXekSXl1aK0eqS/utOUwGVpp88RrHkbs9z0XrXo3wnTxrqdjrPiLx1qF2ZkkksLSykwkUe04lcIvy9RtB9m9RQB5r4wga21Z1cEOM8VLpDbrUc9+ak8f721p3k6t3qnozfKVxQBoynHekB79aV1yc46UuwZx+dADs4Uc0jHDDBx2pR/rFHqcU69TyrkjIIHp60AS6NE8+s2iKRuMgxX0n8PtGk0uG7eb70sm79K8E+Hdp9r8XaehwQHyc19SsVht2bGFRSfyFAHyn8d9RF743uwhysQCD8K8vJO6ul8c3n23xHfT9d0jc/jXMMTQA7OSD29qKaPvdqKAO38QzEBue1ePeNZd80a+5NeqeIZPlavHfFEm/UAPQUAY1KOtJTl5YfWgDo9HjG1R6V12nRZ2+9c1o65we9dnosPmTwoONzAfrQB9GeGYfsvg23THJUUlsuT06mtKKIQ6BboOwFVLSMGRRnjOTQB0Niu2IccVPO4igkkYgBRmktF/dYHas/wAT3Qg0p16MwwKAPPbqV7q7lmc53EmocFicDipFAHAqQIcZx0oApyxMQDWbdIQDWy4NVLmPIJxQBzF1H1JFYmpRnYeK6q5iBBHrWBqSfJQBwGsg7mFcxdcGuq17iTNcpc8vigD6G/ZK03dqWo33/POPYPxNRftrH954PHtef+0K7D9lKy8nwpqFyQMyShc/QVxf7ajZufCS9wt2fz8n/CgD5mr0z9m5gvxp8Ok9Abj/ANJ5a8zr0z9m0Z+NPhwf9fH/AKTS0AfcxYMQRzmmt9456ClYYOOKjk6HrnrQBQv32p1Poa5PUb6OGZCSQCcAZ4FdFqzlY87iM9a8n8Y6t5FxhDznJz0FAHrWkTiW3U8cHtWjyfpXAfDzV1vLMKzZZTg9+a71T06DigCQHgcnIp7MQPf0pgxjggipQQQOmaAEB5JPendwT6duaUAcDI+lAABBB7UABPHvikG7gZpzKeDjNNySOBzQAyRwqlnIUdMk4pmTkAg5p0gyADjHoeaQnLe9ADGY4IHaqckn7z3JxVtgBnsKqMcOc4wemaALUJ7H0qZTheBn8arxAbs+3SpuNuM0ALuIHHTvmviD9o/H/C5/EOOn+jf+k0VfbjrkkkYA5xXxF+0d/wAlm8Q/S2/9JoqAPNa6Dw3xY3hP/PaL/wBBlrn66Dw3/wAeN5/12i/9BloA1F9xgU5BjntTexp69BQB1ngV/L1ywbIH7wfzr2n4xfNrcDr/ABQLzXhXhh/Lv7VvRxXuvxVYS/2VNjAe2WgDz4HA9/eqN5Y2eqWYttSgM0KP5kZRyjxt/eVh0/IirgOR2+lQQn5OPegDZ+EFtZ2/iovBDJ5iKV8+eUzTEZ6bj90eyge+a+nryzS6tI96Bo9vTHFfMXwok2eKpDgH1/OvqpJN1mpA9ODQB8s/GKzFtrpKrtU9BXHaSx83IB6etelftAQeXrEbAj5hnGa820lepFAGyrYHNKM80xQfwpwOOc80APKthSOSTwKSdSshDdc05ZMyKw5I5qG4cliWOSTQB6R8DtPW68TSTuMpDGSOOM17V4xvRpvhXUbgn7sLAfUiuA+Alh5emXl4y/6xtoNa/wAcr77H4EmQ8NM4XigD5N1GTzZ5HJ5Yk1RznGM1POeT61X7e1ADv4gf1opFxgevpRQBt+I5MK3pivItafzNRlPocV6l4llAVwDxXkt6++7lb1Y0AQU6P/WLj1ptS24zOgHrQB1mjjpXoPhKHztWsU9ZFrhNGT7temfD2DzPENkvXDZ/SgD6Du126dEp9Kz7cKsgLsFz6nFaOo/LBEO+OlcD4sXSJvF/hlPEIsvsHlXZxeECPftTHXjPXFAHoWjazYajPqFrZXMclzYSiK5iB+aMkAg49CDwa5j4k6rFpmmXV5cOBBaxNI31A4H54qhrsWh2Gm6bdeCvscevGRk06PTdrLc9DJHKAcGLGCzH7vBHOAV1RU1B3i1KOCdWIZom+dAw579cHpmgDlvAutS+I9DgvLiyubSUqA5lj2I7dyncrXSbflqZU9vYYpSvy9fzoApMDuyMdahuU+XPSrpGPrUM2CpoAwbqMHJ6dq5nVBjeO3NdbeHO7niuX1YfM/bigDzvxF96uTl5lA5611viLhunSuUVd92o9SKAPtP9nmzFp8NbV8YMzlz714/+2c+7U/DC55WO4/8AaVfQHwttvsXw90aI8HyAx/GvnL9sCcTa3oe3on2hc/8AfqgD56r039mw4+Nfhwn1uP8A0nlrzKvTv2av+S1+HP8At4/9JpaAPuiQgkYHWq0pHNWJF+YfpUE4zk9CKAOa8QTiKI4c4xyCOleEeI45de8SJp0Nx5bMGdn2s2EXk9AccdzwO/FezeNZCsLcAYByfWvmfxuJ7jWA9oWSQMD5i8HINAHpHgpLnw14uOmiVp4H/eRuUKkoWIXJPDHA5K/LnODXvlq6uinnpXh/ws0OQ5v75mmuZWMkkjnLFick/iST+Ne22S7YVHTHb0oAtpjJ/PFSjljUa5/GpQMjIGTQA8Z44pQoz1IJpyqeCMZp4X5vegCNhyPU1E4CkHv3qxKOVHfHFQFicA4FAER+8DjNRkZ54/GpTjBzTQPfj3oAifkduapn/X8jqKuuMA4AqoxBYgHmgCWHAJBznpUy4xnpUcC/n71OF4AxQAwjJ45FfEP7SH/JZ/EP0tv/AEmir7iKHPA+lfD37SIx8aPEI/69v/SaKgDzOug8Of8AHhec/wDLaL/0GWufroPDn/Hjd/8AXaL/ANBloA1B19acpOeMUxTTl4BoA2NIk2SwkdmH86938bzfa/DGhXGMjytmfpXgNk2PL6DHNe8Xki3Pws0uQnMkTkUAcOhxuwc1HbMDEQexP406Pk98ntUEDAK+ezEUAdH8I1DeK3z0zzX1VEmLZRjgivlH4RMw8XfIQcnv9a+r0YtbggZO3kUAfO/7QcWL2FvQ9a8x0pSEBHfrXrP7QqPmIuOhNeV6Up8jPagC3u+Yj0FL34pMHr6UDBxnigBy5TLZp8UbSyouDlmAAqGUnHHWr2hI8urWSICzeauB+IoA+mPhzpzaV4at7WdQkxy5HqDXnf7S1/s07TrNT95mcjP0r2a1T/R4SVw6qB+lfM37Qupm68WvbZJS3UKB6GgDyC4OW9KjbpilmPBJqJjx70ASR43UUIB0H6UUAP8AE74jck15c5y7H1Oa9E8WzYt5ef4TXnNABU1oM3CfWoasWP8Ax8pQB2ejLytetfCu383xHAf7oJryfReor2j4QRBtbyCDiPP60Aev6xkFR6LiqkFrBcFRdW8MwB4EsYfH0zVrVT+/GfpTbThwMc0ARaP4Z0nQ7nVb+wtkS81By8smBlRgfIoHCrxnA6nk1zV3Eq3cgzyTnpXoEv8AqCK4zUox9rccfjQBURSFwP0px3BO1OCHFMcEZFAEDg/xCqd0QFJFXGLgGqE7E5yOaAMq4fg1zWqDrXTzp19a5vVyBvJoA868R4yawNKh87VoEzklwP1rb8Rvkn3NQeAbb7Z4v06EDO6dR+tAH3RpEYsfDdjF0EVuv8q+UP2oH81/DsvXzHu2z68xV9XeIJRaaFcHpshIH5V8hftEStJa+GVY5C/aSPx8qgDxivT/ANmfH/C7vDeembn/ANJpa8wr0/8AZp/5Lb4b+tx/6TS0AfdchGQOh7VVmxggj8Ksyjgk1VnGR8uc0AcJ40lCWjux+mK+bNem2axleV3896+j/HYK2sjjn27mvmzxcGF2WxtJfOKAPevhzKs+lo0Qw3Q16VbBli2k5NeJfBm+MlssbkjsO9e5QLlFxnpQBOnAJzUin5+ny44NNUHjA46kGnDFAE0cnI9KkBy2e1RBSGXkYqQnD47UANnO0AiqwkLfL6VZlHqMjHFQDG7p1PWgCPI7imlgV7Z+tOfJPXApgHWgCNj8uCeart/rDkAnpVmRQASDiq5I6E80AS2+dw9etWQOMAAd6gt+xFTAAnIP50ASAkZ46Cvhv9pE5+NHiI/9e3/pNFX3Fg4PNfDv7SP/ACWjxD/27f8ApNFQB5nW/wCHf+PG7/67Rf8AoMlYFdF4YQvZXm0E/voun+7LQBoj2PFOB56UFD34pV4AoAu2h+RDXu3hVvtvwkuosZaGUMK8Jg/1a9u+B2r3D4OSi78NazZHHMRYD6UAckPv+9VIAPMlUn+KrrqUncc8EiqS8Xkq464NAG98KSE8WnnkNwK+rIHDWqMQenNfJ/w0IXxhwcc9a+prWRhZxAnLFelAHi/7Qj71jPoOa8p0zP2ZfSvVvj0qmEAcHrzXlOmEfZ0x9KALPTrTwBjkcelMYguEPbk0qmgBr47ZrpvhzafavF2moDwsgb8jXNgY3d69G+B9h9p8SNM44ijJB96APoOSRYYHkJ+VQWJNfF3xH1I6p4s1C5JzvlbH0zX1V8R9VXR/Bt7KWO9k8tSPU18ZajKZbiRzyWJNAFN+cjORUYHQkinY6H+KmnlsHrQA9OG4FFCjB/WigDF8ZS4gcepAriq6jxjJnav+1XL0AFTWhxcJ9ahqa1/4+E+tAHa6Mele4fBVS2pzsOyr/WvDdGcZWve/gcmZLqTHcD9KAPS9UYG4Y556Yos8715+tR3uDMcetTWXDj1oA1ZCRDxXI6k+Lx84P1rrpCdn4VyeoJm8kY9aAKyEYpGGRkYpmSGpefTrQAx14yKp3sIIDr17irpOASc1Wnkby2GeP5UAYd3gKcj8a47X5AFfHc12GoNwe9cJ4hkwG5oA898RSfvCM10PwFtDf/EjTFI4STf+Vch4glw7nNemfspWv2nx355GfKiZqAPpb4k3Yg0N0DcysEFfK37QgxB4b/7eP/aVfQ/xSvfM1C0s1PC5dhXz7+0WpEPhrPpc/wDtKgDxavT/ANmg4+Nvhv63H/pNLXmFenfs1f8AJbPDn1uP/SaWgD7uc7mPH4Gq02GBAGDUrcd81WlPUe9AHF+MoXliZcn14rwy8tNN/wCEnj/tkqtmM9WIy+RtHTBz0wcDGckV9B+IIg8Tevc+grxbxtoKXUjhcMobr60AXPAy2sfiuZNH2vYBuSrlgrbjuHI4wegGRjGCa95tWPlDP6V5T8J9CFjDuCBcdiP616vEMKBx9KAJkbuMc09TkHio1GenWnD7vWgCdG3EcE0of5yDUSjBA5pc/OCOlAD2Y4A9qiY8Ag9Kcxx9AKY+D1NAETP6jOKC3AGKXPQdRTWGOgoAiYkg/wA6rFcMx7+nrVpgMcEdarSYDZyaAJbZhgn8qm3YU981HCAF6cmnYwck0AShunA6dK+H/wBpD/ks/iH6W3/pNFX2/wAfWviD9pA5+M/iE/8AXt/6TRUAeaV6x8DtSu7Cy19LG2sbiSV7YlLm8FsflWb7rEgHryPp6V5PXofwq0GDWrTVftU1xDFFNbrughWTBKTHLbmUKoCnJJ9KANLxq8M3iG9eC6N0rMD5pwcnaMjI4IByM+1c+v5itjxTpEmg6zdadLLHK0LAb4zlWBAIIP0IrIjJCsvY4yKALsGRGleu/Am5C6zPbNjEsTD9K8ghBCL9K734T3n2TxTasDnccEUAamuQ/ZtVuVxwJCP1rJlGLtWBPzLiup8dxGPxJdnGAz5ArmrhQJYz6elAF3wKxh8WgjBIwa+nLK72WEDSAZI7mvlvww6x+KFJJAyOlfQ0F4r2VuOMhepoA4f46yJJaocfvCuea8n0sbbaPI/GvQPjBctIoDHtiuCsQVtI8g9KAJR80rv74xTmbb0zUdvuwc9yasbVLc9KAI85wB3r3f4H2P2XR7y+dfvDHSvDbWMzXKIB1IAr6U8M239j+CbdOjONzfTvQB5p8f8AxCWt7TTom+XG9h7mvn+Zst15rsPiTrDap4guJNxKg7R7AVxbnJPHFADeSfp1oPWm7snHrRztBFAEmeRnNFInJ5ooA43xVJuukH1NYdaWvvvvyAegrNoAKktyRMhHrUdPiOJFPvQB2Okt06V9EfA5cafPJ33n+VfOWkN0xX0l8Evl0CRz6saAO0lbdKcnmrdnneMYzWa7fvlx61q2WSVI60Aabnhee1c7qu1L9sLwR+ddFIOFrn9aOLkNjnFAGZOhLBlAx6CkjXcOnIpjXGxtzHCgZY+g9a5/wN4sj8TaRPew7AY7mWAhTnAB+U/ipBoA3LjvjtWfO5CEDHWrpmBY5/i4rLvHUZwaAMfVJtqOK888RXI2sc11uvXaxqQCcV5x4ju8gjNAHE67MWcrnrXvX7IduFvdXu2GAkQUH6mvnfUZfMuD7V9E/s63C6V4C16/JwWKop98UAdbrl62peJ7qXdlVfYv0FeWftIoVtvC5Pf7T/7Sr0LQ/wB5NubkscmuG/afXbD4VA7C6H/omgDwivTf2azj41+HCfW4/wDSaWvMq9O/ZrGfjX4cA/6eP/SaWgD7leQt0qB3J9uetWZVwc54qu6jJAIoAxdWTcpAAwQfwrkdR01JSD5Y9hXaammNp464Ax0rPEB3bjg0AP8AD9r9mgAA5I9MCt2PGM4qvZriNRjauOKuIvy8YoAVQMZ9aQMQ544oyc8cYpM8cfjQBIGOf60m7nA4pFApF5yDx2oAkZjjpimE/MQe1OYEYyc1HJuBG3Bz60AMdtoyAfoKT164p+DwWIz3pjA44IoAiYcdKhPXg1YdjjoKrnLZIP6UASRbjxj5etTgEjH4VHCQAA1T9ABgkfWgBNvY9K+IP2j+PjP4h/7dv/SaKvuM4zzXw7+0j/yWjxF/27f+k0VAHmddz8O9cfSNM1iE2ttd211JAssFyrMjYWXHAI9T+dcNXSeFIhNaXi+ZFHiSNt0jYHCS8fU9qAOh1G7vde1OW4kR57qXBKxIWOAABgDsAAKpPG8TMkqujqcMrKVIPoR2rtPhre6fCmpRXd21ndyLG1tKs3k8qxLKZeqAjg4yai+JmqWOpalp7WZgeaGySC7eDJR5wzFiGPL8FfmPWgDmYvuL16V0Xg2Yxa7ZMrbcSDmucib90vWtbQpAuoQH+64oA9m+Kluy6pbzcASRA5H0rhn+6ueqmvT/AIlRLN4c0e5B3ZjAJ/CvLAM5DH5geOaAI9IPleIVJ7kV7c1yV021b+IDpXhtsCmsI2O/Feqm5A0yDLFuPyoA5X4lXf2jbg89656MstgjEcEYFWfFknnXOAeCaqzFl0xFY8dhQA22J8tQO/rU4OSc9arxZ2ADPA6VJFnJzxigDq/h9px1HXYF25UOM17H8TNQGi+GpFjOCkewc+orkPgrp6rcS3sijbEu6sv47aw3kJaNJmRiXceme1AHht/OZbl3Y9TVE9fvU+dgSag3c4xxQA7t9KT8eP5Uh4GfypVOBQBJGcgE0U3d8wwetFAHn2pvvvpT74qrU8gM14yjALvgZ+teqf8ADO/xM/6AEX/gdb//ABdAHklKpwwIr1r/AIZ3+Jn/AEAIv/A63/8Ai6B+zv8AEvI/4kEf/gdb/wDxdAHH6UefWvpf4PfJ4SL+oP8AOvnrVNA1Lwtrk+j65b/ZtRt9vmxB1fbuUMOVJB4YHg19EfCwCPwRGfUD+dAHRb8zDn1rb077y+9c8jZuBnmuh0sDcOKANlxnA7VzetjM5HXArpnwAD7VxmvzgJL8zKZCVBB5HuKAMi68u5ilt5lDwyKUdckZB6iqemaTpekiX+y7G3sxKFDrCu0NjoSBxn3rxjXvH3i3wdr82nai1tfxKd0ck0IUyxnoQVx/LrmvRPh14suvF2mXF5caWllBG/lo6yl/MbvwRxjj86AOlnb5jj0rJ1GXCnpWjcsAjN/Wua1i5Co30oA5jXbne7c8CvOvENz9856V12tTgI3qa861+cMSvcmgDEYlmJPU17x8Prg2/wAO7WzXhridpG+g6V4NXtPw8Jl0azB6AcCgD1TwvblpE44HNefftTrtj8K+/wBq/wDaNeueEYNkIcjlq8s/a0XavhPA7Xf/ALRoA+eq9N/Zsz/wurw5g4Obj/0nlrzKvTP2bjj40+HT73H/AKTy0Afc7n8jUD4yOevFM1rUIdK0a/1K5WR4LOCS5kVACxVFLEDJAzgetZ51DWSc/wDCG65/3/sf/kigBup5VjubKkY246VXtgGBJyDgZBqK8m16YjZ4Q1kDrzPY/wDyRVeIeIF5bwhrGSef9Isv/kigDo4M45wRjtVgH+XSsjQtRa/a+imsrqwurKcW80NyYyysY0kBBjdlIKyL3rW6YO7OfagBB0560HIPA74pQCzc/hSng/4UALnmgHk9KF65oPHbFAC9eOtJxgk04c4poz+XrQAwA9yaRvpT2GetMYZHtQBBKwGe59qrnduwxA/GrE4AUcdKqO2AOec4HvQBctxheAOlTfTNR2qnbzkfWpz8qnPHvQAzGSBzXxB+0f8A8ln8Q/8Abt/6TRV9xkZPFfDv7SX/ACWjxD9Lb/0mioA8zruPhtaWN9HfwX1tqNw7SwmJbJkXGFlyWL8AY78Vw9dt4AsdZ1HS9YttFt7q4RpIDcJbqT8oEuN2O2aANDxLa2Nhrl3baTdNd2Mb7YpmxlxgZzjjrkfhUGm28V3fW8FxObeKRwrTbC+weu0dfpXT+Cvh/wCLfEUTan4e0ZL6C1uDC/mzQqvmBQSpV3UkYYdsVv6f8H/iNY6hDdp4ZileJ/MCTXVs6E+hXzOR7UAch4m0qPRfEGoaZFK80dpMYlkYAFwO5A6VX09ttzGQejCvR/EHww+JOvapLqF94YhS5l5k+z3NtGrH1x5vU1zuu+A/FHhG2trzxDpLWdrLOIEkNxDJlyrMBhHJ6K3bHFAHtetwm++GljN3iUH9K8ij+a4I75r2PQQbz4dMXbCJDtUevvXkEa/6a4bgZoAguIjFewk455rrJrlxYR4IC46Vzmpx7ZYCO/Srk8p+yIuT70AZOpuZ5884Bq1fQeXZWhI4fmqwj8242jpmuh8QQFbWxTAAVaAMIbc5AxUlohlnCjuaiPDmt7whZfbdVijHXcKAPaPAtpHZaRHCTtJXzZSPT0rwP4r6sdS8R3TAkqHIHNfSHiUQ6H4TnlQbH8naT6mvkPWrgz3szseSx5oAzJGOT1qPr0HHvQxJzSZxQAAcjGKUnk4pqnOcfnThzgHv3oAUcEdwKKXuOceoooA87tTm7hJ/vj+dfqdX5YWpC3MJJAAcEk9ua/QD/hffwz/6GiL/AMBLj/43QBiW/wAXriT42f8ACOl9OPhuS7k0mNw3+kC8SNWJYbvuFiYxxyRXtVfP/wDwl/wEGm21iL21ENtdfbYpBDd+cs28vv8AN2+YTuJPLe3Sux/4X38M/wDoaIv/AAEuP/jdAHzf+0W2343eIR6i2/8ASeOvT/AJ8vwPaD1Ufyrxj40eItL8T/FXWNX0G7W7064EHlTBWXdthRTwwBGCpHIr2Pwy/keCbAdMr/SgDUt5c3AxXXaT8wHPNcJZS7p+O1d5onKr+dAGrfN5duSeoFeaa9d7rxlzwnH416H4ik8mxLHoBzXi9/eGW5ZufmJNAGZ458KW/i+ytY3kEF1BICk2MnYT8y/1HvXP6j4Q1XwfdNqfgO6lkgwPO0+Y7vMA9P738x2rvbaT+I/lTprj5Pb1oA5Tw/47svEERgcNZamnElrLxz32k9fp1qtrF1uYgnmovGegaXrMy3EytBeIQftEPDEA9D6/XrWRqN0qqcZwBgZOTigDB1q55bngVwV/L5twx7A4ro9dugqPiuUPJoASvcvh/Ds060XnhBXh6Dc6r6nFfQPgmIiGEDsAKAPZPDar5UYU/WvIf2uQQvhLPpd/+0a9l8Nw/Iprx/8AbAXavhD6Xf8A7RoA+ca9N/Zs/wCS1eHPrcf+k0teZV6b+zZ/yWvw59bj/wBJ5aAPsb4jE/8ACv8AxNn/AKBd0P8AyE1eg1wnj62muvA/iGC1jknnl025SOONdzOxiYAADkkmtL/hO9G/55a5/wCCK+/+M0AeVeN/ix4l0H4k+INPt1sxoOj3enRTSS2MjpHFcIpd5Z1fEeGPy5U5z7c+/V5Jq+mfDjWNeu9Y1LRNeuL68eKS53aZqnlTmJQse+IJ5bbQBgFf512X/CeaL/zy1z/wRX3/AMZoAyNNXPirxkcZ/wCJnF/6Q2tawBAwOnWsfw3OL/VPFF9FDdR211qKPCbm2kt2dRaW6Ftkiq2NyMM47Vule3egBq55560v8PWm49TTiMYoATnkfyp24bQKb1/OgcHB4oAeOCM4oyKRRnPagDg0ANJzjHNNPI45qUrzQEOOn0oAqyRs+Ow9aEREbgc+p5qwVwCT1qrLuaXCj8e1AE69e2KU5xg9KEGFweDSkjIHPQ4oATJNfD37SAx8aPEOf+nb/wBJoq+4x19D618O/tI8/GjxF/27f+k0VAHmdem/B26sbWz1p7vUYbC6WW2a2knWR4ywWbO5EB3deAePrXmVei/CeysLu01j+0YrWRUeDZ9o1L7GAdsvQ7W3HjpxQB9f/ALVYNb0bxNqVpGY4LjW5HVSoX/lhAOg4HSt34u+LLrwZ4Kn1PToYZr55orWD7QSIkeRwod8c7Rkn9OK8w+BXjDwt4T8Ma/ay6jeSWkWpvOlwunzuvlNFEqsxRGC5KMOT2rsvE/xO+G2paXLpXiO9aSxvYVdoLnTbpRLGeVYZj6cZDD0yDQB1/hG08SWa3MXijV9P1RjsaGS1tDbMuc7lZd7Ajpg8d8153+1P/yIuj5/6C8f/oiemeEPHvwi8JQzx+H9Tlt1uNvmF4L2dm2ghRukVjgZOBnHNcv8ePiJ4X8XeF9MsfD2pNd3UWpJO6G1mjwgilUnLoB1ZeM55oA6rwNHnwFEGGQyY+nFeUakoj1eXbgAHHAr1HwY4j+H8bsTgIefwrydxJPqzKAW3SYHqaAI9WRhNFkHgcVXnlYRpwea3fE8LR3ix7MFFAxWK6EomfWgCbR4PNv4UHOWGa77XvD7NaSzEMgjjB5Fcr4ch/4mkCpwdwNeqXV+NQs7nTp1CzeV8h6bqAPDXX5yBk12fwwgaXXoiuAVI61yV7Gba6kjYcg4Ndv8KMHXEyOT0oA7X4337WnhlLctzKMmvly5OWY569vWvf8A9om5K/ZYS3/LP+tfPkxz+HWgCHgnmmde/FKaQZI4NADm9M8daQ/d60057cdqXoPagB4I4zzRSdMYooA84ooooAKWiigDU0kAbcnqa+o7CVYvCumrn+DP6CiigB+lTL5mM9/SvS/DhjYDLfpRRQAz4kTJBojlW5Ix0rw0zB7rG7vRRQBprOFXrVa6uQFIBNFFAHNavd5RsHrXI6tOQuAeKKKAOI1iYvNt7Dms6iigCxp6h763U9C4/nX0R4KVcRjd6dqKKAPbvDMaeWmW7ehrxn9s1FRPBu0g8Xmf/IFFFAHzPXpf7N7BPjR4dYnAH2j/ANJ5aKKAPuX7Smc7v0NN8+PP3ufoaKKADzowPvfoaTzo853fpRRQAvnRgY3nFJ5seBlv0oooADLFnO79KDLEerdPY0UUAHmxf3uPpSGSLH3v0oooABJEOAx/KlEsWB836GiigBTNH/e/SgzR/wB79KKKAAzRd2/Sm+ZEf4v0oooAQPFj7xP1zS+ZF/eP5UUUAG+L+8a+H/2kCD8aPEJU5H+jf+k0VFFAHmddl4D1u+0az1E6fOYfNlhD/IrZwsuPvA+tFFAGzaeJtUtb6e6huiJp23SnYpVz6lSNufwqjqepXOp3JuL2Z5pCMZY9AOgHoPYcCiigBI2G0A9AKt2pxKn1oooA+j/DkmPh+gkyoCb+O/FcX4KL/wBvySSw+Z8xKBiMZoooAu+IopZdTmkcAsSSRmsZ4uFJAAzRRQBv+F1QaiHccqQeK73xJZC7t47q3ISeLk444oooA8f8QxMuqyc/e+auh+GkjL4it1Bx8wFFFAEXx+1AXGurGpOI0C8968bm4JPUUUUAR56jFOWJzzRRQACJjyKAhzz60UUALtYHAooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Anteroposterior radiograph of femur shows cortical thickening (with Codman triangles [solid arrows] superiorly and inferiorly) that is eroded by a broad-based soft-tissue mass, with involvement of the underlying preexisting cortex (open arrow). Perpendicular periosteal reaction extends into the soft-tissue mass (arrowheads). (B) Bone scintigram (anterior projection) shows marked and eccentric increased radionuclide uptake (*). (C) Coronal T1-weighted MR image (650/17) also shows thickened cortex, which is extrinsically eroded centrally (r) by the broad-based intermediate-signal-intensity soft-tissue mass (m). The marrow shows focal areas of decreased signal intensity (arrows) that are separated from the soft-tissue mass by normal intervening cortex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Murphey MD, Robbin MR, McRae GA, et al. The many faces of osteosarcoma. Radiographics 1997; 17:1205. Copyright &copy; Radiological Society of North America.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_49_33552=[""].join("\n");
var outline_f32_49_33552=null;
var title_f32_49_33553="Miliary TB high resolution CT";
var content_f32_49_33553=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    High resolution computed tomography of the chest in a patient with miliary tuberculosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous 2 mm nodules and septal thickening are seen diffusely throughout the lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jo-Anne Shepard, MD, Massachusetts General Hospital, Boston.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_49_33553=[""].join("\n");
var outline_f32_49_33553=null;
var title_f32_49_33554="Patient information: Acetaminophen poisoning (The Basics)";
var content_f32_49_33554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17049\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/39/19066\">",
"         The different parts of a medicine label (Drug Facts)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/34/32290\">",
"         Patient information: Taking medicines when you're older (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/56/37762\">",
"         Patient information: Taking over-the-counter medicines during pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/6/23651\">",
"         Patient information: Toxic hepatitis (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Acetaminophen poisoning (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/acetaminophen-poisoning-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H29501006\">",
"      <span class=\"h1\">",
"       What is acetaminophen poisoning?",
"      </span>",
"      &nbsp;&mdash;&nbsp;",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      poisoning happens when a person takes too much of the pain relieving medicine acetaminophen (sample brand name: Tylenol&reg;). Acetaminophen poisoning can cause serious, long-lasting problems. It can even lead to death.",
"     </p>",
"     <p>",
"      Unfortunately, people often overdose (take too much",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ) by accident. That happens, in part, because hundreds of nonprescription medicines have acetaminophen in them. When people take two or more of these medicines, they do not always realize that they are taking more acetaminophen than they should take. Acetaminophen poisoning can also happen when children get access to medicine and take too much. In some cases, people take too much acetaminophen on purpose, because they want to kill themselves.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29501021\">",
"      <span class=\"h1\">",
"       What are the symptoms of acetaminophen poisoning?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people have no symptoms after an overdose. In people who do have symptoms, the symptoms follow a pattern based on how long it has been since the overdose. &nbsp;",
"     </p>",
"     <p>",
"      Within the first 24 hours after overdose, the symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Nausea and vomiting",
"       </li>",
"       <li>",
"        Sweating",
"       </li>",
"       <li>",
"        Paleness",
"       </li>",
"       <li>",
"        Feeling tired and sick",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      On days 2 and 3, the symptoms from the first day often go away, but that does not mean the person is fine. During this time, the liver or kidneys can stop working correctly. Symptoms during this stage can include belly pain and not urinating as much as normal.",
"     </p>",
"     <p>",
"      After day 3, the symptoms from the first day can come back. The person can also become confused and develop jaundice, a condition in which the skin and the whites of the eyes turn yellow. When poisoning is severe, people can die during this stage.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29501036\">",
"      <span class=\"h1\">",
"       Is there a test for acetaminophen poisoning?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If the doctor or nurse suspects",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      poisoning, he or she can order a blood test to check the level of acetaminophen in the blood. He or she will probably also order blood tests to check how the liver and kidneys are working. That&rsquo;s because acetaminophen poisoning can damage the liver and kidneys.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29501051\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you think you or your child took too much",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      , call the Poison Control Center in the US at 1-800-222-1222. See a doctor or nurse (or go to the emergency room) if the poison control center tells you to do so. If possible, be prepared to tell the doctor or nurse exactly which medicines you or your child took, how much of each medicine, and when. You can even bring the medicines to the doctor in a bag, so he or she can look at all the ingredients.",
"     </p>",
"     <p>",
"      People living outside the US can find information about poison control centers at the following web site:",
"      <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"       www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"      </a>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29501066\">",
"      <span class=\"h1\">",
"       How is acetaminophen poisoning treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        N-acetylcysteine, also called &ldquo;NAC&rdquo; &ndash; NAC is a medicine that can keep",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        from doing harm to the body. It is an &ldquo;antidote.&rdquo; But it must be given soon after an overdose to work.",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?20/33/21012?source=see_link\">",
"         Activated charcoal",
"        </a>",
"        &ndash; This is a medicine that binds to any",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        that is still in the stomach or intestines. This keeps the body from absorbing it.",
"       </li>",
"       <li>",
"        Liver transplant &ndash; This is when a doctor replaces a person&rsquo;s damaged liver with a healthy one. People who have too much liver damage as a result of",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        poisoning sometimes need a new liver.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29501081\">",
"      <span class=\"h1\">",
"       Can acetaminophen poisoning be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To prevent",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      poisoning:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Never take more than the recommended amount of any medicine.",
"       </li>",
"       <li>",
"        Never take 2 medicines that both contain",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        at the same time.",
"       </li>",
"       <li>",
"        Never leave any medicine any place where a child could find it.",
"       </li>",
"       <li>",
"        When giving",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        to a child, follow the instructions on the medicine bottle and use a medicine dosing cup or syringe. If you have questions about the dose for your child, ask your pharmacist, nurse, or doctor.",
"       </li>",
"       <li>",
"        If you have liver disease, ask your doctor before taking medicines that have",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        in them.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You can find out if",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      is one of the ingredients in a medicine by looking at the label (",
"      <a class=\"graphic graphic_figure graphicRef73468 \" href=\"UTD.htm?18/39/19066\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29501096\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/34/32290?source=see_link\">",
"       Patient information: Taking medicines when you're older (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/56/37762?source=see_link\">",
"       Patient information: Taking over-the-counter medicines during pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/6/23651?source=see_link\">",
"       Patient information: Toxic hepatitis (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?32/49/33554?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17049 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-9C98E7F444-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_49_33554=[""].join("\n");
var outline_f32_49_33554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29501006\">",
"      What is acetaminophen poisoning?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29501021\">",
"      What are the symptoms of acetaminophen poisoning?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29501036\">",
"      Is there a test for acetaminophen poisoning?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29501051\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29501066\">",
"      How is acetaminophen poisoning treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29501081\">",
"      Can acetaminophen poisoning be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29501096\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17049\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/39/19066\">",
"      The different parts of a medicine label (Drug Facts)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/34/32290?source=related_link\">",
"      Patient information: Taking medicines when you're older (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/56/37762?source=related_link\">",
"      Patient information: Taking over-the-counter medicines during pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/6/23651?source=related_link\">",
"      Patient information: Toxic hepatitis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_49_33555="Hooking maneuver";
var content_f32_49_33555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F82160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F82160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hooking maneuver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 394px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The hooking maneuver is performed by hooking the fingers under the anterior costal margins and pulling the rib cage anteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_49_33555=[""].join("\n");
var outline_f32_49_33555=null;
var title_f32_49_33556="Lansoprazole, amoxicillin, and clarithromycin: Patient drug information";
var content_f32_49_33556=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lansoprazole, amoxicillin, and clarithromycin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33209?source=see_link\">",
"     see \"Lansoprazole, amoxicillin, and clarithromycin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prevpac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hp-PAC&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10016269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691503",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat GI (gastrointestinal) ulcers caused by infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lansoprazole, amoxicillin, clarithromycin, any penicillin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705251",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a long QT on ECG.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703884",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you turned yellow or had liver side effects with azithromycin, clarithromycin, erythromycin, or telithromycin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for soft, brittle bones called osteoporosis (alcohol use, cigarette smoking, other family members with brittle bones, taking drugs to treat seizures, taking steroids).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hip, spine, or wrist fractures may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bone pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695874",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take every morning and evening for 2 weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10790 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-201.211.0.116-2CA427E3D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_49_33556=[""].join("\n");
var outline_f32_49_33556=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186897\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186898\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016269\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016271\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016270\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016275\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016276\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016278\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016273\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016274\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016279\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016280\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33209?source=related_link\">",
"      Lansoprazole, amoxicillin, and clarithromycin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_49_33557="Ivermectin (systemic): Pediatric drug information";
var content_f32_49_33557=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ivermectin (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40613?source=see_link\">",
"    see \"Ivermectin (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/43/12980?source=see_link\">",
"    see \"Ivermectin (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13841863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Stromectol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F13853113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anthelmintic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-ectoparasitic Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F13853122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40613?source=see_link\">",
"      see \"Ivermectin (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Children &ge;15 kg, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onchocerciasis: 150 mcg/kg/dose as a single dose; may repeat every 3-12 months until asymptomatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Strongyloidiasis: Manufacturer recommendations: 200 mcg/kg as a single dose; perform follow-up stool examinations; Alternative dosing: 200 mcg/kg/day once daily for 2 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009). In immunocompromised patients or patients with disseminated disease, may need to repeat therapy at 2-week intervals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ascariasis: 150-200 mcg/kg/dose as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Cutaneous larva migran",
"     </i>",
"     due to",
"     <i>",
"      Ancylostoma braziliense",
"     </i>",
"     : 200 mcg/kg once daily for 1-2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gnathostomiasis due to",
"     <i>",
"      Gnathostoma spinigerum",
"     </i>",
"     : 200 mcg/kg once daily for 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Filariasis due to",
"     <i>",
"      Mansonella streptocerca",
"     </i>",
"     : 150 mcg/kg/dose as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Filariasis due to",
"     <i>",
"      Mansonella ozzardi",
"     </i>",
"     : 200 mcg/kg/dose as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pediculosis: 400 mcg/kg/dose as a single dose on days 1 and 8 (Chosidow, 2010); alternatively, 200 mcg/kg/dose every 7 days for 3 doses (Foucault, 2006)",
"     <b>",
"      or",
"     </b>",
"     200 mcg/kg/dose repeated once after 10 days (Jones, 2003) have been shown to be effective",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Scabies due to",
"     <i>",
"      Sarcoptes scabiei",
"     </i>",
"     : 200 mcg/kg/dose as a single dose; may need to repeat in 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Trichuriasis due to",
"     <i>",
"      Trichuris trichiura",
"     </i>",
"     :  200 mcg/kg once daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Filariasis due to",
"     <i>",
"      Wucheria bancrofti",
"     </i>",
"     : 200 mcg/kg/dose as a single dose given in combination with albendazole",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Alternatively, the following weight-based dosing can be used: See tables.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Weight-Based Dosage to Provide ~150 mcg/kg",
"     </caption>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <thead>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Patient Weight",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (kg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Single Oral Dose",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15-25",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         26-44",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         45-64",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         65-84",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;85",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150 mcg/kg",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Weight-Based Dosage to Provide ~200 mcg/kg",
"     </caption>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <thead>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Patient Weight",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (kg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Single Oral Dose",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15-24",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25-35",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         36-50",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         51-65",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         66-79",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;80",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200 mcg/kg",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13841927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stromectol&reg;: 3 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13841865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13853123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer on an empty stomach with water",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13853119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at temperatures below 30&deg;C (86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13853114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of intestinal strongyloidiasis (FDA approved in pediatric patients &ge;15 kg and adults); treatment of onchocerciasis due to the immature form of",
"     <i>",
"      Onchocerca volvulus",
"     </i>",
"     (FDA approved in pediatric patients &ge;15 kg and adults). Has also been used for the treatment of other parasitic infections including but not limited to:",
"     <i>",
"      Ancylostoma braziliense",
"     </i>",
"     ,",
"     <i>",
"      Ascaris lumbricoides",
"     </i>",
"     ,",
"     <i>",
"      Gnathostoma spinigerum",
"     </i>",
"     ,",
"     <i>",
"      Mansonella ozzardi",
"     </i>",
"     ,",
"     <i>",
"      Mansonella streptocerca",
"     </i>",
"     ,",
"     <i>",
"      Pediculus humanus capitis",
"     </i>",
"     ,",
"     <i>",
"      Pediculus humanus corporis",
"     </i>",
"     ,",
"     <i>",
"      Phthirus pubis",
"     </i>",
"     ,",
"     <i>",
"      Trichuris trichiura",
"     </i>",
"     ,",
"     <i>",
"      Sarcoptes scabiei",
"     </i>",
"     ,",
"     <i>",
"      Wucheria bancrofti",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F13841884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Facial edema, orthostatic hypotension, peripheral edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia, hemoglobin increased, leukocytes decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Mazzotti-type reaction (with onchocerciasis): Arthralgia/synovitis, fever, lymph node enlargement/tenderness, pruritus, skin involvement (edema/urticarial rash)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal  distention, abdominal pain, anemia, anorexia, anterior uveitis, asthma exacerbation, back pain, bilirubin increased, chest discomfort, chorioretinitis, choroiditis, coma, confusion, conjunctival hemorrhage (associated with onchocerciasis), conjunctivitis, constipation, dyspnea, encephalopathy (rare; associated with loiasis), eyelid edema, eye sensation abnormal, fatigue, fecal incontinence, headache, hepatitis, hypotension, INR increased (with concomitant warfarin), keratitis, lethargy, leukopenia, mental status changes, myalgia, neck pain, rash, red eye, seizure, somnolence, standing/walking difficulty, Stevens-Johnson syndrome, stupor, toxic epidermal necrolysis, tremor, urinary incontinence, urticaria, vertigo, vision loss (transient), vomiting, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13853115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ivermectin or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13853144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hyper-reactive onchodermatitis who are more likely than others to experience severe adverse reactions such as edema and aggravation of onchodermatitis after treatment with ivermectin. Repeated courses of treatment for intestinal strongyloidiasis may be required in immunocompromised patients (eg, HIV); control of extraintestinal strongyloidiasis may necessitate suppressive (once monthly) therapy.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13853116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     May cause cutaneous and/or systemic reactions of varying severity (Mazzoti reaction) and ophthalmological reactions in patients with onchocerciasis; usually reported during the first 4 days after treatment and includes reactions such as arthralgia, edema, fever, hypotension, lymph node enlargement and tenderness, pruritus, synovitis, and urticarial rash. These reactions are probably due to allergic and inflammatory responses to the death of microfilariae. Supportive treatment of Mazzoti reaction includes oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids to treat postural hypotension; antihistamines, corticosteroids, and/or aspirin have been used to treat mild to moderate cases.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Serious and/or fatal encephalopathy has been reported rarely following treatment with ivermectin in patients with onchocerciasis and loiasis. In addition, back pain, conjunctival hemorrhage, dyspnea, urinary and/or fecal incontinence, difficulty standing/walking, mental status changes, confusion, lethargy, stupor, seizures, or coma has also been reported. Pretreatment assessment for",
"     <i>",
"      Loa loa",
"     </i>",
"     infection is recommended in any patient with significant exposure to endemic areas (West and Central Africa) prior to treatment with ivermectin. Safety and efficacy has not been established in children &lt;15 kg. The American Academy of Pediatrics (AAP) cautions against using ivermectin in children weighing &lt;15 kg or &lt;2 years of age since their blood-brain barrier may be less developed than in older patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13841889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13841887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azithromycin (Systemic): May increase the serum concentration of Ivermectin (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Ivermectin (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13853118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Bioavailability is increased 2.5-fold when administered following a high-fat meal.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13841873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13841874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal reproduction studies; therefore, the manufacturer classifies ivermectin as pregnancy category C. Ivermectin is not recommended for use in pregnancy. Although studies during pregnancy are limited, several mass treatment programs have not identified an increased risk of adverse fetal, neonatal, or maternal outcomes following ivermectin use in the first and second trimesters.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13853124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Skin and eye microfilarial counts, periodic ophthalmologic exams; follow up stool examinations",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13853120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve and muscle cells. This leads to increased permeability of cell membranes to chloride ions then hyperpolarization of the nerve or muscle cell, resulting in paralysis and death of the parasite.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13853121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3.1-3.5 L/kg; High concentration in the liver and adipose tissue; excreted in breast milk in low concentrations; does not readily cross the blood-brain barrier in patients &gt;15 kg or &gt;2 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 93% primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 18 hours (range: 16-35 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: &gt;97% in the liver by CYP3A4; substrate of the p-glycoprotein transport system",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &lt;1% in urine; feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F13853125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/43/12980?source=see_link\">",
"      see \"Ivermectin (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     You may have edema (peripheral or facial), dizziness, gastrointestinal upset (nausea or diarrhea), skin rash, or ophthalmic reaction.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33557/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chosidow O, Giraudeau B, Cottrell J, et al, \"Oral Ivermectin Versus Malathion Lotion for Difficult-to-Treat Head Lice,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 362(10):896-905.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33557/abstract-text/20220184/pubmed\" id=\"20220184\" target=\"_blank\">",
"        20220184",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Drugs for Parasitic Infections,\"",
"      <i>",
"       Treatment Guidelines from the Medical Letter",
"      </i>",
"      , 2007, 5(Suppl):e1-15.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foucault C, Ranque S, Badiaga S, et al, \"Oral Ivermectin in the Treatment of Body Lice,\"",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 2006, 193(3):474-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33557/abstract-text/16388498/pubmed\" id=\"16388498\" target=\"_blank\">",
"        16388498",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frankowski BL, Bocchini JA Jr, and Council on School Health and Committee on Infectious Diseases, \"Head Lice,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 126(2):392-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33557/abstract-text/20660553/pubmed\" id=\"20660553\" target=\"_blank\">",
"        20660553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gonz&aacute;lez Canga A, Sahag&uacute;n Prieto AM, Diez Li&eacute;bana MJ, et al, \"The Pharmacokinetics and Interactions of Ivermectin in Humans - A Mini-Review,\"",
"      <i>",
"       AAPS J",
"      </i>",
"      , 2008, 10(1):42-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33557/abstract-text/18446504/pubmed\" id=\"18446504\" target=\"_blank\">",
"        18446504",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jones KN and English JC 3rd, \"Review of Common Therapeutic Options in the United States for the Treatment of Pediculosis Capitis,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2003, 36(11):1355-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33557/abstract-text/12766828/pubmed\" id=\"12766828\" target=\"_blank\">",
"        12766828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83316 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-9C35C7E240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_49_33557=[""].join("\n");
var outline_f32_49_33557=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841863\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13853113\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13853122\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841927\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841865\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13853123\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13853119\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13853114\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841884\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13853115\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13853144\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13853116\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841889\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841887\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13853118\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841873\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841874\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13853124\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13853120\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13853121\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13853125\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/83316\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/83316|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40613?source=related_link\">",
"      Ivermectin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/43/12980?source=related_link\">",
"      Ivermectin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/16/1283?source=related_link\">",
"      Ivermectin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/34/9764?source=related_link\">",
"      Ivermectin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/53/37714?source=related_link\">",
"      Ivermectin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_49_33558="Oxaliplatin: Pediatric drug information";
var content_f32_49_33558=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxaliplatin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"    see \"Oxaliplatin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/31/33269?source=see_link\">",
"    see \"Oxaliplatin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Eloxatin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6821523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Eloxatin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1028793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Alkylating Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1028825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"      see \"Oxaliplatin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Details concerning dosing in combination regimens should also be consulted. Delay dosage in subsequent cycles until recovery of neutrophils &ge;1.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and platelets &ge;75 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Protocol ADVL0421 for relapsed/recurrent childhood solid tumors:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &le;12 months: 4.3 mg/kg over 2 hours every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;12 months: 130 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 2 hours every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advanced colorectal cancer: 85 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks until disease progression or unacceptable toxicity (in combination with fluorouracil/leucovorin calcium)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stage III colon cancer (adjuvant): 85 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks for 12 cycles (in combination with fluorouracil/leucovorin calcium)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colon/colorectal cancer (unlabeled doses or combinations): 85 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose on days 1, 15, and 29 of an 8-week treatment cycle in combination with fluorouracil/leucovorin calcium (Kuebler, 2007)",
"     <b>",
"      or",
"     </b>",
"     85 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks in combination with fluorouracil/leucovorin calcium/irinotecan (Falcone, 2007)",
"     <b>",
"      or",
"     </b>",
"     130 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks in combination with capecitabine (Cassidy, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustments for toxicity:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute toxicities: Longer infusion times (up to 6 hours) may mitigate acute toxicities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Persistent grade 2 neurosensory event: Reduce dose to 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     for Stage III colon cancer adjuvant treatment or 65 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     for advanced colorectal cancer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Grade 3 neurosensory event: Consider discontinuing therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recovery from grade 3/4 GI or grade 4 neutropenia or grade 3/4 thrombocytopenia: Reduce dose to 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     for Stage III colon cancer adjuvant treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recovery from grade 3/4 GI or grade 4 neutropenia or grade 3/4 thrombocytopenia: Reduce dose to 65 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     for advanced colorectal cancer; next dose should be delayed until neutrophils &gt;1.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and platelets &gt;75 x10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Adults: The FDA-approved labeling does not contain renal dosing adjustment guidelines. Oxaliplatin is primarily eliminated renally; in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute, the AUC is increased ~190%. Oxaliplatin use has been studied in 25 patients with renal dysfunction; treatment was well tolerated in patients with mild-to-moderate impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-59 mL/minute), suggesting that dose reduction is not necessary in this patient population (Takimoto, 2003). Patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute) have not been adequately studied; consider omitting dose or changing chemotherapy regimen if Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Mild, moderate, or severe hepatic impairment: Dosage adjustment not necessary (Doroshow, 2003; Synold, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F204242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate, preservative free]: 5 mg/mL (10 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eloxatin&reg;: 5 mg/mL (10 mL, 20 mL, 40 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F204229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1028831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Administer as I.V. infusion over 2-6 hours. The final concentration should not be less than 0.2 mg/mL. For patients in which volume may be of concern, a final concentration of 0.3-0.6 mg/mL is acceptable. Flush infusion line with D",
"     <sub>",
"      5",
"     </sub>",
"     W prior to administration of any concomitant medication. Do",
"     <b>",
"      not",
"     </b>",
"     use I.V. administration sets containing aluminum.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F204292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W;",
"     <b>",
"      incompatible",
"     </b>",
"     with alkaline solutions (eg, fluorouracil) and chloride-containing solutions. Flush infusion line with D",
"     <sub>",
"      5",
"     </sub>",
"     W prior to, and following, administration of concomitant medications via same I.V. line.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, aminophylline, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, chlorpromazine, cimetidine, cyclophosphamide, dexamethasone, diphenhydramine, dobutamine, docetaxel, dolasetron, dopamine, doxorubicin, droperidol, enalaprilat, epirubicin, etoposide phosphate, famotidine, fentanyl, furosemide, gemcitabine, granisetron, haloperidol lactate, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, ifosfamide, irinotecan, leucovorin calcium, lorazepam, magnesium sulfate, mannitol, meperidine, mesna, methotrexate, methylprednisolone sodium succinate, metoclopramide, mitoxantrone, morphine, nalbuphine, ondansetron, paclitaxel, palonosetron, potassium chloride, prochlorperazine, promethazine, ranitidine, sodium bicarbonate, theophylline, topotecan, verapamil, vincristine, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Diazepam.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1028812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; protect from light; do not freeze. Diluted solution is stable up to 6 hours at room temperature or up to 24 hours under refrigeration. Do not dilute using chloride-containing solutions (eg, NaCl) due to rapid conversion to monochloroplatinum, dichloroplatinum, and diaquoplatinum; all highly reactive in sodium chloride (Takimoto, 2007). Diluted infusion solutions do not require protection from light.  Do not reconstitute or dilute oxaliplatin using needles containing aluminum. Incompatible with alkaline solutions (eg, fluorouracil), chloride-containing solutions, and diazepam.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1028794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of stage III colon cancer (adjuvant) and advanced colorectal carcinoma (FDA approved in adults); has also been used in the treatment of esophageal cancer, gastric cancer, hepatobiliary cancer, nonsmall cell lung cancer, non-Hodgkin&rsquo;s lymphoma, ovarian cancer, pancreatic cancer, testicular cancer, relapsed/refractory childhood solid tumors including CNS and non-CNS tumors",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F204295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Oxaliplatin may be confused with Aloxi&reg;, carboplatin, cisplatin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F204291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema, flushing, peripheral edema, thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, fever, headache, insomnia, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, hand-foot syndrome, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dyspepsia, dysphagia, flatulence, gastroesophageal reflux, mucositis, nausea, stomatitis, taste perversion, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased, total bilirubin increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction (redness/swelling/pain)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, peripheral neuropathy (may be dose limiting), rigors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal lacrimation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, epistaxis, pharyngitis, pharyngolaryngeal dysesthesia, rhinitis, URI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, hiccup, hypersensitivity (includes urticaria, pruritus, facial flushing, shortness of breath, bronchospasm, diaphoresis, hypotension, syncope)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening (reported with mono- and combination therapy): Acute renal failure, alkaline phosphatase increased, anaphylactic/anaphylactoid reactions, anaphylactic shock, angioedema, aphonia, ataxia, colitis, cranial nerve palsies, deep tendon reflex loss, deafness, diplopia, dysarthria, dysphonia, eosinophilic pneumonia, extravasation (including necrosis), fasciculations, gait abnormal, hematuria, hemolysis, hemolytic anemia (immuno-allergic), hemolytic uremia syndrome, hemorrhage, hepatic failure, hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive disease), hepatitis, hepatotoxicity, hypertension, hypomagnesemia, hypoxia, ileus, INR increased, interstitial lung disease, interstitial nephritis (acute), intestinal obstruction, intracerebral bleeding, Lhermittes' sign, metabolic acidosis, myoclonus, neutropenic fever, neutropenic sepsis, neutropenic typhlitis, nodular regenerative hyperplasia, optic neuritis, pancreatitis, peliosis, prothrombin time increased, ptosis, rectal hemorrhage, reversible posterior leukoencephalopathy syndrome (RPLS), rhabdomyolysis, seizure, sepsis, thrombocytopenia (immuno-allergic), trigeminal neuralgia, tubular necrosis (acute),  visual disturbance (acuity decreased, field disturbance, transient loss)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1028799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxaliplatin, other platinum-containing compounds, or any component; pregnancy; grade 3 to 4 neuropathy usually due to prior exposure",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4426176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution in patients with renal impairment since increased toxicity may occur. Should be administered under the supervision of a physician experienced in the use of cancer chemotherapy agents",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1028800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Anaphylactic-like reactions may occur within minutes of oxaliplatin administration",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; manage reactions with supportive therapy, epinephrine, corticosteroids, and antihistamines. Two different types of neuropathy may occur: 1) an acute (within first 2 days), reversible (resolves within 14 days) sensory neuropathy with peripheral symptoms that are often exacerbated by cold (may include pharyngolaryngeal dysesthesia); 2) persistent (&gt;14 days) sensory neuropathy which presents with paresthesias, dysesthesias, hypoesthesias, and impaired proprioception that often interferes with daily activities (eg, writing, buttoning, swallowing); these symptoms may improve in some patients upon discontinuing treatment. May cause pulmonary fibrosis or hepatotoxicity (including rare cases of hepatitis and hepatic failure). The presence of hepatic vascular disorders, including veno-occlusive disease, should be considered, especially in individuals developing portal hypertension or who present with elevated liver function tests. When administered as sequential infusions, taxane derivatives (docetaxel, paclitaxel) should be administered before platinum derivatives to limit myelosuppression and enhance efficacy. Oxaliplatin may cause fetal harm (pregnancy should be avoided during therapy).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F204236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Taxane Derivatives: Platinum Derivatives may enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: Platinum Derivatives may enhance the adverse/toxic effect of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F204238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F204249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreased fetal weight, decreased ossification, and increased fetal deaths were observed in animal reproduction studies at one-tenth the equivalent human dose. Women of childbearing potential should be advised to avoid pregnancy and use effective contraception during treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Use in pregnant women is contraindicated in the Canadian labeling. Males should be advised not to father children during and for up to 6 months following therapy. May cause permanent infertility in males. Prior to initiating therapy, advise males desiring to father children, to seek counseling on sperm storage.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1028833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, hemoglobin, platelet count, blood chemistries including serum creatinine and liver function tests; signs of neuropathy, hypersensitivity reaction, and respiratory effects.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1028817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oxaliplatin, a platinum derivative alkylating agent, binds to DNA forming cross-links which inhibit DNA replication and transcription, resulting in cell death; cytotoxicity is cell-cycle nonspecific",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1028819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 440 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Nonenzymatic biotransformation (rapid and extensive), forms active and inactive derivatives",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Oxaliplatin ultrafilterable platinum:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Distribution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alpha phase: 0.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Beta phase: 16.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Terminal: 391 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oxaliplatin: Beta: 200.6 hours (median range: 162.5-299 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oxaliplatin ultrafilterable platinum: Beta: 217.6 hours (median range: 79.7-936.6 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (~54%); feces (~2%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1028836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/31/33269?source=see_link\">",
"      see \"Oxaliplatin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintain adequate hydration. Inform physician of sore throat, fever, chills, unusual fatigue or unusual bruising/bleeding, persistent diarrhea, rash, cough, swelling of throat, difficulty breathing, muscle cramps or twitching, tingling/numbness in arms, fingers, legs, or toes (avoid exposure to cold temperature, cold drinks, or cold objects since symptoms of acute sensory neuropathy may be exacerbated by cold temperature). Avoid becoming pregnant during or for 1 month following therapy; effective contraceptive measures must be used. Do not breast-feed.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cassidy J, Clarke S, D&iacute;az-Rubio E, et al, \"Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin as First-Line Therapy for Metastatic Colorectal Cancer,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(12):2006-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33558/abstract-text/18421053 /pubmed\" id=\"18421053 \" target=\"_blank\">",
"        18421053",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doroshow JH, Synold TW, Gandara D, et al, \"Pharmacology of Oxaliplatin in Solid Tumor Patients With Hepatic Dysfunction: A Preliminary Report of the National Cancer Institute Organ Dysfunction Working Group,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2003, 30(4 Suppl 15):14-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33558/abstract-text/14523790 /pubmed\" id=\"14523790 \" target=\"_blank\">",
"        14523790",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Falcone A, Ricci S, Brunetti I, et al, \"Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) as First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(13):1670-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33558/abstract-text/17470860/pubmed\" id=\"17470860\" target=\"_blank\">",
"        17470860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khushalani NI, Leichman CG, Proulx G, et al, \"Oxaliplatin in Combination With Protracted-Infusion Fluorouracil and Radiation: Report of a Clinical Trial for Patients With Esophageal Cancer,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(12):2844-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33558/abstract-text/12065561 /pubmed\" id=\"12065561 \" target=\"_blank\">",
"        12065561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuebler JP, Wieand HS, O'Connell MJ, et al, \"Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin as Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(16):2198-204.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33558/abstract-text/17470851/pubmed\" id=\"17470851\" target=\"_blank\">",
"        17470851",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Synold TW, Takimoto CH, Doroshow JH, et al, \"Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients With Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study,\"",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2007, 13(12):3660-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33558/abstract-text/17575231/pubmed\" id=\"17575231\" target=\"_blank\">",
"        17575231",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Takimoto CH, Graham MA, Lockwood G, et al, \"Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients With Impaired Renal Function,\"",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2007, 13(16):4832-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33558/abstract-text/17699862/pubmed\" id=\"17699862\" target=\"_blank\">",
"        17699862",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Takimoto CH, Remick SC, Sharma S, et al, \"Dose-Escalating and Pharmacological Study of Oxaliplatin in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(14):2664-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33558/abstract-text/12860942/pubmed\" id=\"12860942\" target=\"_blank\">",
"        12860942",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13031 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4AAF914B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_49_33558=[""].join("\n");
var outline_f32_49_33558=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709183\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204261\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821523\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028793\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028825\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204242\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204229\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028831\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204292\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028812\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028794\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204295\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204291\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028799\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426176\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028800\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299798\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204236\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204238\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204249\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028833\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028817\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028819\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028836\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13031\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13031|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=related_link\">",
"      Oxaliplatin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/31/33269?source=related_link\">",
"      Oxaliplatin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_49_33559="Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)";
var content_f32_49_33559=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/49/33559/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/49/33559/contributors\">",
"     Alfred K Cheung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/49/33559/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/49/33559/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/49/33559/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/49/33559/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/49/33559/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/49/33559/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/49/33559/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/49/33559/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of cardiovascular disease is an important predictor of mortality in patients with end-stage renal disease, as it accounts for almost 50 percent of deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33559/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Of these, approximately 20 percent can be attributed to the consequences of coronary artery disease (CAD). Patients with varying stages of chronic kidney disease (CKD) but who are not yet dialysis-dependent also have a markedly increased risk of morbidity and mortality from CVD, including coronary heart disease (CHD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many of the issues related to CHD are similar in patients with and without CKD. This topic review will emphasize only those aspects of the clinical manifestations and diagnosis of CHD that distinguish the dialysis patient from those without kidney dysfunction. Other aspects of CHD in dialysis patients are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29703?source=see_link\">",
"     \"Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STABLE CORONARY ARTERY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the issues concerning the presentation and evaluation of the stable patient suspected of having CHD are the same in those with and without end-stage renal disease. The following sections will specifically address issues unique to dialysis patients. However, as noted in the following sections, very few randomized trials have been performed in these individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis patients with angina often have a fairly typical history of exercise-induced chest discomfort that is similar to those with normal renal function. However, given the frequent episodes of hypotension during hemodialysis, angina during dialysis is perhaps the most common clinical manifestation of coronary disease in dialysis patients. Additional symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs, such as exertional dyspnea, (intradialytic or interdialytic) hypotension, sudden cardiac arrest or death, and arrhythmias, can be observed [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33559/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26634?source=see_link\">",
"     \"Differential diagnosis of chest pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=see_link\">",
"     \"Pathophysiology and clinical presentation of ischemic chest pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=see_link\">",
"     \"Acute complications during hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Silent myocardial ischemia is also common in dialysis patients. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28180?source=see_link\">",
"     \"Silent myocardial ischemia: Diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Who should be screened",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary purpose of screening for CHD is to identify dialysis patients whose prognosis could be improved with medical therapy or myocardial revascularization. Since end-stage renal disease is considered a coronary equivalent and appropriate secondary prevention measures would already be warranted, the results of screening do NOT change medical therapy.",
"   </p>",
"   <p>",
"    It is important to realize that a large number of dialysis patients have significant CHD despite being asymptomatic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    manifesting atypical symptoms. This is probably best shown in studies that examined the incidence of heart disease in dialysis patients who are candidates for kidney transplantation. The prevalence of coronary artery disease in asymptomatic diabetic patients evaluated for transplant is 30 to 50 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36472?source=see_link\">",
"     \"Renal transplantation in diabetic nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At the initiation of maintenance dialysis, we evaluate for heart disease by a complete history and physical examination, baseline electrocardiography, and an echocardiogram [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33559/abstract/6\">",
"     6",
"    </a>",
"    ]. Based on the results of this assessment, additional studies may be indicated. However, there is no evidence that this initial evaluation clearly leads to better clinical outcomes. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Kidney transplant candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis patients undergoing initial evaluation for a possible kidney transplant should be screened for the presence of CHD. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the initial evaluation is negative, asymptomatic kidney transplant waitlist patients undergoing maintenance dialysis should also be reevaluated for coronary artery disease at regular intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33559/abstract/6\">",
"     6",
"    </a>",
"    ]. Given that progression of coronary artery disease varies among dialysis patients, the period will vary based upon perceived risk, history of coronary artery disease, and history of revascularization:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetic waitlist patients with an initial negative evaluation should undergo yearly screening.",
"     </li>",
"     <li>",
"      Nondiabetic waitlist patients classified at high cardiovascular risk (in addition to the high risk imparted by end-stage renal disease) should be rescreened every 24 months.",
"     </li>",
"     <li>",
"      Those classified as not high cardiovascular risk (independent of the risk imparted by end-stage renal disease) should be re-evaluated every 36 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data supporting these recommendations are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11240?source=see_link\">",
"     \"The kidney transplant waiting list\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, we evaluate for the presence of heart disease in incident dialysis patients and kidney transplant candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33559/abstract/6\">",
"     6",
"    </a>",
"    ]. At any time, evaluation for coronary artery disease should be also performed in dialysis patients with symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs of coronary artery disease, a change in symptoms and signs, including recurrent hypotension, heart failure that is unresponsive to changes in dry weight, and intradialytic hypotension that prevents attaining dry weight [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33559/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A careful history and physical examination, complemented by an electrocardiogram and an echocardiogram, should be performed. Based upon this initial assessment, the patient may require additional studies, such as stress studies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coronary angiography. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Stress tests'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11\">",
"     'Coronary angiography'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This initial evaluation will help classify patients according to their risks of experiencing an adverse cardiovascular event. In the general population, the",
"    <span class=\"nowrap\">",
"     Framingham/ATP",
"    </span>",
"    III criteria was used to estimate the distribution of CHD risk in the United States in an analysis of data from patients without self-reported CHD, stroke, peripheral artery disease, or diabetes. It is based upon different risk factors for CHD, such as age, gender, LDL-cholesterol, HDL-cholesterol, blood pressure (including whether the patient is treated or not), and smoking.",
"   </p>",
"   <p>",
"    The 10-year risk of developing CHD (defined as MI, coronary death, and angina) is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low risk (&lt;10 percent)",
"     </li>",
"     <li>",
"      Intermediate risk (10 to 20 percent)",
"     </li>",
"     <li>",
"      High risk (&gt;20 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Details concerning these criteria are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These criteria do not apply directly to dialysis patients, given that they were derived from the general population. Blood pressure and serum LDL-cholesterol levels are particularly difficult to evaluate, since the relationships between these putative risk factors and clinical outcomes are somewhat unconventional in dialysis patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Stress tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-invasive imaging may be appropriate in the following dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33559/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Kidney transplant waitlist patients who have diabetes, have a high Framingham risk score, have known CHD (but not revascularized) or underwent angioplasty or stent placement at least one year ago",
"     </li>",
"     <li>",
"      Selected dialysis patients with a high risk of an adverse cardiovascular event but are not kidney transplant candidates",
"     </li>",
"     <li>",
"      History of complete coronary revascularization with coronary artery bypass surgery that occurred at least three years ago",
"     </li>",
"     <li>",
"      History of incomplete coronary revascularization with coronary artery bypass surgery that occurred at least one year ago",
"     </li>",
"     <li>",
"      Left ventricular systolic ejection fraction less than 40 percent",
"     </li>",
"     <li>",
"      Change in symptoms related to ischemic heart disease or change in clinical status",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Options",
"    </span>",
"    &nbsp;&mdash;&nbsp;When testing is performed for the diagnosis of CHD in the general population, many experts recommend standard exercise ECG testing if the resting ECG is normal, since the exercise response will be an important factor in determining prognosis. If the resting ECG has abnormalities that will interfere with interpretation during exercise or if localization of ischemia is expected to be important, an exercise test with imaging can be performed (eg, echocardiography or radionuclide myocardial perfusion imaging). For patients who cannot exercise, pharmacologic stress testing should be performed.",
"   </p>",
"   <p>",
"    These tests most commonly include exercise electrocardiography,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography, adenosine- or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    -induced echocardiography, and stress by adenosine or dipyridamole plus nuclear scintigraphy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The overall accuracy and predictive value of noninvasive testing is only fair in the ESRD population, with accuracy of the different non-invasive imaging tests being center-specific and dependent upon the expertise of the examiner [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33559/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. There are also problems associated with advanced kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33559/abstract/9\">",
"     9",
"    </a>",
"    ]. These include baseline abnormalities on the electrocardiogram and thallium scintigraphy induced by the abnormal metabolic milieu and a frequent inability to perform adequately during an exercise test. Thus, exercise electrocardiography and exercise echocardiography are not generally recommended because of poor exercise capabilities in the dialysis population [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33559/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These techniques can also be used to help stratify risk, with each of the modalities of varying accuracy in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33559/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. This was assessed in a meta-analysis that evaluated the prognostic value of thallium scintigraphy (four studies with pharmacologic stress and four with exercise stress) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography (four trials) in dialysis patients undergoing assessment for kidney or kidney-pancreas transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33559/abstract/10\">",
"     10",
"    </a>",
"    ]. Overall, positive tests, compared with negative tests, resulted in a significantly increased risk of myocardial infarction (relative risk of 2.73, 95% CI 1.25-5.97) and coronary death (RR of 2.92, 95% CI 1.66-5.12).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    -induced stress echocardiography appears to be more sensitive than other non-invasive tests, including vasodilator-induced stress nuclear scintigraphy. This is largely derived from studies in diabetic kidney transplant candidates. In one study of 125 candidates, all patients underwent coronary angiography, dobutamine stress echocardiography, and resting and exercise electrocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33559/abstract/12\">",
"     12",
"    </a>",
"    ]. Independent predictors of severe coronary artery disease (defined as luminal stenosis &gt;70 percent by visual estimation in at least one epicardial artery) were a positive stress echo result (odds ratio of 23, 95% CI 6-88) or an abnormal resting ECG (OR 7, 95% CI 2-34). Overall, the sensitivity and specificity of dobutamine stress echocardiography was approximately 75 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36472?source=see_link\">",
"     \"Renal transplantation in diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A paucity of data exists concerning the use of electron beam CT (EBCT) to detect coronary artery calcification in dialysis patients. The use of this technique is further complicated by the occurrence of medial vascular calcification that may not be associated with luminal atherosclerotic coronary disease in the dialysis patients. Thus, we agree with the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines that further study is required prior to recommending the use of this modality to screen for coronary artery disease in this patient population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;With respect to noninvasive tests, the diagnostic test selected will depend upon local experience and expertise. In general, we prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography rather than other non-invasive tests. However, this technique may be associated with a relatively increased risk of transient atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33559/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Coronary angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary angiography is the gold standard for the diagnosis of coronary disease in patients with and without advanced kidney disease. This test should be considered in dialysis patients who are candidates for coronary revascularization and have positive stress tests or have signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms of coronary artery disease.",
"   </p>",
"   <p>",
"    Cardiologists should minimize the amount of contrast administered with angiography because of volume concerns and nephrotoxicity for patients with residual kidney function. The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines also suggest that iso-osmolar radiocontrast media be administered.",
"   </p>",
"   <p>",
"    Among those with residual renal function, the administration of N-acetylcysteine and iso-osmolar radiocontrast media is recommended to help decrease the risk of radiocontrast nephropathy. However, the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    hydration is not recommended, given the increased intravascular volume.",
"   </p>",
"   <p>",
"    Issues surrounding the use of radiocontrast agents in non-dialysis patients with kidney disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=see_link\">",
"     \"Prevention of contrast-induced nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/42/42665?source=see_link\">",
"     \"Complications of diagnostic cardiac catheterization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ACUTE CORONARY SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in the general population, evaluation and diagnosis of dialysis patients with an acute coronary syndrome is based upon the constellation of symptoms and signs, findings on electrocardiogram, and levels of cardiac biomarkers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=see_link\">",
"     \"Classification of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been speculated that the extremely poor prognosis in dialysis patients with an acute myocardial infarction (AMI) may be due in part to a relatively increased number of \"atypical clinical presentations,\" resulting in underdiagnosis and undertreatment [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33559/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. As an example, the presence of dyspnea alone due to an acute myocardial infarction in an individual scheduled to undergo a regular chronic dialysis procedure may be mistakenly attributed to volume overload. In addition, baseline abnormalities on the electrocardiogram, such as left ventricular hypertrophy, may mask characteristic changes with ischemia.",
"   </p>",
"   <p>",
"    Atypical presentations of AMI in dialysis patients were best shown in a retrospective cohort matched study using data from the USRDS and National Registry of Myocardial Infarction databases [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33559/abstract/15\">",
"     15",
"    </a>",
"    ]. Compared with nondialysis patients with an AMI, dialysis patients with an AMI were significantly less likely to have a diagnosis of acute coronary syndrome on admission (55 versus 79 percent), present with chest pain (44 versus 68 percent), or have ST elevation (19 versus 36 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Evaluation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the patient suspected of having an acute coronary syndrome is generally the same as in patients without kidney disease. It is based upon the clinical presentation, electrocardiogram, and relevant laboratory tests. A detailed discussion of the diagnosis of acute myocardial infarction in patients without kidney disease is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electrocardiographic changes with an acute coronary syndrome that are normally observed in the general population are less likely to be observed in dialysis patients. This is due in part to the frequent presence of left ventricular hypertrophy as well as ST-T changes without ischemia in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33559/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is also important to realize that the serologic diagnosis of acute myocardial infarction may be more difficult in patients with end-stage renal disease because of false positive elevations in serum creatine kinase (CK) and troponin T levels. As discussed in detail separately, the most specific marker for myocardial damage in patients with end-stage renal disease appears to be serial measurements of cTnI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/27/11701?source=see_link\">",
"     \"Serum cardiac enzymes in patients with renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Stable coronary artery disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As in those without kidney disease, dialysis patients with stable coronary artery disease can have angina and other classic symptoms. Additional manifestations may include exertional dyspnea, (intradialytic or interdialytic) hypotension, sudden cardiac arrest or death, and arrhythmias. Silent ischemia is also common. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We screen incident dialysis patients and kidney transplant candidates for the presence of heart disease. If the initial evaluation is negative, asymptomatic kidney transplant waitlist patients should be reevaluated at regular intervals. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Who should be screened'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Kidney transplant candidates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation for heart disease should be performed in asymptomatic incident dialysis patients and kidney transplant candidates and dialysis patients with symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs of coronary artery disease, a change in symptoms and signs, including recurrent hypotension, heart failure that is unresponsive to changes in dry weight, and hypotension that prevents attaining dry weight. The initial evaluation should include a careful history and physical examination, an electrocardiogram, and an echocardiogram. Based upon this initial assessment, further studies may be required. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional diagnostic tests, such as noninvasive tests and coronary angiography, may be indicated based upon classification of the patient as high cardiovascular risk, the presence or development of specific symptoms or signs, abnormal screening tests, desire for kidney transplantation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      placement on the transplant waiting list:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      With respect to noninvasive tests, the diagnostic test selected will depend upon local experience and expertise. In general, we prefer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      echocardiography rather than other non-invasive tests. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Stress tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coronary angiography is the gold standard for the diagnosis of coronary disease. This test should be considered in dialysis patients who are candidates for coronary revascularization and have positive stress tests",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      have signs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptoms of coronary artery disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Coronary angiography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As in the general population, the evaluation and diagnosis of the dialysis patients with an acute coronary syndrome is based upon the constellation of symptoms and signs, findings on electrocardiogram, and levels of cardiac biomarkers.",
"      <br/>",
"      <br/>",
"      In addition to classic symptoms and signs, dialysis patients with an acute coronary syndrome may present with atypical symptoms and signs. Therefore, a high index of suspicion for acute coronary syndrome is warranted. The approach to the patient suspected of having an acute coronary syndrome is generally the same in patients with and without renal failure. It is based upon the clinical presentation, electrocardiogram, and relevant laboratory tests. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33559/abstract/1\">",
"      Farias MA, McClellan W, Soucie JM, Mitch WE. A prospective comparison of methods for determining if cardiovascular disease is a predictor of mortality in dialysis patients. Am J Kidney Dis 1994; 23:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33559/abstract/2\">",
"      Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33559/abstract/3\">",
"      Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33559/abstract/4\">",
"      Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004; 65:2380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33559/abstract/5\">",
"      Goldsmith DJ, Covic A. Coronary artery disease in uremia: Etiology, diagnosis, and therapy. Kidney Int 2001; 60:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33559/abstract/6\">",
"      K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33559/abstract/7\">",
"      Gill JS, Ma I, Landsberg D, et al. Cardiovascular events and investigation in patients who are awaiting cadaveric kidney transplantation. J Am Soc Nephrol 2005; 16:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33559/abstract/8\">",
"      Elsner D. How to diagnose and treat coronary artery disease in the uraemic patient: an update. Nephrol Dial Transplant 2001; 16:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33559/abstract/9\">",
"      Schmidt A, Stefenelli T, Schuster E, Mayer G. Informational contribution of noninvasive screening tests for coronary artery disease in patients on chronic renal replacement therapy. Am J Kidney Dis 2001; 37:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33559/abstract/10\">",
"      Rabbat CG, Treleaven DJ, Russell JD, et al. Prognostic value of myocardial perfusion studies in patients with end-stage renal disease assessed for kidney or kidney-pancreas transplantation: a meta-analysis. J Am Soc Nephrol 2003; 14:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33559/abstract/11\">",
"      De Vriese AS, De Bacquer DA, Verbeke FH, et al. Comparison of the prognostic value of dipyridamole and dobutamine myocardial perfusion scintigraphy in hemodialysis patients. Kidney Int 2009; 76:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33559/abstract/12\">",
"      Sharma R, Pellerin D, Gaze DC, et al. Dobutamine stress echocardiography and the resting but not exercise electrocardiograph predict severe coronary artery disease in renal transplant candidates. Nephrol Dial Transplant 2005; 20:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33559/abstract/13\">",
"      Herzog CA, Marwick TH, Pheley AM, et al. Dobutamine stress echocardiography for the detection of significant coronary artery disease in renal transplant candidates. Am J Kidney Dis 1999; 33:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33559/abstract/14\">",
"      Herzog CA. How to manage the renal patient with coronary heart disease: the agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol 2003; 14:2556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33559/abstract/15\">",
"      Herzog CA, Littrell K, Arko C, et al. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 2007; 116:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33559/abstract/16\">",
"      Surana SP, Riella LV, Keithi-Reddy SR, et al. Acute coronary syndrome in ESRD patients. Kidney Int 2009; 75:558.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1892 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-50DD9E1A11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_49_33559=[""].join("\n");
var outline_f32_49_33559=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STABLE CORONARY ARTERY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Who should be screened",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Kidney transplant candidates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Stress tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Coronary angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ACUTE CORONARY SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Stable coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=related_link\">",
"      Acute complications during hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=related_link\">",
"      Classification of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/42/42665?source=related_link\">",
"      Complications of diagnostic cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26634?source=related_link\">",
"      Differential diagnosis of chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=related_link\">",
"      Evaluation of the potential renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=related_link\">",
"      Pathophysiology and clinical presentation of ischemic chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36472?source=related_link\">",
"      Renal transplantation in diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29703?source=related_link\">",
"      Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=related_link\">",
"      Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/27/11701?source=related_link\">",
"      Serum cardiac enzymes in patients with renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28180?source=related_link\">",
"      Silent myocardial ischemia: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11240?source=related_link\">",
"      The kidney transplant waiting list",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_49_33560="Darbepoetin alfa: Drug information";
var content_f32_49_33560=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Darbepoetin alfa: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/26/21925?source=see_link\">",
"    see \"Darbepoetin alfa: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/43/21175?source=see_link\">",
"    see \"Darbepoetin alfa: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F156983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aranesp&reg;;",
"     </li>",
"     <li>",
"      Aranesp&reg; SingleJect&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F156984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aranesp&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F157010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Colony Stimulating Factor;",
"     </li>",
"     <li>",
"      Erythropoiesis-Stimulating Agent (ESA);",
"     </li>",
"     <li>",
"      Growth Factor;",
"     </li>",
"     <li>",
"      Recombinant Human Erythropoietin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F156985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Anemia associated with chronic kidney disease (CKD):",
"     </b>",
"     Individualize dosing and use the lowest dose necessary to reduce the need for RBC transfusions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Chronic kidney disease patients",
"     </i>",
"     <b>",
"      <i>",
"       ON dialysis",
"      </i>",
"     </b>",
"     (I.V. route is preferred for hemodialysis patients; initiate treatment when hemoglobin is &lt;10 g/dL; reduce dose or interrupt treatment if hemoglobin approaches or exceeds 11 g/dL): I.V., SubQ: Initial: 0.45 mcg/kg once weekly",
"     <b>",
"      or",
"     </b>",
"     0.75 mcg/kg once every 2 weeks",
"     <b>",
"      or",
"     </b>",
"     epoetin alfa doses of &lt;1500 to &ge;90,000 units per week may be converted to doses ranging from 6.25-200 mcg darbepoetin alfa per week (see adult column in conversion table below).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Chronic kidney disease patients",
"     </i>",
"     <b>",
"      <i>",
"       NOT on dialysis",
"      </i>",
"     </b>",
"     (consider initiating treatment when hemoglobin is &lt;10 g/dL; use only if rate of hemoglobin decline would likely result in RBC transfusion and desire is to reduce risk of alloimmunization or other RBC transfusion-related risks; reduce dose or interrupt treatment if hemoglobin exceeds 10 g/dL): I.V., SubQ: Initial: 0.45 mcg/kg once every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dosage adjustments for chronic kidney disease patients (either on dialysis or not on dialysis):",
"     </i>",
"     Do not increase dose more frequently than every 4 weeks (dose decreases may occur more frequently).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If hemoglobin increases &gt;1 g/dL in any 2-week period: Decrease dose by &ge;25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If hemoglobin does not increase by &gt;1 g/dL after 4 weeks: Increase dose by 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Inadequate or lack of response: If adequate response is not achieved over 12 weeks, further increases are unlikely to be of benefit and may increase the risk for adverse events; use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions",
"     <b>",
"      and",
"     </b>",
"     evaluate patient for other causes of anemia; discontinue treatment if responsiveness does not improve",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Anemia due to chemotherapy in cancer patients:",
"     </b>",
"     Initiate treatment only if hemoglobin &lt;10 g/dL and anticipated duration of myelosuppressive chemotherapy is &ge;2 months. Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions. Discontinue darbepoetin following completion of chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     SubQ: Initial: 2.25 mcg/kg once weekly",
"     <b>",
"      or",
"     </b>",
"     500 mcg once every 3 weeks until completion of chemotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dosage adjustments:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Increase dose: If hemoglobin does not increase by 1 g/dL",
"     <b>",
"      and",
"     </b>",
"     remains below 10 g/dL after initial 6 weeks (for patients receiving weekly therapy only), increase dose to 4.5 mcg/kg once weekly (no dosage adjustment if using every 3 week dosing).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Reduce dose by 40% if hemoglobin increases &gt;1 g/dL in any 2-week period",
"     <b>",
"      or",
"     </b>",
"     hemoglobin reaches a level sufficient to avoid red blood cell transfusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Withhold dose if hemoglobin exceeds a level needed to avoid red blood cell transfusion. Resume treatment with a 40% dose reduction when hemoglobin approaches a level where transfusions may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Discontinue: On completion of chemotherapy or if after 8 weeks of therapy there is no hemoglobin response or RBC transfusions still required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Symptomatic anemia associated with MDS (unlabeled use):",
"     </b>",
"     SubQ: 150-300 mcg once weekly (NCCN MDS guidelines v.2.2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Conversion from epoetin alfa to darbepoetin alfa: See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Conversion From Epoetin Alfa to Darbepoetin Alfa (Initial Dose)",
"     </caption>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         Previous Dosage of Epoetin Alfa",
"        </p>",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         (units/week)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         Children",
"        </p>",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         Darbepoetin Alfa Dosage",
"        </p>",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         (mcg/week)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         Adults",
"        </p>",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         Darbepoetin Alfa Dosage",
"        </p>",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         (mcg/week)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Note:",
"         </b>",
"         In patients receiving epoetin alfa 2-3 times per week, darbepoetin alfa is administered once weekly. In patients receiving epoetin alfa once weekly, darbepoetin alfa is administered once every 2 weeks. The darbepoetin dose to be administered every 2 weeks is derived by adding together 2 weekly epoetin alfa doses and then converting to the appropriate darbepoetin dose. Titrate dose to hemoglobin response thereafter.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;1500",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Not established",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6.25",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1500-2499",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6.25",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6.25",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2500-4999",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5000-10,999",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11,000-17,999",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         18,000-33,999",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         34,000-89,999",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;90,000",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5026026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/43/21175?source=see_link\">",
"      see \"Darbepoetin alfa: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Anemia associated with chronic kidney disease (CKD):",
"     </b>",
"     Individualize dosing and use the lowest dose necessary to reduce the need for RBC transfusions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Chronic kidney disease patients",
"     </i>",
"     <b>",
"      <i>",
"       ON dialysis",
"      </i>",
"     </b>",
"     (I.V. route is preferred for hemodialysis patients; initiate treatment when hemoglobin is &lt;10 g/dL; reduce dose or interrupt treatment if hemoglobin approaches or exceeds 11 g/dL): Children &ge;1 year: I.V., SubQ: Conversion from epoetin alfa: Initial dose: Epoetin alfa doses of 1500 to &ge;90,000 units per week may be converted to doses ranging from 6.25-200 mcg darbepoetin alfa per week (see pediatric column in conversion table below).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dosage adjustments for chronic kidney disease patients:",
"     </i>",
"     Do not increase dose more frequently than every 4 weeks (dose decreases may occur more frequently).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If hemoglobin increases &gt;1 g/dL in any 2-week period: Decrease dose by &ge;25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If hemoglobin does not increase by &gt;1 g/dL after 4 weeks: Increase dose by 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Inadequate or lack of response: If adequate response is not achieved over 12 weeks, further increases are unlikely to be of benefit and may increase the risk for adverse events; use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions",
"     <b>",
"      and",
"     </b>",
"     evaluate patient for other causes of anemia; discontinue treatment if responsiveness does not improve",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F156986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15795977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15795978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F156961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aranesp&reg;: 25 mcg/mL (1 mL); 40 mcg/mL (1 mL); 60 mcg/mL (1 mL); 100 mcg/mL (1 mL); 150 mcg/0.75 mL (0.75 mL); 200 mcg/mL (1 mL); 300 mcg/mL (1 mL) [contains polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aranesp&reg; SingleJect&reg;: 25 mcg/0.42 mL (0.42 mL); 40 mcg/0.4 mL (0.4 mL); 60 mcg/0.3 mL (0.3 mL); 100 mcg/0.5 mL (0.5 mL); 150 mcg/0.3 mL (0.3 mL); 200 mcg/0.4 mL (0.4 mL); 300 mcg/0.6 mL (0.6 mL); 500 mcg/mL (1 mL) [contains natural rubber/natural latex in packaging, polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F156947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11218431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     As a requirement of the REMS program, access to this medication is restricted. Healthcare providers and hospitals must be enrolled in the ESA APPRISE (Assisting Providers and Cancer Patients with Risk Information for the Safe use of ESAs) Oncology Program (866-284-8089; file://www.esa-apprise.com) to prescribe or dispense ESAs (ie, darbepoetin alfa, epoetin alfa) to patients with cancer.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM085918.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM085918.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F156963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered by SubQ or I.V. injection. The I.V. route is recommended in hemodialysis patients. Do not shake; vigorous shaking may denature darbepoetin alfa, rendering it biologically inactive. Do not dilute or administer in conjunction with other drug solutions. Discard any unused portion of the vial; do not pool unused portions.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F157017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not dilute or administer with other solutions.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F156962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of anemia due to concurrent myelosuppressive chemotherapy in patients with cancer (nonmyeloid malignancies) receiving chemotherapy (palliative intent) for a planned minimum of 2 additional months of chemotherapy; treatment of anemia due to chronic kidney disease (including patients on dialysis and not on dialysis)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Darbepoetin is",
"     <b>",
"      not",
"     </b>",
"     indicated for use under the following conditions:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cancer patients receiving hormonal therapy, therapeutic biologic products, or radiation therapy unless also receiving concurrent myelosuppressive chemotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cancer patients receiving myelosuppressive chemotherapy when the expected outcome is curative",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; As a substitute for RBC transfusion in patients requiring immediate correction of anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     In clinical trials, darbepoetin has not demonstrated improved quality of life, fatigue, or well-being.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F6721874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of symptomatic anemia in myelodysplastic syndrome (MDS)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2136826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Aranesp&reg; may be confused with Aralast, Aricept&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Darbepoetin alfa may be confused with dalteparin, epoetin alfa, epoetin beta",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F157008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (31%), peripheral edema (17%), edema (6% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (10% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (17%), cough (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Angina, fluid overload, hypotension, MI, thromboembolic events",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Cerebrovascular disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash/erythema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: AV graft thrombosis, vascular access complications",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pulmonary embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction, anaphylactic reactions, anemia associated with neutralizing antibodies (severe; with or without other cytopenias), angioedema, bronchospasm, hypertensive encephalopathy, pure red cell aplasia (PRCA), seizure, stroke, tumor progression/recurrence (cancer patients), urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F156966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to darbepoetin or any component of the formulation; uncontrolled hypertension; pure red cell aplasia (due to darbepoetin or other erythropoietin protein drugs)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F156951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reactions: Potentially serious allergic reactions have been reported (rarely), including rash and urticaria. Discontinue immediately (and permanently) in patients who experience serious allergic/anaphylactic reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: Erythropoiesis-stimulating agents (ESAs) increased the risk of serious cardiovascular events, thromboembolic events, stroke, and mortality in clinical studies when administered to target hemoglobin levels &gt;11 g/dL",
"     </b>",
"     (and provide no additional benefit); a rapid rise in hemoglobin (&gt;1 g/dL over 2 weeks) may also contribute to these risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pure red cell aplasia (PRCA): Cases of severe anemia and PRCA  (with or without other cytopenias) have been reported, predominantly in patients with chronic kidney disease receiving SubQ darbepoetin (the I.V. route is preferred for hemodialysis patients). Cases have also been reported in patients with hepatitis C who were receiving ESAs, interferon, and ribavirin. Patients with a sudden loss of response to darbepoetin (with severe anemia and a low reticulocyte count) should be evaluated for PRCA with associated neutralizing antibodies to erythropoietin; discontinue treatment (permanently) in patients with PRCA secondary to neutralizing antibodies to erythropoietin. Antibodies may cross-react; do not switch to another ESA in patients who develop antibody-mediated anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cancer patients:",
"     <b>",
"      [U.S. Boxed Warning]: A shortened overall survival and/or increased risk of time-to-tumor progression or recurrence has been reported in studies with breast, cervical, head and neck, lymphoid, and nonsmall cell lung cancer patients.",
"     </b>",
"     It is of note that in these studies, patients received ESAs to a target hemoglobin of &ge;12 g/dL; although risk has not been excluded when dosed to achieve a target hemoglobin of &lt;12 g/dL.",
"     <b>",
"      [U.S. Boxed Warnings]: To decrease these risks, and risk of cardio- and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusions. Use ESAs in cancer patients only for the treatment of anemia related to concurrent myelosuppressive chemotherapy; discontinue ESA following completion of the chemotherapy course. ESAs are",
"      <span style=\"text-decoration: underline\">",
"       not",
"      </span>",
"      indicated for patients receiving myelosuppressive therapy when the anticipated outcome is curative.",
"     </b>",
"     A dosage modification is appropriate if hemoglobin levels rise &gt;1 g/dL per 2-week time period during treatment (Rizzo, 2010). Use of ESAs has been associated with an increased risk of venous thromboembolism (VTE) without a reduction in transfusions in patients &gt;65 years of age with cancer (Hershman, 2009). Improved anemia symptoms, quality of life, fatigue, or well-being have not been demonstrated in controlled clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic kidney disease patients:",
"     <b>",
"      [U.S. Boxed Warning]: An increased risk of death, serious cardiovascular events, and stroke was reported in chronic kidney disease (CKD) patients administered ESAs to target hemoglobin levels &ge;11 g/dL; use the lowest dose sufficient to reduce the need for RBC transfusions. An optimal target hemoglobin level, dose or dosing strategy to reduce these risks has not been identified in clinical trials.",
"     </b>",
"     Hemoglobin rising &gt;1 g/dL in a 2-week period may contribute to the risk (dosage reduction recommended). CKD patients who exhibit an inadequate hemoglobin response to ESA therapy may be at a higher risk for cardiovascular events and mortality compared to other patients. ESA therapy may reduce dialysis efficacy (due to increase in red blood cells and decrease in plasma volume); adjustments in dialysis parameters may be needed. CKD patients not requiring dialysis may have a better response to darbepoetin and may require lower doses. Patients treated with ESAs may require increased heparinization during dialysis to prevent clotting of the extracorporeal circuit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension/cardiovascular disease: Use with caution in patients with a history of hypertension; use is contraindicated in patients with uncontrolled hypertension. An excessive rate of rise of hemoglobin may be associated with exacerbation of hypertension; decrease the darbepoetin dose if the hemoglobin increase exceeds 1 g/dL in any 2-week period. Blood pressure should be controlled prior to start of therapy and monitored closely throughout treatment. Hypertensive encephalopathy has been reported with patients receiving erythropoietic therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Perisurgical patients: Increased mortality was observed in patients undergoing coronary artery bypass surgery who received epoetin; these deaths were associated with thrombotic events. An increased risk of DVT has been observed in patients treated with epoetin undergoing surgical orthopedic procedures. Darbepoetin is",
"     <b>",
"      not",
"     </b>",
"     approved for reduction in allogeneic red blood cell transfusions in patients scheduled for surgical procedures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: The risk for seizures is increased with darbepoetin use in patients with CKD; use with caution in patients with a history of seizures. Monitor closely for neurologic symptoms during the first several months of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Severe anemia or acute blood loss: Due to the delayed onset of erythropoiesis, darbepoetin is not recommended for acute correction of severe anemia or as a substitute for emergency transfusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Albumin: Product may contain albumin, which confers a theoretical risk of transmission of viral disease or Creutzfeldt-Jakob disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: The packaging of some formulations may contain latex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Factors impairing erythropoiesis: Prior to treatment, correct or exclude deficiencies of iron, vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     , and/or folate, as well as other factors which may impair erythropoiesis (inflammatory conditions, infections, bleeding). Poor response to therapy should prompt evaluation of potential factors impairing erythropoiesis, as well as possible malignant processes and hematologic disease (thalassemia, refractory anemia, myelodysplastic disorder), occult blood loss, hemolysis, osteitis fibrosa cystic, and/or bone marrow fibrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Iron supplementation: Prior to and during therapy, iron stores must be evaluated. Supplemental iron is recommended if serum ferritin &lt;100 mcg/L or serum transferrin saturation &lt;20%. Most patients with CKD will require iron supplementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; REMS program:",
"     <b>",
"      [U.S. Boxed Warning]: Because of the risks of decreased survival and increased risk of tumor growth or progression, all healthcare providers and hospitals are required to enroll and comply with the ESA APPRISE Oncology Program prior to prescribing or dispensing ESAs to cancer patients.",
"     </b>",
"     Prescribers and patients will have to provide written documentation of discussed risks prior to each new course.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F156955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F156981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Should be avoided due to adverse effects on erythropoiesis.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F156957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F156969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Darbepoetin has been shown to have adverse effects (reduced weights, early postimplantation loss) in animal studies. There are no adequate and well-controlled studies in pregnant women. Darbepoetin alfa should be used in a pregnant woman only if potential benefit justifies the potential risk to the fetus. Women who become pregnant during treatment with darbepoetin are encouraged to enroll in Amgen&rsquo;s Pregnancy Surveillance Program (1-800-772-6436).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F156991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F156970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Supplemental iron intake may be required in patients with low iron stores.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F156968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Aranesp (Albumin Free) Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mcg/0.42 mL (0.42 mL): $192.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mcg/mL (1 mL): $192.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mcg/0.4 mL (0.4 mL): $308.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mcg/mL (1 mL): $308.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mcg/0.3 ml (0.3 mL): $463.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mcg/mL (1 mL): $463.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg/0.5 mL (0.5 mL): $771.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg/mL (1 mL): $771.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mcg/0.3 ml (0.3 mL): $1157.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mcg/0.75 mL (0.75 mL): $1157.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg/0.4 mL (0.4 mL): $1543.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg/mL (1 mL): $1543.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mcg/0.6 mL (0.6 mL): $2315.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mcg/mL (1 mL): $2315.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mcg/mL (1 mL): $3859.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F156959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemoglobin (at least once per week until maintenance dose established and after dosage changes; monitor less frequently once hemoglobin is stabilized); CKD patients should be also be monitored at least monthly following hemoglobin stability); iron stores (transferrin saturation and ferritin) prior to and during therapy; serum chemistry (CKD patients); blood pressure; fluid balance (CKD patients); seizures (CKD patients following initiation for first few months, includes new-onset or change in seizure frequency or premonitory symptoms)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Cancer patients: Examinations recommended by the ASCO/ASH guidelines (Rizzo, 2010) prior  to treatment include peripheral blood smear (in some situations a bone marrow exam may be necessary), assessment for iron, folate, or vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency, reticulocyte count, renal function status, and occult blood loss; during ESA treatment, assess baseline and periodic iron, total iron-binding capacity, and transferrin saturation or ferritin levels.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aranesp (AT, AU, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, HK, HN, IE, IL, IT, NL, NO, NZ, PL, SE, TR, TW);",
"     </li>",
"     <li>",
"      NESP (KP, MY, SG, TH, TW);",
"     </li>",
"     <li>",
"      Nespo (SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F156950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induces erythropoiesis by stimulating the division and differentiation of committed erythroid progenitor cells; induces the release of reticulocytes from the bone marrow into the bloodstream, where they mature to erythrocytes. There is a dose response relationship with this effect. This results in an increase in reticulocyte counts followed by a rise in hematocrit and hemoglobin levels. When administered SubQ or I.V., darbepoetin's half-life is ~3 times that of epoetin alfa concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F156965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Increased hemoglobin levels not generally observed until 2-6 weeks after initiating treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: SubQ: Slow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.06 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: CKD: SubQ: Adults: ~37% (range: 30% to 50%); Children: 54% (range: 32% to 70%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CKD: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 21 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     SubQ: Nondialysis patients: 70 hours (range: 35-139 hours); Dialysis patients: 46 hours (range: 12-89 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cancer: Adults: SubQ: 74 hours (range: 24-144 hours); Children: 49 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Darbepoetin half-life is approximately threefold longer than epoetin alfa following I.V. administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CKD: Adults: 48 hours (range: 12-72 hours; independent of dialysis); Children: 36 hours (range: 10-58 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cancer: Adults: 71-90 hours (range: 28-123 hours); Children: 71 hours (range: 21-143 hours)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Andre JL, Deschenes G, Boudaillies B, et al, &ldquo;Darbepoetin, Effective Treatment of Anaemia in Paediatric Patients With Chronic Renal Failure,&rdquo;",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2007, 22(5):708-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/17216497/pubmed\" id=\"17216497\" target=\"_blank\">",
"        17216497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bennett CL, Silver SM, Djulbegovic B, et al, &ldquo;Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2008, 299(8):914-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/18314434/pubmed\" id=\"18314434\" target=\"_blank\">",
"        18314434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Besarab A, Bolton WK, Browne JK, et al, &ldquo;The Effects of Normal as Compared With Low Hematocrit Values in Patients With Cardiac Disease Who Are Receiving Hemodialysis and Epoetin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 339(9):584-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/9718377/pubmed\" id=\"9718377\" target=\"_blank\">",
"        9718377",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bristoyiannis G, Germanos N, Grekas D, et al, &ldquo;Unit Dosing of Darbepoetin Alfa for the Treatment of Anemia in Patients With End-Stage Renal Disease Being Switched From Recombinant Human Erythropoetin: Results of a Phase IIIb, 27-Week, Multicenter, Open-Label Study in Greek Patients,&rdquo;",
"      <i>",
"       Curr Ther Res",
"      </i>",
"      , 2005, 66(3):195-211.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canon JL, Vansteenkiste J, Bodoky G, et al, &ldquo;Randomized, Double-Blind, Active-Controlled Trial of Every-3-Week Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2006, 98(4):273-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/16478746/pubmed\" id=\"16478746\" target=\"_blank\">",
"        16478746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Corwin HL, Gettinger A, Fabian TC, et al, \"Efficacy and Safety of Epoetin Alfa in Critically Ill Patients,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(10):965-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/17804841/pubmed\" id=\"17804841\" target=\"_blank\">",
"        17804841",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Corwin HL, Gettinger A, Pearl RG, et al, &ldquo;Efficacy of Recombinant Human Erythropoietin in Critically Ill Patients: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(22):2827-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/12472324/pubmed\" id=\"12472324\" target=\"_blank\">",
"        12472324",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2008, 34(1):17-60. Available at",
"      <a href=\"file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf\" target=\"_blank\">",
"       file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/18058085/pubmed\" id=\"18058085\" target=\"_blank\">",
"        18058085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Drueke TB, Locatelli F, Clyne N, et al, &ldquo;Normalization of Hemoglobin Level in Patients With Chronic Kidney Disease and Anemia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(20): 2071-84.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Egrie JC and Browne KJ, &ldquo;Development and Characterization of Novel Erythropoiesis Stimulation Protein (NESP),&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2001, 84(Suppl 1):3-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/11308268/pubmed\" id=\"11308268\" target=\"_blank\">",
"        11308268",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giraldo P, Nomdedeu B, Loscertales J, et al, &ldquo;Darbepoetin Alpha for the Treatment of Anemia in Patients With Myelodysplastic Syndromes,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 107(12):2807-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/17115424/pubmed\" id=\"17115424\" target=\"_blank\">",
"        17115424",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hebert PC, Wells G, Blajchman MA, et al, &ldquo;A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 340(6):409-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/9971864/pubmed\" id=\"9971864\" target=\"_blank\">",
"        9971864",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hershman DL, Buono DL, Malin J, et al, &ldquo;Patterns of Use and Risks Associated With Erythropoiesis-Stimulating Agents Among Medicare Patients With Cancer,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2009, 101(23):1-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/19903808/pubmed\" id=\"19903808\" target=\"_blank\">",
"        19903808",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hesketh PJ, Arena F, Patel D, et al, &ldquo;A Randomized Controlled Trial of Darbepoetin Alfa Administered as a Fixed or Weight-Based Dose Using a Front-Loading Schedule in Patients With Anemia Who Have Nonmyeloid Malignancies,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2004, 100(4):859-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/14770445/pubmed\" id=\"14770445\" target=\"_blank\">",
"        14770445",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jadoul M, Vanrenterghem Y, Foret M, et al, &ldquo;Darbepoetin Alfa Administered Once Monthly Maintains Haemoglobin Levels in Stable Dialysis Patients,&rdquo;",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2004, 19(4):898-903.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/15031347/pubmed\" id=\"15031347\" target=\"_blank\">",
"        15031347",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lerner G, Kale AS, Warady BA, et al, &ldquo;Pharmacokinetics of Darbepoetin Alfa in Pediatric Patients With Chronic Kidney Disease,&rdquo;",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2002, 17(11):933-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/12432437/pubmed\" id=\"12432437\" target=\"_blank\">",
"        12432437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Napolitano LM, Fabian TC, Kelly KM, et al, \"Improved Survival of Critically Ill Trauma Patients Treated With Recombinant Human Erythropoietin,\"",
"      <i>",
"       J Trauma",
"      </i>",
"      , 2008, 65(2):285-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/18695463/pubmed\" id=\"18695463\" target=\"_blank\">",
"        18695463",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Practice Guidelines in Oncology&trade;: Cancer- and Chemotherapy-Induced Anemia Version 1.2011.&rdquo; Available at file://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Practice Guidelines in Oncology&trade;: Myelodysplastic Syndromes Version 2.2011.&rdquo; Available at file://www.nccn.org/professionals/physician_gls/PDF/mds.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Kidney Foundation, &ldquo;KDOQI Clinical Practice Guidelines and Clinical Practice Recommentaions for Anemia in Chronic Kidney Disease,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2007, 50(3):529-30. Available at file://www.kidney.org/professionals/KDOQI/guidelines_anemiaUP/index.htm or  file://www.kidney.org/professionals/KDOQI",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parissis JT, Kourea K, Panou F, et al, &ldquo;Effects of Darbeopoetin Alpha on Right and Left Ventricular Systolic and Diastolic Function in Anemic Patients With Chronic Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 2008, 155(4): 751.e1-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/18371487/pubmed\" id=\"18371487\" target=\"_blank\">",
"        18371487",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, Burdmann EA, Chen CY, et al, &ldquo;A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 361(21):2019-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/19880844/pubmed\" id=\"19880844\" target=\"_blank\">",
"        19880844",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phronmmintikul A, Haas SJ, Elsik M, et al, &ldquo;Mortality and Target Haemoglobin Concentrations in Anaemic Patients with Chronic Kidney Disease Treated With Erythropoietin: A Meta-Analysis,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2007, 369(9559):381-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/17276778/pubmed\" id=\"17276778\" target=\"_blank\">",
"        17276778",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rizzo JD, Brouwers M, Hurley P, et al, &ldquo;American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(33):4996-5010.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/20975064/pubmed\" id=\"20975064\" target=\"_blank\">",
"        20975064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rizzo JD, Somerfield MR, Hagerty LK, et al, &ldquo;American Society of Hematology/American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(1):25-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/17954703/pubmed\" id=\"17954703\" target=\"_blank\">",
"        17954703",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh AJ, Szczech L, Tang Kl, et al, &ldquo;Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(20):2085-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/17108343/pubmed\" id=\"17108343\" target=\"_blank\">",
"        17108343",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Teehan G and Benz RL, &ldquo;An Update on the Controversies in Anemia Management in Chronic Kidney Disease: Lessons Learned and Lost,&rdquo;",
"      <i>",
"       Anemia",
"      </i>",
"      , 2011, 2011:623673.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/21541213/pubmed\" id=\"21541213\" target=\"_blank\">",
"        21541213",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Toto RD, Pichette V, Brenner R, et al, &ldquo;Darbepoetin Alfa Effectively Treats Anemia in Patients With Chronic Kidney Disease With de novo Every-Other-Week Administration,&rdquo;",
"      <i>",
"       Am J Nephrol",
"      </i>",
"      , 2004, 24(4):453-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/15331889/pubmed\" id=\"15331889\" target=\"_blank\">",
"        15331889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vadhan-Raj S, Mirtsching B, Charu V, et al, &ldquo;Assessment of Hematologic Effects and Fatigue in Cancer Patients With Chemotherapy-Induced Anemia Given Darbepoetin Alfa Every Two Weeks,&rdquo;",
"      <i>",
"       J Support Oncol",
"      </i>",
"      , 2003, 1(2):131-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/15352656/pubmed\" id=\"15352656\" target=\"_blank\">",
"        15352656",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, et al, &ldquo;Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Two Dosing Regimens of Darbepoetin Alfa in Patients With Heart Failure and Anaemia,&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 2007, 28(18):2208-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/17681958/pubmed\" id=\"17681958\" target=\"_blank\">",
"        17681958",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warady BA, Arar MY, Lerner G, et al, &ldquo;Darbepoetin Alfa for the Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease,&rdquo;",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2006, 21(8):1144-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/49/33560/abstract-text/16724235/pubmed\" id=\"16724235\" target=\"_blank\">",
"        16724235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8662 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-0869272E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_49_33560=[""].join("\n");
var outline_f32_49_33560=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708695\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156983\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156984\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157010\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156985\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5026026\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156986\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795977\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795978\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156961\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156947\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11218431\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874543\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156963\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157017\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156962\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6721874\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136826\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157008\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156966\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156951\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299127\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156955\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156981\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156957\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156969\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156991\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156970\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156968\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156959\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038595\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156950\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156965\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8662\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8662|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/26/21925?source=related_link\">",
"      Darbepoetin alfa: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/43/21175?source=related_link\">",
"      Darbepoetin alfa: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_49_33561="Retinal vasculitis associated with systemic disorders and infections";
var content_f32_49_33561=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Retinal vasculitis associated with systemic disorders and infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/49/33561/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/49/33561/contributors\">",
"     Michael Tolentino, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/49/33561/contributors\">",
"     Reza Dana, MD, MPH, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/49/33561/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/49/33561/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/49/33561/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/49/33561/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/49/33561/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/49/33561/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal vasculitis is characterized by inflammation of the vessels of the retina [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/1\">",
"     1",
"    </a>",
"    ]. Positive findings on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    examination may be diagnostic, with fluorescein angiography demonstrating vascular leakage (perivascular staining) and capillary nonperfusion.",
"   </p>",
"   <p>",
"    The detection and characterization of retinal vasculitis may help in the diagnosis and management of certain disorders associated with ocular inflammation. These include systemic autoimmune disorders, some infectious diseases, and certain ocular disorders.",
"   </p>",
"   <p>",
"    This topic will review the clinical features of retinal vasculitis associated with systemic disorders and infections. Vasculitis of the retinal vessels due to local ocular inflammatory disorders and an overview of the classification of vasculitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13590?source=see_link\">",
"     \"Retinal vasculitis associated with primary ocular disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic symptom of retinal vasculitis is a painless decrease in vision. Other symptoms may include a blind spot from ischemia-induced scotomas or floaters from vitritis. With macular involvement, patients may present with metamorphopsia (change in shape of an object) or abnormalities in color vision. Retinal vasculitis can also be asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in the retinal vessels may be observed upon physical examination. Fundoscopic findings include vascular sheathing (visible accumulation of inflammatory cells along vessel walls) (",
"    <a class=\"graphic graphic_picture graphicRef54347 \" href=\"UTD.htm?43/0/44046\">",
"     picture 1",
"    </a>",
"    ) and vitreous hemorrhage. The peripheral vessels are often more involved than central arteries and veins, and there are frequently skip areas. With certain disorders such as sarcoidosis, lesions resembling candle-wax drippings or extensive perivascular inflammation may also be observed.",
"   </p>",
"   <p>",
"    The retinal vascular abnormalities are better demonstrated by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54057 \" href=\"UTD.htm?7/33/7698\">",
"     image 1",
"    </a>",
"    ). One of the main changes on fluorescein angiography is perivascular staining, which reflects the increase in vascular permeability (",
"    <a class=\"graphic graphic_picture graphicRef66049 \" href=\"UTD.htm?22/56/23424\">",
"     picture 2",
"    </a>",
"    ). Cystoid macular edema and capillary nonperfusion also may be seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We actively discourage a non-targeted &ldquo;shotgun&rdquo; approach to diagnostic testing among patients suspected of or at risk for developing retinal vasculitis. The diagnosis of retinal vasculitis is purely clinical and is made by fundus examination. Ancillary testing is more useful in delineating the extent and severity of the condition and is also helpful in ruling-in or ruling-out associated systemic morbidities.",
"   </p>",
"   <p>",
"    Once retinal vasculitis is definitely diagnosed, we recommend that the workup begin with a thorough history, review of systems, and physical examination to help narrow the differential diagnosis. Retinal vasculitis can be due to systemic, usually immune-mediated conditions, infections, or inflammatory disorders of the eye (",
"    <a class=\"graphic graphic_table graphicRef56959 \" href=\"UTD.htm?2/38/2669\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/2\">",
"     2",
"    </a>",
"    ]. We, therefore, recommend a complete blood count, urinalysis, sedimentation rate or C-reactive protein, antineutrophil cytoplasmic antibody (ANCA), antinuclear antibody (ANA), chest x-ray, and syphilis and HIV serologies. However, it is important to emphasize that retinal vasculitis is an extremely uncommon manifestation of the classical systemic vasculitides [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cases in which the diagnosis of sarcoidosis is entertained, further evaluation is warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link&amp;anchor=H37#H37\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H14\">",
"     'Sarcoidosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Thus, once a diagnosis of retinal vasculitis is entertained, the next step should be to determine if one of the systemic conditions described below is present. Establishing the correct diagnosis is essential if therapy and prognosis are to be optimized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SYSTEMIC DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasculitis of the retinal vessels may occur in association with a number of systemic diseases (",
"    <a class=\"graphic graphic_table graphicRef56959 \" href=\"UTD.htm?2/38/2669\">",
"     table 1",
"    </a>",
"    ), although, in a majority of cases, retinal vasculitis is not associated with systemic disease. One classification system for the retinal vasculitides associated with systemic disease is by the type and size of the involved retinal vessels (",
"    <a class=\"graphic graphic_table graphicRef55568 \" href=\"UTD.htm?16/59/17339\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/1\">",
"     1",
"    </a>",
"    ]. Knowledge of the systemic and ocular features in these disorders can help differentiate between the various causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Beh&ccedil;et's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beh&ccedil;et&rsquo;s disease is a multisystem inflammatory syndrome characterized by recurrent oral aphthae, genital ulcers, and ocular inflammation. Minor criteria include arthritis, intestinal ulcers, epididymitis, vascular disease, and neuropsychiatric symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Involvement of the eyes is common among patients with Beh&ccedil;et&rsquo;s disease. In one series of 1700 patients in Japan, for example, ocular attacks were described in nearly 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/4\">",
"     4",
"    </a>",
"    ]. In another study of 39 patients, 25 total eyes lost the perception of light [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/5\">",
"     5",
"    </a>",
"    ]. On average, vision was lost 3.6 years after the onset of ocular symptoms.",
"   </p>",
"   <p>",
"    The loss of sight among patients with Beh&ccedil;et&rsquo;s disease most commonly occurs in association with retinal vasculitis. The retinal veins are usually affected, being manifested clinically as recurrent retinal vasoocclusive disease in association with the permanent loss of vision (",
"    <a class=\"graphic graphic_picture graphicRef63242 \" href=\"UTD.htm?11/7/11391\">",
"     picture 3",
"    </a>",
"    ). In one Japanese study, patients with skin lesions and arthritis had an increased risk of visual loss [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Upon examination, patients with acute attacks of retinal vasculitis often have retinal hemorrhages and edema in association with vitreous cells, findings which have to be differentiated from those resulting from viral retinitis. Retinal infiltrates, branch retinal vein occlusion, neovascularization, and vitritis are common posterior pole findings.",
"   </p>",
"   <p>",
"    Retinal vasculitis in Beh&ccedil;et&rsquo;s can be treated with a variety of agents, including glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . The effectiveness, dose, and duration of therapy are based upon the patient response [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/7\">",
"     7",
"    </a>",
"    ]. The treatment of ocular involvement in Beh&ccedil;et&rsquo;s disease is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33498?source=see_link\">",
"     \"Treatment of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular manifestations in systemic lupus erythematosus (SLE) result from localized ischemia and may include involvement of the eyelids, episclera, sclera, cornea, orbit, retina, choroid, extraocular muscles, and optic nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retinal involvement is an under-recognized manifestation of SLE. Mild and visually nonthreatening manifestations of lupus retinopathy are common, consisting of cotton-wool spots with or without hemorrhages; they are observed in 3 to 30 percent of ambulatory and hospitalized patients with SLE, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Cotton-wool spots represent edematous and ischemic neuronal tissue. While many of these small retinal lesions may be appreciated on fundoscopic examination,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography may be helpful in diagnosing subtle lesions, so the prevalence of angiographic retinopathy is likely even higher than that cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/11\">",
"     11",
"    </a>",
"    ]. Severe lupus retinopathy is characterized by severe ischemia because of vasculitic or thrombotic occlusion; it is observed more commonly in patients with active and severe systemic disease and, hence, correlates with decreased survival [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/9,11-13\">",
"     9,11-13",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Retinal vasculitis in SLE typically affects the small arterioles and arteries and correlates with avascular areas on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography. More severe ischemia can result in neovascularization and hemorrhaging (",
"    <a class=\"graphic graphic_picture graphicRef50474 \" href=\"UTD.htm?42/35/43582\">",
"     picture 4",
"    </a>",
"    ). However, other nonspecific findings including capillary or venous dilatation, arteriolar constriction, and venous engorgement can also be seen in SLE. Very severe and sight-threatening retinal disease in SLE is typically associated with thrombotic occlusion of larger retinal vessels, findings that are often associated with antiphospholipid and anticardiolipin antibodies observed in Hughes syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/14\">",
"     14",
"    </a>",
"    ]. The larger retinal vessels affected in SLE can lead to branch or central retinal vein or artery occlusion, leading to profound and irreversible vision loss (",
"    <a class=\"graphic graphic_picture graphicRef72037 \" href=\"UTD.htm?0/23/368\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/11,15,16\">",
"     11,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is beyond the scope of this discussion to review the diagnostic criteria of the antiphospholipid syndrome. However, SLE patients presenting with acute occlusion of large retinal vessels should be evaluated for this condition, and relevant therapy, possibly including anticoagulation, should be instituted [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=see_link\">",
"     \"Treatment of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While associations between severe retinal and nonocular morbidity in SLE have been established, it is important to recognize that no prospective studies have been performed evaluating treatment modalities for the various subgroups of lupus retinopathy. Thus, patients diagnosed with the more severe variants of retinopathy should undergo a full systemic workup, with treatment focused upon systemic management of vasculitis and arterial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients with extensive retinal ischemia that develop neovascularization should also be evaluated for laser photocoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Giant cell arteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giant cell arteritis (GCA), or temporal arteritis, is a systemic vasculitis which primarily involves the medium-sized arteries. Ocular manifestations are frequent and include blurred vision, diplopia, and blindness. Ischemic optic neuropathy is the most frequent pathologic consequence within the eye [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retinal involvement with giant cell arteritis is manifested as cotton wool spots, hemorrhages, or both. Other less common retinal findings include central and branch retinal artery occlusions, ocular ischemic syndrome, hypotony, choroidal ischemia, and cortical blindness.",
"   </p>",
"   <p>",
"    The likelihood of visual loss decreases with early diagnosis and treatment of the arteritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34217?source=see_link\">",
"     \"Treatment of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Granulomatosis with polyangiitis (Wegener's)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatosis with polyangiitis (Wegener's), which can be abbreviated as GPA, is characterized by necrotizing granulomatous vasculitis of the lower and upper respiratory tracts, necrotizing glomerulonephritis, systemic small-vessel vasculitis, and antineutrophil cytoplasmic antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ocular involvement is present in 30 to 60 percent of patients. Such involvement includes inflammatory orbital pseudotumor, episcleritis, scleritis, and, less often, keratitis, conjunctivitis, uveitis, and retinal vasculopathy. Significant visual loss occurs in up to 8 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The retinal vasculitis associated with GPA is characterized by involvement of the medium- to small-size arterioles, resulting in cotton-wool spots and arteriolar occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/21\">",
"     21",
"    </a>",
"    ]. Branch retinal vein occlusions have also been reported. Retinal vasculitis is less common than optic neuropathy or optic disk vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with ocular involvement are treated the same as other patients with GPA. Those with vision-threatening disease should receive the regimen used for fulminant renal or respiratory disease. Therapy for the first three days should be initiated with pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (250 to 1000 mg) and either oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or intravenous pulse cyclophosphamide. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Polyarteritis nodosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyarteritis nodosa is a systemic necrotizing vasculitis which involves the medium- to small-size arteries of multiple organs [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ocular findings occur in 10 to 20 percent of patients with polyarteritis nodosa [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/24\">",
"     24",
"    </a>",
"    ]. Anterior segment findings may include episcleritis, scleritis, corneal or scleral ulcers, and uncommonly iritis. Pseudotumor or extraocular muscle dysfunction may also be observed.",
"   </p>",
"   <p>",
"    Although the choroidal arteries are most commonly affected, retinal vessel involvement may result in cotton-wool spots, retinal edema, vitritis, and hypertensive changes. Retinal venules may also be affected [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment regimen is similar to that for other patients with severe polyarteritis nodosa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28119?source=see_link\">",
"     \"Treatment and prognosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     HLA-B27 associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of the HLA-B27 haplotype is strongly associated with the seronegative spondyloarthropathies, such as ankylosing spondylitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=see_link\">",
"     \"Pathogenesis of spondyloarthritis\"",
"    </a>",
"    .) Although the main ocular complication in these conditions is recurrent anterior uveitis, posterior uveitis may be observed.",
"   </p>",
"   <p>",
"    The prevalence of posterior segment disease has varied from 4 to 17 percent in different studies [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Specific disorders included severe vitritis (93 percent), papillitis (84 percent), macular edema (38 percent), retinal vasculitis (24 percent), and vitreous and pars plana exudates (7 percent). The retinal vasculitis may affect both arteries and veins. Occasional patients develop central retinal vein occlusion with disc neovascularization or occult peripheral venular vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concurrent retinal vasculitis and posterior segment involvement must be entertained when evaluating a patient with seronegative spondyloarthropathy and HLA-B27. As a result, a dilated fundoscopic examination should be performed when such patients develop visual symptoms.",
"   </p>",
"   <p>",
"    Patients diagnosed with or suspected of having HLA-associated ocular inflammation are best referred to ophthalmologists expert in the care of patients with ocular inflammation. Uveitis limited to the anterior portions of the eye (iritis, iridocyclitis) is generally adequately treated with topical corticosteroids. However, involvement of posterior structures (retinitis, vasculitis, vitritis, optic neuritis) is best treated with periocular injections of glucocorticoids (eg, 1 mL",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    40",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    or systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (eg, starting dose 0.75 to 5.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day). The dose of the therapy is then adjusted based upon the patient&rsquo;s response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Relapsing polychondritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapsing polychondritis is a rare connective tissue disorder that is clinically defined as having three or more of the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inflammation of ocular structures",
"     </li>",
"     <li>",
"      Cochlear or vestibular damage with hearing loss",
"     </li>",
"     <li>",
"      Recurrent chondritis of the auricles",
"     </li>",
"     <li>",
"      Nonerosive polyarthritis",
"     </li>",
"     <li>",
"      Chondritis of the nasal cartilage",
"     </li>",
"     <li>",
"      Chondritis of the respiratory tract involving laryngeal or tracheal cartilage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4856?source=see_link\">",
"     \"Diagnostic evaluation of relapsing polychondritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inflammation of the eye is a common finding in patients with relapsing polychondritis. In a retrospective study of 112 patients, for example, ocular manifestations were present in 21 percent at presentation and eventually developed in 57 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/31\">",
"     31",
"    </a>",
"    ]. The most common findings were scleritis and episcleritis (14 and 39 percent, respectively).",
"   </p>",
"   <p>",
"    In this same study, retinal findings were observed in 9 percent of patients; vasculitis of the retinal vessels was manifested as hemorrhages, vascular occlusions, and cotton-wool spots. These findings were not found at presentation but developed over time.",
"   </p>",
"   <p>",
"    Treatment of severe ocular inflammation in RP is similar to that for other patients with severe RP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15673?source=see_link\">",
"     \"Treatment of relapsing polychondritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ophthalmic involvement may occur in patients with ulcerative colitis and Crohn&rsquo;s disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\"",
"    </a>",
"    .) Ocular involvement in ulcerative colitis is generally characterized by acute monocular iritis. By comparison, ocular disease in Crohn&rsquo;s disease can be extensive and chronic and is frequently complicated by scleritis and bilateral involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/32\">",
"     32",
"    </a>",
"    ]. Other ocular conditions observed in Crohn&rsquo;s disease include stromal keratitis, peripheral ulcerative keratitis, Sj&ouml;gren&rsquo;s syndrome, blepharitis, retrobulbar neuritis, and neuroretinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have been few case reports of retinal vasculitis accompanying Crohn&rsquo;s disease. In one report, retinal vasculitis resulted in central retinal vein occlusion in one patient and in branch retinal artery occlusion in another [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/34\">",
"     34",
"    </a>",
"    ]. In one of these patients, the retinal vasculitis preceded the diagnosis of Crohn&rsquo;s disease. In the other, arteritis and phlebitis resulted in marked loss of vision [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/35\">",
"     35",
"    </a>",
"    ]. Posterior pole involvement should be considered in patients with visual abnormalities and Crohn&rsquo;s disease. As with severe inflammatory bowel disease, the treatment of retinal vasculitis is largely the administration of systemic glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular manifestations occur in 20 to 25 percent of patients with sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    .) In a retrospective review of 183 patients with chronic sarcoidosis, 19, 18, 7, and 6 percent developed uveitis, anterior uveitis, posterior uveitis, and secondary glaucoma, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/37\">",
"     37",
"    </a>",
"    ]. The risk of severe visual loss was enhanced in those with both glaucoma and chronic uveitis. In patients with sarcoidosis and posterior segment involvement, possible findings include retinal periphlebitis, retinal neovascularization, vitreous inflammation, choroidal granulomas, and optic nerve disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Findings with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography in patients with sarcoid and ocular disease may include focal periphlebitis, diffuse capillary leakage, new vessel formation, and acute retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/39\">",
"     39",
"    </a>",
"    ]. The periphlebitis is described as resembling candle wax drippings, a finding considered by some to be pathognomonic of sarcoidosis (",
"    <a class=\"graphic graphic_picture graphicRef73985 \" href=\"UTD.htm?24/48/25344\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Focal periphlebitis primarily occurs around the vein and rarely occurs around arteries. Infiltration and vein occlusions of the retina are not usually observed in sarcoidosis but are seen in Beh&ccedil;et&rsquo;s disease, a characteristic that can differentiate these two disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/39\">",
"     39",
"    </a>",
"    ]. Although vessel occlusions are not typical in sarcoidosis, involvement of the posterior segment is associated with a poor visual outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ocular involvement with sarcoidosis can usually be identified at disease presentation. It is important to have an ophthalmic evaluation when sarcoidosis is diagnosed to help detect ocular disease, particularly uveitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glaucoma. One study demonstrated that the factors most associated with a poor final visual acuity",
"    <span class=\"nowrap\">",
"     (20/40",
"    </span>",
"    or worse) were the development of glaucoma, intermediate or posterior uveitis, and a delay in presentation to a uveitis subspecialist [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most ocular manifestations of sarcoidosis do not require systemic treatment. To treat retinal vasculitis, however, glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    have been used [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/80?source=see_link\">",
"     \"Episcleritis\"",
"    </a>",
"    .) In general, anterior uveitis in sarcoidosis responds nicely to topical therapy alone. However, severe or chronic ocular inflammation is best managed with periocular glucocorticoid injections",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/41\">",
"     41",
"    </a>",
"    ]. Once the inflammation is quiescent, systemic therapy is tapered gradually over at least six months to minimize the chances of recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Multiple sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple sclerosis (MS) is associated with demyelination of the optic nerve, brainstem, or spinal cord. Optic neuritis is a common presenting manifestation, while retinal vasculitis is rare.",
"   </p>",
"   <p>",
"    The presence of retinal vasculitis in patients presenting with optic neuritis enhances the likelihood of the eventual development of multiple sclerosis. In one study of 50 patients with optic neuritis, for example, 25 percent had retinal abnormalities including retinal venous sheathing and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    leakage without sheathing [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/42\">",
"     42",
"    </a>",
"    ]. Retinal vasculitis was predictive for the development of multiple sclerosis in this cohort.",
"   </p>",
"   <p>",
"    Although most reports have found that retinal vasculitis in MS is limited to perivascular sheathing and vitreous cells, vascular occlusions, capillary closure, vitreous hemorrhage, and neovascularization can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/43\">",
"     43",
"    </a>",
"    ]. As a result, the possibility of serious retinal vascular disease in patients with multiple sclerosis, although rare, requires that these individuals should be periodically monitored for evidence of retinal involvement.",
"   </p>",
"   <p>",
"    Given the heterogeneity of the ocular involvement in MS and, hence, the required management strategies, we recommend that all newly diagnosed patients be evaluated ophthalmologically. In addition, periodic examination of the eye is recommended, particularly in those with a severe or progressive variant of the disease. In general, while systemic immunosuppression can be of some short-term benefit in patients with MS-associated ocular inflammation, there are few data demonstrating significant change in long-term outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INFECTIOUS CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identifying an infectious cause of retinal vasculitis is of critical importance since effective treatment may be available and since the incorrect administration of immunosuppressive therapy may be disastrous (",
"    <a class=\"graphic graphic_table graphicRef56959 \" href=\"UTD.htm?2/38/2669\">",
"     table 1",
"    </a>",
"    ). The most common cause of infectious retinal vasculitis is toxoplasmosis, followed by tuberculosis, syphilis, and herpes viral infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Toxoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasmosis accounts for as much as 25 percent of cases of posterior uveitis in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/44\">",
"     44",
"    </a>",
"    ]. The retina is the primary site of eye infection. Whereas, in immunocompromised patients, toxoplasmic involvement of the brain is more common than retinal toxoplasmosis, the reverse is true in immunocompetent individuals. Active lesions usually appear as white focal lesions with a severe vitreous inflammatory reaction (",
"    <a class=\"graphic graphic_picture graphicRef74181 \" href=\"UTD.htm?41/57/42910\">",
"     picture 7",
"    </a>",
"    ). Vitreoretinitis is a sine qua non of active ocular toxoplasmosis (",
"    <a class=\"graphic graphic_picture graphicRef62410 \" href=\"UTD.htm?24/10/24750\">",
"     picture 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The retinal vasculitis usually occurs near active lesions and can affect both venules and arterioles. The arteriolar involvement is often characterized by &ldquo;skip lesions,&rdquo; in which focal areas of vasculitis are flanked by apparently normal vessels (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64718 \" href=\"UTD.htm?38/26/39342\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Treatment for this condition may require a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    . Patients with severe vitreous inflammation may also benefit from the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    and prednisone therapy may also be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/45\">",
"     45",
"    </a>",
"    ]. To prevent severe pancytopenia, folinic acid is recommended in patients treated with pyrimethamine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although tuberculosis (TB) can affect any tissue in the eye and was once a frequent cause of retinal vasculitis, involvement of the eye is an uncommon manifestation of extrapulmonary tuberculosis, being seen in approximately 1 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Infection with this organism also represented less than 1 percent of all cases of uveitis in a United States cohort. However, tuberculosis should be strongly considered as a cause of unexplained uveitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=see_link\">",
"     \"Uveitis: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other than sophisticated molecular biological techniques, such as polymerase chain reaction, the diagnosis of ocular TB is based upon the clinical correlation of characteristic ocular lesions with systemic signs of disease activity (eg, positive PPD, chest x-rays, etc).",
"   </p>",
"   <p>",
"    Ocular manifestations of tuberculosis include eyelid disease, phlyctenulosis, interstitial keratitis, scleritis, uveitis, choroidal tubercles, choroiditis, and retinal vasculitis. The anterior uveitis is usually granulomatous with mutton-fat keratic precipitates, but it can be nongranulomatous [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retinal involvement is commonly an extension of choroidal disease, which usually results from miliary tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Retinal vasculitis is the most common manifestation of retinal tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/48\">",
"     48",
"    </a>",
"    ]. In one series of 12 patients with intraocular tuberculosis, nine had florid ischemic retinal vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/48\">",
"     48",
"    </a>",
"    ]. Retinal vasculitis may result in retinal vein occlusion and in subsequent neovascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of ocular disease is based upon the systemic therapy of TB. In addition, antiinflammatory therapy is used to suppress ocular inflammation once the patient has been placed on systemic antimycobacterial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired syphilis is caused by the spirochete Treponema pallidum and is almost exclusively transmitted by sexual contact. Two stages of disease are recognized, and these depend upon the duration of infection. Early syphilis (also referred to as primary, secondary, and early latent syphilis) refers to disease of one year or less. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    .) Late syphilis (or tertiary syphilis) refers to disease of more than one year&rsquo;s duration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of late syphilis\"",
"    </a>",
"    .) Co-infection with HIV may accelerate the progression of disease, allowing what are typically late manifestations to develop within months rather than years of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Late syphilis can manifest as a benign gumma, cardiovascular syphilis, or neurosyphilis. The last disorder may occur in 5 to 10 percent of untreated patients and may present with unilateral or bilateral cranial nerve palsies and with Argyll-Robertson pupil (a small pupil unreactive to light but reactive to accommodation).",
"   </p>",
"   <p>",
"    Ocular manifestations usually occur during early (secondary) and late syphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/53\">",
"     53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In early (secondary) syphilis, anterior segment findings include blepharitis, conjunctivitis, iritis, episcleritis, and scleritis. Posterior segment findings include chorioretinitis, vitritis, neuroretinitis, disc edema, retinal detachment, and retinal vasculitis.",
"     </li>",
"     <li>",
"      With late syphilis, anterior segment findings include unilateral interstitial keratitis, lens dislocation, episcleritis, scleritis, and uveitis. Posterior segment involvement includes chorioretinitis, venous and arteriolar occlusive disease, macular edema, vitritis, pseudoretinitis pigmentosa, and chorioretinal neovascularization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of syphilitic retinitis is focused upon the systemic therapy of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both herpes simplex and varicella-zoster may cause retinal vasculitis. Herpes simplex retinitis occurs in patients who are congenitally infected or immunosuppressed because of chemotherapy. White retinal infiltrates accompanied by a retinal vasculitis are a hallmark finding in this setting.",
"   </p>",
"   <p>",
"    Herpes simplex and varicella-zoster are also associated with acute retinal necrosis (ARN), a necrotizing retinitis that may occur in healthy immunocompetent individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/54\">",
"     54",
"    </a>",
"    ]. The retinal findings associated with ARN start as patchy white-yellow areas that become confluent over time (",
"    <a class=\"graphic graphic_picture graphicRef81368 \" href=\"UTD.htm?8/45/8926\">",
"     picture 9",
"    </a>",
"    ). Retinal vasculitis with this disorder typically affects the arterioles more than the veins [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cytomegalovirus retinitis commonly observed in association with HIV infection may also manifest with retinal vasculitis. This disorder is characterized by a slowly progressive necrotizing retinitis of the posterior pole. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Appropriate treatment of these disorders requires the accurate identification of an underlying viral etiology. If there are adequate extraocular or systemic data to suggest a specific viral pathogen, a vitreous biopsy and the use of PCR may be indicated to identify the specific virus responsible for the vitreoretinal pathology.",
"   </p>",
"   <p>",
"    The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    for herpetic infections and of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    for cytomegalovirus is of some benefit in the treatment of these infections and associated ocular manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/57\">",
"     57",
"    </a>",
"    ]. Appropriate management of these patients requires a close collaboration between the infectious disease and ophthalmology experts so as to tailor the dose and duration of therapy to the patient&rsquo;s response to the treatment regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Whipple's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whipple&rsquo;s disease is a multisystem infectious disorder characterized by weight loss, diarrhea, abdominal pain, and arthralgias [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/35/11833?source=see_link\">",
"     \"Whipple's disease\"",
"    </a>",
"    .) In a review of the ocular manifestations of Whipple&rsquo;s disease, involvement of the eye was commonly due to central nervous system damage, being manifested as nystagmus, ophthalmoplegia, and gaze palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33561/abstract/59\">",
"     59",
"    </a>",
"    ]. Keratitis, vitritis, uveitis, and retinal vasculitis in conjunction with abnormalities of the central nervous system were seen; intraocular involvement alone was rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/35/11833?source=see_link\">",
"     \"Whipple's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial treatment of central nervous system involvement in Whipple&rsquo;s disease consists of an intravenous agent that attains high cerebrospinal fluid levels and that is active against T. whippelii, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    administered intravenously (IV) for two weeks) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    IV for 10 to 14 days). This should be followed by one year of maintenance therapy with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (one double strength tablet twice daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    (400 mg by mouth twice daily). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/35/11833?source=see_link\">",
"     \"Whipple's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H366931\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The classic symptom of retinal vasculitis is a painless decrease in vision. Other symptoms may include a blind spot, floaters, metamorphopsia, and abnormalities in color vision. Retinal vasculitis can also be asymptomatic. Abnormalities in the retinal vessels may be observed upon physical examination; the fundoscopic findings include vascular sheathing and vitreous hemorrhage. The retinal vascular abnormalities are better demonstrated by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      angiography, with which one of the main changes is perivascular staining. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical characteristics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of retinal vasculitis is purely clinical and is made by fundus examination. Ancillary testing is more useful in delineating the extent and severity of the condition and in identifying or excluding potentially associated systemic morbidities. Once retinal vasculitis is diagnosed, a thorough history, review of systems, and physical examination should be performed to help narrow the differential diagnosis. Initial laboratory testing should include a complete blood count, urinalysis, sedimentation rate or C-reactive protein, antineutrophil cytoplasmic antibody (ANCA), antinuclear antibody (ANA), chest x-ray, and syphilis and HIV serologies. Additional testing depends upon the clinical assessment and upon the suspected underlying condition. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis and differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vasculitis of the retinal vessels may occur in association with a number of systemic diseases (",
"      <a class=\"graphic graphic_table graphicRef56959 \" href=\"UTD.htm?2/38/2669\">",
"       table 1",
"      </a>",
"      ), although the vast majority of cases of retinal vasculitis are not associated with classic systemic vasculitis syndromes and are manifestations of the local (ocular) inflammatory process. Systemic disorders associated with retinal vasculitis include Beh&ccedil;et&rsquo;s disease, systemic lupus erythematosus, various forms of systemic vasculitis, and others. One classification system for the retinal vasculitides associated with systemic disease is by the type and size of the involved retinal vessels (",
"      <a class=\"graphic graphic_table graphicRef55568 \" href=\"UTD.htm?16/59/17339\">",
"       table 2",
"      </a>",
"      ). Knowledge of the systemic and ocular features in these disorders can help differentiate between the various causes. Treatment is determined by the underlying disorder but usually involves administration of systemic immunosuppressive agents. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Systemic diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Identifying an infectious cause of retinal vasculitis is of critical importance since effective treatment may be available and since the incorrect administration of immunosuppressive therapy may be disastrous (",
"      <a class=\"graphic graphic_table graphicRef56959 \" href=\"UTD.htm?2/38/2669\">",
"       table 1",
"      </a>",
"      ). The most common cause of infectious retinal vasculitis is toxoplasmosis, followed by tuberculosis, syphilis, and herpes viral infections. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Infectious causes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/1\">",
"      Stanford MR, Graham EM. Systemic associations of retinal vasculitis. Int Ophthalmol Clin 1991; 31:23.",
"     </a>",
"    </li>",
"    <li>",
"     Nussenblatt R, Whitcup S, Palestine A. Retinal vasculitis. In: Uveitis, Nussenblatt R, Whitcup S, Palestine A (Eds), Mosby, St Louis 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/3\">",
"      Rosenbaum JT, Ku J, Ali A, et al. Patients with retinal vasculitis rarely suffer from systemic vasculitis. Semin Arthritis Rheum 2012; 41:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/4\">",
"      Mishima S, Masuda K, Izawa Y, et al. The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Beh&ccedil;et's disease in Japan: ophthalmologic aspects. Trans Am Ophthalmol Soc 1979; 77:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/5\">",
"      Mamo JG. The rate of visual loss in Beh&ccedil;et's disease. Arch Ophthalmol 1970; 84:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/6\">",
"      Sakamoto M, Akazawa K, Nishioka Y, et al. Prognostic factors of vision in patients with Beh&ccedil;et disease. Ophthalmology 1995; 102:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/7\">",
"      Benezra D, Cohen E. Treatment and visual prognosis in Beh&ccedil;et's disease. Br J Ophthalmol 1986; 70:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/8\">",
"      Huey C, Jakobiec FA, Iwamoto T, et al. Discoid lupus erythematosus of the eyelids. Ophthalmology 1983; 90:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/9\">",
"      Gold DH, Morris DA, Henkind P. Ocular findings in systemic lupus erythematosus. Br J Ophthalmol 1972; 56:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/10\">",
"      Dunn JP, Noorily SW, Petri M, et al. Antiphospholipid antibodies and retinal vascular disease. Lupus 1996; 5:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/11\">",
"      Lanham JG, Barrie T, Kohner EM, Hughes GR. SLE retinopathy: evaluation by fluorescein angiography. Ann Rheum Dis 1982; 41:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/12\">",
"      Stafford-Brady FJ, Urowitz MB, Gladman DD, Easterbrook M. Lupus retinopathy. Patterns, associations, and prognosis. Arthritis Rheum 1988; 31:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/13\">",
"      Hall S, Buettner H, Luthra HS. Occlusive retinal vascular disease in systemic lupus erythematosus. J Rheumatol 1984; 11:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/14\">",
"      Giorgi D, Pace F, Giorgi A, et al. Retinopathy in systemic lupus erythematosus: pathogenesis and approach to therapy. Hum Immunol 1999; 60:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/15\">",
"      Coppeto J, Lessell S. Retinopathy in systemic lupus erythematosus. Arch Ophthalmol 1977; 95:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/16\">",
"      Jabs DA, Fine SL, Hochberg MC, et al. Severe retinal vaso-occlusive disease in systemic lupus erythematous. Arch Ophthalmol 1986; 104:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/17\">",
"      Graham EM, Spalton DJ, Barnard RO, et al. Cerebral and retinal vascular changes in systemic lupus erythematosus. Ophthalmology 1985; 92:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/18\">",
"      WHITFIELD AG, BATEMAN M, COOKE WT. TEMPORAL ARTERITIS. Br J Ophthalmol 1963; 47:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/19\">",
"      Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/20\">",
"      Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/21\">",
"      Spalton DJ, Graham EM, Page NG, Sanders MD. Ocular changes in limited forms of Wegener's granulomatosis. Br J Ophthalmol 1981; 65:553.",
"     </a>",
"    </li>",
"    <li>",
"     Jabs D. Rheumatic disease. In: Retina, Ryan S (Ed), Mosby, St Louis 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/23\">",
"      ALARCON SEGOVIA D, BROWN AL Jr. CLASSIFICATION AND ETIOLOGIC ASPECTS OF NECROTIZING ANGIITIDES: AN ANALYTIC APPROACH TO A CONFUSED SUBJECT WITH A CRITICAL REVIEW OF THE EVIDENCE FOR HYPERSENSITIVITY IN POLYARTERITIS NODOSA. Mayo Clin Proc 1964; 39:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/24\">",
"      Morgan CM, Foster CS, D'Amico DJ, Gragoudas ES. Retinal vasculitis in polyarteritis nodosa. Retina 1986; 6:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/25\">",
"      Ebringer A, Baines M, Ptaszynska T. Spondyloarthritis, uveitis, HLA-B27 and Klebsiella. Immunol Rev 1985; 86:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/26\">",
"      Lee DA, Barker SM, Su WP, et al. The clinical diagnosis of Reiter's syndrome. Ophthalmic and nonophthalmic aspects. Ophthalmology 1986; 93:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/27\">",
"      Rodriguez A, Akova YA, Pedroza-Seres M, Foster CS. Posterior segment ocular manifestations in patients with HLA-B27-associated uveitis. Ophthalmology 1994; 101:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/28\">",
"      Rothova A, Buitenhuis HJ, Meenken C, et al. Uveitis and systemic disease. Br J Ophthalmol 1992; 76:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/29\">",
"      Mapstone R, Woodrow JC. HL-A 27 and acute anterior uveitis. Br J Ophthalmol 1975; 59:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/30\">",
"      McAdam LP, O'Hanlan MA, Bluestone R, Pearson CM. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore) 1976; 55:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/31\">",
"      Isaak BL, Liesegang TJ, Michet CJ Jr. Ocular and systemic findings in relapsing polychondritis. Ophthalmology 1986; 93:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/32\">",
"      Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976; 55:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/33\">",
"      Petrelli EA, McKinley M, Troncale FJ. Ocular manifestations of inflammatory bowel disease. Ann Ophthalmol 1982; 14:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/34\">",
"      Ruby AJ, Jampol LM. Crohn's disease and retinal vascular disease. Am J Ophthalmol 1990; 110:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/35\">",
"      Duker JS, Brown GC, Brooks L. Retinal vasculitis in Crohn's disease. Am J Ophthalmol 1987; 103:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/36\">",
"      Siltzbach LE, James DG, Neville E, et al. Course and prognosis of sarcoidosis around the world. Am J Med 1974; 57:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/37\">",
"      Jabs DA, Johns CJ. Ocular involvement in chronic sarcoidosis. Am J Ophthalmol 1986; 102:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/38\">",
"      Obenauf CD, Shaw HE, Sydnor CF, Klintworth GK. Sarcoidosis and its ophthalmic manifestations. Am J Ophthalmol 1978; 86:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/39\">",
"      Sanders MD, Graham EM. Retinal vasculitis. Postgrad Med J 1988; 64:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/40\">",
"      Sanders MD, Shilling JS. Retinal, choroidal, and optic disc involvement in sarcoidosis. Trans Ophthalmol Soc U K 1976; 96:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/41\">",
"      Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Prognosticators for visual outcome in sarcoid uveitis. Ophthalmology 1996; 103:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/42\">",
"      Lightman S, McDonald WI, Bird AC, et al. Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis. Brain 1987; 110 ( Pt 2):405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/43\">",
"      Graham EM, Francis DA, Sanders MD, Rudge P. Ocular inflammatory changes in established multiple sclerosis. J Neurol Neurosurg Psychiatry 1989; 52:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/44\">",
"      Henderly DE, Genstler AJ, Smith RE, Rao NA. Changing patterns of uveitis. Am J Ophthalmol 1987; 103:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/45\">",
"      Soheilian M, Sadoughi MM, Ghajarnia M, et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology 2005; 112:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/46\">",
"      Dutt AK, Moers D, Stead WW. Short-course chemotherapy for extrapulmonary tuberculosis. Nine years' experience. Ann Intern Med 1986; 104:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/47\">",
"      Donahue HC. Ophthalmologic experience in a tuberculosis sanatorium. Am J Ophthalmol 1967; 64:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/48\">",
"      Rosen PH, Spalton DJ, Graham EM. Intraocular tuberculosis. Eye (Lond) 1990; 4 ( Pt 3):486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/49\">",
"      Cangemi FE, Friedman AH, Josephberg R. Tuberculoma of the choroid. Ophthalmology 1980; 87:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/50\">",
"      ILLINGWORTH RS, WRIGHT T. Tubercles of the choroid. Br Med J 1948; 2:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/51\">",
"      Fountain JA, Werner RB. Tuberculous retinal vasculitis. Retina 1984; 4:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/52\">",
"      Psilas K, Aspiotis M, Petroutsos G, et al. Antituberculosis therapy in the treatment of peripheral uveitis. Ann Ophthalmol 1991; 23:254.",
"     </a>",
"    </li>",
"    <li>",
"     Whitcup S, Raizman M. Spirochetal infections and the eye. In: Principles and Practice of Ophthalmology, Alberts D, Jakobiec F (Eds), WB Saunders, 1994. p.3078.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/54\">",
"      Ludwig IH, Zegarra H, Zakov ZN. The acute retinal necrosis syndrome. Possible herpes simplex retinitis. Ophthalmology 1984; 91:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/55\">",
"      Fisher JP, Lewis ML, Blumenkranz M, et al. The acute retinal necrosis syndrome. Part 1: Clinical manifestations. Ophthalmology 1982; 89:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/56\">",
"      Culbertson WW, Blumenkranz MS, Pepose JS, et al. Varicella zoster virus is a cause of the acute retinal necrosis syndrome. Ophthalmology 1986; 93:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/57\">",
"      Henderly DE, Freeman WR, Causey DM, Rao NA. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology 1987; 94:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/58\">",
"      Clancy RL, Tomkins WA, Muckle TJ, et al. Isolation and characterization of an aetiological agent in Whipple's disease. Br Med J 1975; 3:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33561/abstract/59\">",
"      Avila MP, Jalkh AE, Feldman E, et al. Manifestations of Whipple's disease in the posterior segment of the eye. Arch Ophthalmol 1984; 102:384.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8232 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-15E18CE5C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_49_33561=[""].join("\n");
var outline_f32_49_33561=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H366931\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SYSTEMIC DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Beh&ccedil;et's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Giant cell arteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Granulomatosis with polyangiitis (Wegener's)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HLA-B27 associated conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Relapsing polychondritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INFECTIOUS CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Toxoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Viruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Whipple's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H366931\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/8232\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8232|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/33/7698\" title=\"diagnostic image 1\">",
"      Retinal vasculitis fluoroscein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/26/39342\" title=\"diagnostic image 2\">",
"      Retinal vasculitis in toxo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8232|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/0/44046\" title=\"picture 1\">",
"      Perivascular sheathing retina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/56/23424\" title=\"picture 2\">",
"      Perivascular staining retina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/7/11391\" title=\"picture 3\">",
"      Retinal ischemia in Behcets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/35/43582\" title=\"picture 4\">",
"      Retinal disease in SLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/23/368\" title=\"picture 5\">",
"      Retinal artery occlusion in SLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/48/25344\" title=\"picture 6\">",
"      Retinal periphlebitis sarcoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/57/42910\" title=\"picture 7\">",
"      Vitreous toxoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/10/24750\" title=\"picture 8\">",
"      Vitreous reaction in toxo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/45/8926\" title=\"picture 9\">",
"      Acute retinal necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8232|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/38/2669\" title=\"table 1\">",
"      Associations retinal vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/59/17339\" title=\"table 2\">",
"      Categories retinal vasculitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=related_link\">",
"      Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=related_link\">",
"      Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4856?source=related_link\">",
"      Diagnostic evaluation of relapsing polychondritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=related_link\">",
"      Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/80?source=related_link\">",
"      Episcleritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=related_link\">",
"      Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=related_link\">",
"      Pathogenesis of spondyloarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of late syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13590?source=related_link\">",
"      Retinal vasculitis associated with primary ocular disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28119?source=related_link\">",
"      Treatment and prognosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33498?source=related_link\">",
"      Treatment of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34217?source=related_link\">",
"      Treatment of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15673?source=related_link\">",
"      Treatment of relapsing polychondritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=related_link\">",
"      Uveitis: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/35/11833?source=related_link\">",
"      Whipple's disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_49_33562="Stress urinary incontinence in women: Retropubic midurethral slings";
var content_f32_49_33562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Stress urinary incontinence in women: Retropubic midurethral slings",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/49/33562/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/49/33562/contributors\">",
"     Charles W Nager, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/49/33562/contributors\">",
"     Jasmine Tan-Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/49/33562/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/49/33562/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/49/33562/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/49/33562/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/49/33562/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25744271\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress urinary incontinence (SUI) affects 4 to 35 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. SUI occurs when an increase in intraabdominal pressure exceeds urethral closure pressure, resulting in the involuntary leakage of urine. This may occur with exertion, sneezing, or coughing [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management options for SUI include conservative and surgical treatments. Midurethral sling placement has replaced other procedures (eg, retropubic colposuspension, bladder neck slings) as the procedure of choice for many women [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/4\">",
"     4",
"    </a>",
"    ]. The tension-free vaginal tape (TVT), introduced by Ulmsten in 1996, was the first synthetic retropubic midurethral sling [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/5\">",
"     5",
"    </a>",
"    ]. Since that time, variations of retropubic midurethral slings as well as midurethral transobturator slings have been introduced.",
"   </p>",
"   <p>",
"    Retropubic midurethral sling procedures are reviewed here. Transobturator midurethral slings and the approach to choosing a procedure for SUI in women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33401?source=see_link\">",
"     \"Stress urinary incontinence in women: Transobturator midurethral slings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16055?source=see_link\">",
"     \"Stress urinary incontinence in women: Choosing a type of midurethral sling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1168793\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several types of sling procedures for treatment of SUI in women. These procedures vary by the location of the sling and by the sling material. Collectively, these slings are referred to as suburethral slings, which is a sling that is inserted through a small vaginal incision and attached to another structure in the pelvis for the purpose of supporting the urethra. Suburethral slings may be either bladder neck or midurethral slings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Midurethral sling",
"      </strong>",
"      &ndash; A suburethral sling that is placed at the level of the midurethra in a tension-free manner. These slings are made of synthetic mesh.",
"     </li>",
"     <li>",
"      <strong>",
"       Retropubic midurethral slings",
"      </strong>",
"      (eg, tension-free vaginal tape [TVT], TVT Exact) are inserted through the retropubic space and exit through the abdominal wall in the suprapubic area (",
"      <a class=\"graphic graphic_figure graphicRef59114 \" href=\"UTD.htm?31/0/31744\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Transobturator midurethral slings",
"      </strong>",
"      are inserted through the two obturator foramens and exit through the skin of the groin area (",
"      <a class=\"graphic graphic_figure graphicRef52240 \" href=\"UTD.htm?31/43/32432\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Single incision midurethral slings",
"      </strong>",
"      (eg, TVT SECUR, MiniArc) differ from full-length retropubic and transobturator slings in two ways: they are shorter (approximately 8 cm rather than 40 cm) and they require only a vaginal incision, and not an abdominal incision. Different types of these slings may be placed in a retropubic (anchored to the urogenital diaphragm) or transobturator fashion (anchored to the obturator internus muscle).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Bladder neck sling",
"      </strong>",
"      &ndash; A suburethral sling that is placed at the level of the proximal urethra and bladder neck (",
"      <a class=\"graphic graphic_figure graphicRef76965 \" href=\"UTD.htm?15/42/16034\">",
"       figure 3",
"      </a>",
"      ). This procedure is usually performed using both vaginal and abdominal incisions. These slings can be made of either biologic materials (including the patient's own tissue) or synthetic mesh.",
"      <br/>",
"      <br/>",
"      Bladder neck slings are also referred to as proximal urethral slings. Alternatively, they are referred to as pubovaginal slings when the arms of the sling material are affixed to the anterior rectus fascia rather than the pubic bone or Cooper's ligament [",
"      <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2819310\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Midurethral sling placement involves the introduction of a polypropylene tape (approximately 1 cm in width) covered in a plastic sheath beneath the midportion of the urethra. This sling functions as a backboard that offers resistance beneath the urethra during increases in intraabdominal pressure, but is tension-free at rest. Ultrasound data suggest that continence is achieved by compression of the urethra between the sling and the pubic symphysis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For retropubic midurethral slings, the tails of the mesh pass through the retropubic space, rectus sheath, subcutaneous tissue and skin (",
"    <a class=\"graphic graphic_figure graphicRef59114 \" href=\"UTD.htm?31/0/31744\">",
"     figure 1",
"    </a>",
"    ). Once the plastic sheaths are removed, the tape is held in place by its interface with the patient&rsquo;s tissue; it is not held in place by sutures. The friction that initially secures the mesh is eventually reinforced with tissue fibrosis develops around and through the mesh. Porcine models demonstrate that 74 percent of the final strength has already been achieved by two weeks postoperatively and maximum strength of tissue in-growth into polypropylene mesh occurs at three months [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25744285\">",
"    <span class=\"h1\">",
"     SURGICAL CANDIDATES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3791434\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for midurethral sling placement are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic SUI",
"     </li>",
"     <li>",
"      Women who are planning repair of prolapse of the vaginal apex and who have known or suspected occult SUI",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptomatic SUI may be treated with a conservative (pelvic floor muscle training, incontinence pessaries) or a surgical approach. Candidates for surgical treatment are women with SUI who decline or have failed conservative treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link&amp;anchor=H3#H3\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\", section on 'Candidates for surgical treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Advanced pelvic organ prolapse and SUI commonly co-exist; however, in many women, the SUI becomes apparent only when the prolapse has been corrected. This phenomenon is known as occult SUI and, unfortunately, is not reliably predicted by preoperative urodynamic testing with prolapse reduction. Concomitant anti-incontinence surgery should be offered to women who are undergoing repair for advanced pelvic organ prolapse. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1546?source=see_link&amp;anchor=H15#H15\">",
"     \"Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment\", section on 'POP with no symptoms of SUI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3793143\">",
"    <span class=\"h3\">",
"     Special considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluating whether a woman with SUI is an appropriate candidate for surgical treatment, and a midurethral sling in particular, may depend upon additional factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary function issues (eg, intrinsic sphincter deficiency, lack of urethral hypermobility, mixed incontinence)",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Age",
"     </li>",
"     <li>",
"      Concomitant procedures",
"     </li>",
"     <li>",
"      Previous anti-incontinence surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice of anti-incontinence surgery in women with additional urinary function issues, obesity, or advanced age is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link&amp;anchor=H23#H23\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\", section on 'Urinary function issues'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link&amp;anchor=H26#H26\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\", section on 'Other patient characteristics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many women undergo anti-incontinence surgery concomitantly with other procedures (eg, pelvic organ prolapse repair, hysterectomy). Most data suggest that concomitant surgery does not decrease midurethral sling success rates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1546?source=see_link&amp;anchor=H502447#H502447\">",
"     \"Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment\", section on 'Concomitant versus staged procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many cases of failed previous stress incontinence surgery can be effectively treated with retropubic midurethral sling. Documented cure rates of 70 to 90 percent for the TVT as a secondary procedure have been shown with one to five years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44409?source=see_link&amp;anchor=H19#H19\">",
"     \"Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment\", section on 'Midurethral sling'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299273\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to midurethral retropubic sling placement include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Current urinary tract infection",
"     </li>",
"     <li>",
"      Current pregnancy",
"     </li>",
"     <li>",
"      Anticoagulation",
"     </li>",
"     <li>",
"      Structures in the retropubic space that are in the path of sling placement (eg, vascular graft, bowel, transplanted pelvic kidney)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Current pregnancy is an absolute contraindication to midurethral sling placement. Plans for future pregnancy are a relative contraindication. Since pelvic support may be disrupted during pregnancy, and particularly following a vaginal birth, most physicians recommend delaying surgical management of SUI until childbearing has been completed. (See",
"    <a class=\"local\" href=\"#H298966\">",
"     'Subsequent pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The procedure is contraindicated in patients who are anticoagulated. Midurethral sling placement involves passing trocars through several tissue layers and may result in hematoma formation or hemorrhage. The risk of hematoma formation is probably more with retropubic approaches than with transobturator approaches, so women with bleeding diatheses (eg, Von Willebrand&rsquo;s) may be better served with administration of preoperative control measures (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    ) and a transobturator approach.",
"   </p>",
"   <p>",
"    Certain conditions or previous retropubic surgery may predispose to complications during sling placement. Previous retropubic surgery may have resulted in the presence of bowel in the retropubic space or an inguinal or abdominal hernia sac may be located along the pathway of trocar placement [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/14\">",
"     14",
"    </a>",
"    ]. Likewise, a transplanted kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] or femoral crossover graft may be in the insertion path of the sling.",
"   </p>",
"   <p>",
"    For women in whom there are concerns that the retropubic space could contain bowel or other structures (eg, a vascular graft, transplanted kidney, inguinal hernia) based upon previous operative procedures or findings, or imaging studies, we suggest a transobturator approach. The retropubic and transobturator approaches have been shown to have comparable efficacy in randomized trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16055?source=see_link&amp;anchor=H2822326#H2822326\">",
"     \"Stress urinary incontinence in women: Choosing a type of midurethral sling\", section on 'Transobturator versus retropubic midurethral slings'",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Some physicians will choose a transobturator route to avoid a scarred retropubic space in women who have had a previous Burch colposuspension, pubovaginal sling procedure, or midurethral sling, but a prior history of any of these procedures is not a contraindication to placement of a midurethral sling [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/10\">",
"     10",
"    </a>",
"    ]. Treatment of recurrent SUI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44409?source=see_link&amp;anchor=H19#H19\">",
"     \"Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment\", section on 'Midurethral sling'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2819431\">",
"    <span class=\"h1\">",
"     CHOOSING A TYPE OF RETROPUBIC SLING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two main variations of full-length retropubic midurethral slings, based upon the initial incision site and direction of insertion: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bottom-to-top &ndash; Two needle trocars are inserted through a vaginal incision and passed through the retropubic space, exiting at the abdominal wall (eg, TVT, TVT-Exact).",
"     </li>",
"     <li>",
"      Top-to-bottom &ndash; Two needle trocars are inserted through abdominal incisions and passed through the retropubic space, exiting through a vaginal incision (eg, SPARC).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other variations to the needle and sling delivery system have been developed (eg, less total mesh content), but are not addressed here. The TVT-Exact is a variation of the standard TVT with a smaller diameter trocar.",
"   </p>",
"   <p>",
"    The bottom-to-top approach appears to be superior. A meta-analysis of five randomized trials compared bottom-to-top (TVT) and top-to-bottom (SPARC) procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/17\">",
"     17",
"    </a>",
"    ]. The TVT was slightly more effective; at up to one-year follow-up, the TVT group had higher subjective cure rates (85 versus 77 percent; RR 1.10, 95% CI 1.01-1.20) and objective cure rates (92 versus 87 percent; RR 1.06, 95% CI 1.01-1.11). In addition, complications occurred less frequently in the TVT group, including: bladder perforation (4.7 versus 8.5 percent; RR 0.55, 95% CI 0.31-0.98); vaginal mesh erosion (0.7 versus 3.5 percent; RR 0.27, 95% CI 0.08-0.95); and voiding dysfunction (2.2 versus 6.0 percent; RR 0.40, 95% CI 0.18-0.90). Some surgeons feel more comfortable with top-to-bottom insertion, because they are familiar with this approach for needle suspension procedures. However, given these data, we suggest use of the bottom-to-top approach.",
"   </p>",
"   <p>",
"    Choosing between retropubic, transobturator, and single incision midurethral slings is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16055?source=see_link\">",
"     \"Stress urinary incontinence in women: Choosing a type of midurethral sling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H297922\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION AND PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H298913\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for symptomatic SUI should be reviewed with the patient. Surgeons should discuss the efficacy of the procedure, the placement of permanent mesh, and the risk of complications (eg, voiding dysfunction). Patients should be counseled that midurethral sling placement is not intended to treat urinary urgency, frequency, or nocturia, and that resolution of these symptoms should not be expected [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25744489\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For women with known or suspected occult SUI, the option of a staged or concomitant procedure and the potential for unnecessary surgery should be discussed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1546?source=see_link&amp;anchor=H502447#H502447\">",
"     \"Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment\", section on 'Concomitant versus staged procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This discussion should be documented on the surgical consent form and in the medical record.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H297972\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are planning midurethral retropubic sling placement should undergo preoperative evaluation to confirm the diagnosis of SUI, exclude other etiologies of urinary incontinence, confirm normal bladder emptying, and assess surgical risk.",
"   </p>",
"   <p>",
"    Components of this evaluation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical and voiding history",
"     </li>",
"     <li>",
"      Pelvic examination",
"     </li>",
"     <li>",
"      Office urinary function testing to demonstrate stress leakage and normal bladder emptying (eg, urinary stress test, postvoid residual volume)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Current evidence does not require urodynamic testing in all women prior to surgery. We suggest that preoperative urodynamics be performed only in women with complicated SUI (eg, previous anti-incontinence surgery, neurogenic lower urinary tract dysfunction, or suspicion of a non-stress etiology of urinary incontinence) or when stress leakage cannot be demonstrated or when symptoms are not consistent with physical examination findings.",
"   </p>",
"   <p>",
"    Preoperative evaluation of women with SUI is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/58/17319?source=see_link\">",
"     \"Stress urinary incontinence in women: Preoperative evaluation for a primary procedure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H297929\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend antibiotic prophylaxis for surgical site infection for procedures for treatment of pelvic organ prolapse or stress urinary incontinence that utilize surgical mesh, such as midurethral sling placement. Infectious complications of such procedures include infections associated with the surgical mesh (eg, abscess, cellulitis) and urinary tract infections, particularly for procedures that involve periurethral dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/21-26\">",
"     21-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our recommendation is in concert with professional society guidelines. American College of Obstetricians and Gynecologists guidelines advise antibiotic prophylaxis for surgical site infection for urogynecologic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/27\">",
"     27",
"    </a>",
"    ]. American Urological Association guidelines also advise use of antibiotic prophylaxis for all patients undergoing open or laparoscopic procedures involving an implanted prosthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/28\">",
"     28",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Use of surgical mesh does not affect the need for antibiotic prophylaxis of bacterial endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link&amp;anchor=H22969468#H22969468\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\", section on 'Guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H297936\">",
"    <span class=\"h2\">",
"     Thromboprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Midurethral sling placement is minor surgery (defined as &lt;30 minutes) and is typically performed in mobile patients. Thus, those patients who have no additional thrombotic risk factors are classified as low risk for venous thromboembolism and do not require specific thromboprophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=see_link&amp;anchor=H17332175#H17332175\">",
"     \"Overview of preoperative evaluation and preparation for gynecologic surgery\", section on 'Thromboprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25744362\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this section, we will describe our technique for inserting the TVT device, based upon the original technique described in 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/5,29\">",
"     5,29",
"    </a>",
"    ]. The mean operative time for this procedure is 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/30\">",
"     30",
"    </a>",
"    ]. A video of the procedure is included (",
"    <a class=\"graphic graphic_movie graphicRef67708 \" href=\"UTD.htm?29/32/30208\">",
"     movie 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2816425\">",
"    <span class=\"h2\">",
"     Operative setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Midurethral sling placement is typically performed in an operating room as an outpatient procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H579368\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Midurethral sling placement may be performed under local, regional, or general anesthesia. Many surgeons combine local anesthesia with conscious sedation.",
"   </p>",
"   <p>",
"    The TVT procedure was initially described using local anesthesia with conscious sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/5\">",
"     5",
"    </a>",
"    ]. The rationale for this approach is that a patient who is awake and has no abdominal muscle blockade can perform a urinary stress (cough) test, allowing sling tension to be adjusted if leakage of urine is noted [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/31\">",
"     31",
"    </a>",
"    ]. The urinary stress test is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of regional anesthesia alters the results of the urinary stress test, but does not appear to affect sling success rates. When the urinary stress test is performed under regional anesthesia, less intraabdominal pressure is generated by the cough, but urethral resistance is lower (increasing the tendency to leak urine) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. These conditions differ from normal function, and thus, it is uncertain whether it is valid to adjust the sling tension based upon these results. In contrast, periurethral infiltration of local anesthetic does not appear to alter urethral function [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice, we do not routinely perform a urinary stress test, regardless of type of anesthesia, since there is no evidence that the results of the test impact outcome. &nbsp;",
"   </p>",
"   <p>",
"    The efficacy of sling placement under regional anesthesia was demonstrated in a randomized trial comparing spinal and local anesthesia in 103 women undergoing a TVT procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/32\">",
"     32",
"    </a>",
"    ]. At 13-month follow-up, the spinal and local anesthesia groups showed no significant differences in subjective SUI cure rates (97 versus 94 percent) and postoperative urinary retention (14 versus 12 percent). Patient comfort level during the procedure was not assessed in this study.",
"   </p>",
"   <p>",
"    Use of general anesthesia may be associated with detrimental effects on midurethral sling outcomes. The best available data comparing midurethral sling placement under local or regional anesthesia with general anesthesia are from two large prospective cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In one study (n = 809), at two-year follow-up, a lower subjective SUI cure rate was associated with general anesthesia compared with local anesthesia (68 versus 81 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/36\">",
"     36",
"    </a>",
"    ]. In another study (n = 500), the rate of postoperative voiding dysfunction was significantly higher in women who received general anesthesia (17 versus 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these data, we suggest use of local anesthesia with conscious sedation or regional anesthesia rather than general anesthesia for midurethral sling placement, when it is being performed as an isolated procedure. General anesthesia may be used if it is preferred by the patient or if it is required for a concomitant procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299003\">",
"    <span class=\"h2\">",
"     Instrumentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TVT system consists of a non-disposable metal handle to which two metal needles and sling can be attached. The sling is 40 cm long, 1 cm wide covered by a plastic sheath and the outer diameter of the trocar is 5 to 6 mm.",
"   </p>",
"   <p>",
"    Additional surgical equipment includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bladder (Foley) catheter (size 18 French)",
"     </li>",
"     <li>",
"      Rigid catheter guide",
"     </li>",
"     <li>",
"      Cystoscope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of size 18 French will allow the rigid catheter guide to be introduced. This catheter guide is used to deviate the bladder away from the side of trocar placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299019\">",
"    <span class=\"h2\">",
"     Sling placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placement of a bottom-to-top full-length retropubic midurethral sling is performed as follows:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4700151\">",
"    <span class=\"h3\">",
"     Patient preparation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Patient set-up",
"      </strong>",
"      &ndash; Position the patient in dorsal lithotomy with careful attention to avoid nerve compression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=see_link\">",
"       \"Nerve injury associated with pelvic surgery\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=see_link&amp;anchor=H21#H21\">",
"       \"Nerve injury associated with pelvic surgery\", section on 'Prevention of nerve injury'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Sterilely prepare and drape the patient. Insert the bladder catheter. The bladder should be completely drained prior to dissection and again prior to placement of the catheter guide.",
"     </li>",
"     <li>",
"      <strong>",
"       Marking abdominal incisions",
"      </strong>",
"      &ndash; Mark the two planned abdominal exit points for the tape at the superior margin of the pubic bone, 2 cm lateral to the midline. Some surgeons make small stab incisions at these locations to facilitate trocar passage through the skin.",
"     </li>",
"     <li>",
"      <strong>",
"       Hydrodissection",
"      </strong>",
"      &ndash; Some surgeons hydrodissect the vaginal incision site",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the path of the trocars. Either local anesthetic (with or without epinephrine) or sterile saline may be used. In the original description of the procedure, 40 ml of fluid was injected into the vaginal wall inferior and lateral to the urethra [",
"      <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/5\">",
"       5",
"      </a>",
"      ]. An additional 60 to 70 mL of fluid was injected at the planned abdominal incision sites and downward along the back of the pubic bone to the retropubic space. Alternatively, fluid may be injected into the retropubic space through the vaginal sulci. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Midurethral vaginal incision",
"      </strong>",
"      &ndash; Make a vertical (longitudinal) vaginal incision, starting 1 cm proximal to the urethral meatus and 1 to 1.5 cm in length to accommodate the width of the sling in the appropriate location. Place Allis clamps on the lateral edges of the incision to provide exposure by retracting the vaginal mucosa laterally.",
"      <br/>",
"      <br/>",
"      Minimal dissection lateral to the midurethra, between the vaginal mucosa and the pubocervical fascia, is performed bilaterally with the Metzenbaum scissors. The scissors are angled towards the retropubic space just behind the pubic symphysis.",
"     </li>",
"     <li>",
"      <strong>",
"       Lateral deviation of the bladder",
"      </strong>",
"      &ndash; Drain the bladder completely and introduce the rigid catheter guide into the bladder catheter. Deviate the bladder to the side opposite of the first trocar insertion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4700179\">",
"    <span class=\"h3\">",
"     Initial trocar insertion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insertion of the trocar along the correct path is the critical part of the procedure to ensure that the procedure is effective and to avoid complications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       General insertion procedure",
"      </strong>",
"      &ndash; Insert the first trocar into the tract lateral to the urethra that was dissected out with Metzenbaum scissors. Pass the trocar behind the pubic symphysis (through the retropubic space) and exit through the abdominal incision sites. The trocar is left in place with the tip just past the level of the abdominal skin.",
"     </li>",
"     <li>",
"      <strong>",
"       Techniques to prevent complications",
"      </strong>",
"      &ndash; The trocars must be passed along the correct path without deviation to avoid complications. Small deviations of the trocar handle create a magnified deviation of the tip of the trocar, resulting in potential injury to adjacent structures.",
"      <br/>",
"      <br/>",
"      Deviation of the trocar in a cephalad direction may result in injury to bowel, bladder, or blood vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/37\">",
"       37",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Deviation of the trocar lateral to the posterior surface of the pubic symphysis may cause serious vascular injury. Major vessels (eg, external iliac vessel, obturator vessels, epigastric vessels) may be located as close as 0.9 cm from the correct path of the trocars and the mean distance from the trocar to the major vessels is 3.2 to 4.9 cm (range 0.9 to 6.6 cm) (",
"      <a class=\"graphic graphic_figure graphicRef70874 \" href=\"UTD.htm?23/26/23971\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/37\">",
"       37",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Techniques for successful placement include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The operator must maintain a firm grasp of the trocar and handle while manipulating the needle through the tissues. Resistance of the tissues may sometimes result in deviation of the needle. Some surgeons use a hand in the vagina to control and direct the trocar while the opposite hand on the handle is used to apply gentle force to advance the trocar.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Care should be taken to aim the trocar handle in the direction of the outer aspect of the patient&rsquo;s ipsilateral shoulder [",
"      <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The tip of the trocar should be positioned just behind the pubic symphysis. It is often helpful to actually place the tip of the trocar on the underside of the pubic symphysis and to gently slide it behind the bone, staying as close to the bone as possible. To do this, the surgeon must lower the hand that is holding the trocar handle so that the curve of the insertion needle follows the posterior surface of the pubic bone through the retropubic space. The trocar should pass easily in the retropubic space in direct opposition to the posterior side of the symphysis. More force is needed when the trocar passes through the rectus sheath and then out through the skin at the suprapubic level.",
"     </li>",
"     <li>",
"      The trocar handle must be kept parallel to the floor during retropubic passage to prevent the lateral rotation of the trocar tip.",
"     </li>",
"     <li>",
"      After insertion, the anterior vaginal sulci are inspected and palpated to ensure that they have not been perforated by the trocar. If there is a perforation, then the trocar or the plastic sheaths with the mesh can be seen traversing the vaginal sulcus. The first sign of a vaginal perforation is often the onset of vaginal bleeding that does not appear to be coming from the midurethral vaginal incision. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4700435\">",
"    <span class=\"h3\">",
"     Cystourethroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;After each trocar is placed, perform cystourethroscopy to inspect for bladder perforation. A 70 degree cystoscope should be used and the bladder filled adequately to allow complete examination of the urethra and bladder surface [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/5\">",
"     5",
"    </a>",
"    ]. Examination of the bladder requires an experienced clinician; a study of surgical trainees reported that 37 percent of bladder injuries were missed on cystourethroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    &nbsp;(2.5 mL of a 0.8 percent solution) may be used to check for ureteric flow if ureteral injury is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2451122\">",
"    <span class=\"h3\">",
"     Completing the trocar insertion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next step in the procedure depends upon the findings of cystourethroscopy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If there is no bladder injury, the bladder catheter and rigid catheter guide are replaced. The rigid catheter guide is deviated to the other side and the contralateral trocar is inserted using the same procedure.",
"     </li>",
"     <li>",
"      If a bladder perforation has occurred, the trocar should be withdrawn and the bladder emptied completely. The trocar can then be replaced while hugging the posterior surface of the pubic bone. Cystourethroscopy is repeated. This can usually be accomplished even in the presence of a bladder perforation, since the defects at the perforation sites result in only a minimal amount of fluid loss. If there is no further bladder injury, the rigid catheter guide is deviated to the other side and the contralateral trocar is inserted using the same procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When both trocars have been inserted and cystourethroscopy is complete, the trocar handles are removed. The remaining portions of both trocars and the mesh are then passed through the skin. The plastic sheaths are left in place and the mesh is left slack at the midurethra to allow the tension to be adjusted. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4700493\">",
"    <span class=\"h3\">",
"     Adjusting sling tension",
"    </span>",
"    &nbsp;&mdash;&nbsp;To ensure that the sling is tension-free and does not compress the urethra while the patient is at rest, many surgeons insert an instrument (eg, Kelly clamp, needle holder, or number 8 Hegar dilator) between the sling and the urethra while adjusting the sling tension.",
"    <br/>",
"    <br/>",
"    An intraoperative urinary (cough) stress test may be performed at this time if the patient is under local anesthesia. If leakage occurs, the sling is tightened slightly. In our practice, we do not routinely perform a urinary stress test, regardless of type of anesthesia, since there is no evidence that the results of the test impact outcome. (See",
"    <a class=\"local\" href=\"#H579368\">",
"     'Anesthesia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <br/>",
"    With the spacer in place, remove the plastic sheaths; this prevents excess tightening of the mesh during plastic sheath removal. The surgeon should assess the entire plastic sheath to confirm that it has been completely removed.",
"    <br/>",
"    <br/>",
"    Trim the mesh at the abdominal incisions. Mesh protrusion and irritation at the skin surface can be prevented by depressing the skin slightly to trim the mesh just below the skin surface. The mesh does not require suturing, since it is held in by friction and then fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4700982\">",
"    <span class=\"h3\">",
"     Closure of incisions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Vaginal incision",
"      </strong>",
"      &ndash; At our institution, we close the vaginal mucosa with a horizontal mattress configuration to evert the edge away from the mesh using an absorbable suture [",
"      <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Suprapubic skin incisions",
"      </strong>",
"      &ndash; This can be performed in a variety of ways (suture, adhesive strips, surgical glue, no closure), based upon surgeon preference.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22194879\">",
"    <span class=\"h2\">",
"     Postoperative voiding trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A voiding trial is performed prior to patient discharge or four to six hours after surgery, if an inpatient admission is planned. A voiding trial can be performed in two different ways: retrograde or spontaneous filling of the bladder.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retrograde bladder filling &ndash; The bladder catheter is left in place at the end of the procedure. Once the patient has completely recovered from anesthesia, the bladder is completely drained through the catheter. The bladder catheter can then be attached to a catheter-tipped syringe with the piston removed or an irrigation syringe. Using only gravity to fill, 300 ml of sterile normal saline or water at room temperature is instilled into the bladder. The catheter is then removed, and the patient is asked to void in a toilet hat or measured container. The postvoid residual volume is calculated (by subtracting the voided volume from the volume instilled). Although there is no consensus on a residual that implies a low rate of subsequent urinary retention, we consider a successful voiding trial to be a postvoid residual that is &lt;150 mL or less than half the filled amount.",
"     </li>",
"     <li>",
"      Spontaneous bladder filling &ndash; The bladder catheter is removed at the end of the procedure. Once the patient has completely recovered from anesthesia and feels that her bladder is full, she is asked to void. The voided volume is collected and measured and the postvoid residual volume is measured either using a bladder ultrasound or a bladder catheter. A successful voiding trial can be defined as a postvoid residual of &lt;150 ml.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is uncertain which approach to bladder filling is superior. This question has been evaluated in two randomized trials of women who underwent transvaginal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In one trial, the proportion of women who failed the voiding test and were discharged home with a bladder catheter was significantly lower in the retrograde group (32 versus 62 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/41\">",
"     41",
"    </a>",
"    ], while in the other trial, the failure rates were the same for both groups (65 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/40\">",
"     40",
"    </a>",
"    ]. The different findings may reflect the different methodology of the two trials; in one, the voiding trial was performed within hours of the end of the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/41\">",
"     41",
"    </a>",
"    ] and, in the other, two voiding trials were performed on the first postoperative day [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/40\">",
"     40",
"    </a>",
"    ]. In addition, the applicability of these results to midurethral sling placement is somewhat limited, since many participants in both trials (55 to 60 percent) underwent procedures other than sling placement.",
"   </p>",
"   <p>",
"    If a patient fails her voiding trial, she can either go home with an indwelling bladder catheter or she can be taught intermittent self catheterization. Management of women with postoperative voiding dysfunction is described below. (See",
"    <a class=\"local\" href=\"#H22194935\">",
"     'Postoperative catheter management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25744489\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retropubic midurethral sling placement is a minimally invasive procedure and complications are uncommon. The most frequent complications of this procedure are bladder perforation, voiding dysfunction, and development of urinary urgency symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4701067\">",
"    <span class=\"h2\">",
"     Urinary tract complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4700528\">",
"    <span class=\"h3\">",
"     Bladder injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative bladder perforation is the most common complication of retropubic midurethral sling placement. In studies of 200 or more procedures, the reported rate ranges between 3.5 to 6.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/42-46\">",
"     42-46",
"    </a>",
"    ]. Bladder perforation does not appear to be associated with reduced SUI cure rates or with long-term sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of bladder perforation depends upon the surgeon&rsquo;s experience. A report of 600 procedures performed by an experienced surgeon had a 1 percent rate of bladder perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/47\">",
"     47",
"    </a>",
"    ], while inexperienced operators have reported rates ranging from 15 to 34 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/38,48\">",
"     38,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bladder perforation is usually diagnosed with intraoperative cystoscopy. Leaving the trocar in place prior to cystourethroscopy facilitates identification of this type of injury. Bladder management after perforation depends upon the site and extent of perforation. Bladder perforations in the posterior bladder closer to the vaginal incision are theoretically at a higher risk of fistula formation than anterior perforations near the dome of the bladder. Management varies, but surgeons typically continuously drain the bladder with a urethral catheter in place for one to several days [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/38\">",
"     38",
"    </a>",
"    ]. In our practice, after the more common anterior perforation, we leave the bladder catheter in place for three days and typically remove the catheter without an imaging study. A posterior perforation near the trigone and near the vaginal incision is more concerning; we drain the bladder for at least seven days and perform a cystogram to exclude extravasation before discontinuing the bladder drainage. (See",
"    <a class=\"local\" href=\"#H4700179\">",
"     'Initial trocar insertion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    It is important to recognize bladder and urethral perforations at the time of the initial procedure because delayed recognition is associated with significantly more morbidity. Occult bladder injury should be suspected if fluid leaks persistently from the vagina or the abdominal incision sites [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/49\">",
"     49",
"    </a>",
"    ]. Unrecognized injuries appear to occur more frequently in women with prior retropubic surgery. In women in whom bladder perforation is recognized after the mesh has been passed, we remove all of the sling material from the bladder. This may be performed using laparotomy, cystoscopy, or cystoscopy assisted by suprapubic laparoscopic instruments.",
"   </p>",
"   <p>",
"    Another mechanism of bladder injury is erosion of the mesh through the bladder wall; this complication is uncommon and the incidence is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Some reported cases of mesh erosion may have been bladder perforations that were not recognized at the time of surgery. Others may represent a true erosion of mesh that slowly extrudes through the tissue over time.",
"   </p>",
"   <p>",
"    Vesical erosion typically presents several weeks to months postoperatively as urinary urgency, hematuria, or bladder stones [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. This condition is diagnosed with cystoscopy. There are a variety of management options, including: cystoscopic resection using laser or scissors, cystoscopic-guided suprapubic laparoscopic resection, and suprapubic telescopy (cystoscopy through a suprapubic incision) with suprapubic or transurethral instrumentation. Depending upon the severity of the erosion and whether a fistula is present, sometimes a complete transvaginal or transabdominal reconstructive procedure is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4701082\">",
"    <span class=\"h3\">",
"     Urethral injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative urethral perforation or laceration occurs in approximately 0.9 percent of midurethral retropubic sling placements [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/54\">",
"     54",
"    </a>",
"    ]. This type of complication may be diagnosed during cystourethroscopy. When recognized immediately, in our practice, we do not complete the procedure, since we consider this a high risk situation for urethral mesh erosion. We then leave a urethral catheter in place for seven days. The midurethral sling may be performed at a later time after urethral healing.",
"   </p>",
"   <p>",
"    Rarely, urethral injury is not recognized immediately or injury occurs postoperatively due to mesh erosion [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. These injuries often present several weeks or months postoperatively with periurethral discomfort, hematuria, voiding difficulty, or irritative voiding symptoms. Urodynamic evaluation may reveal evidence of outflow obstruction. Management includes excision of the eroded portion of the mesh and urethroplasty with the use of local flaps where necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4701170\">",
"    <span class=\"h3\">",
"     Urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract infection is a common complication after midurethral sling placement. Urinary tract infections have been reported in up to 34 percent of patients within the first three postoperative months [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/59\">",
"     59",
"    </a>",
"    ]. At one-year follow-up, the rate is 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/59\">",
"     59",
"    </a>",
"    ]. Urinary tract infection should be treated, as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link&amp;anchor=H899949198#H899949198\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\", section on 'Treatment'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4701484\">",
"    <span class=\"h3\">",
"     Voiding dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary retention or incomplete bladder emptying are commonly reported after retropubic midurethral sling placement [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/60\">",
"     60",
"    </a>",
"    ]. The reported rate of voiding dysfunction varies from 19.7 to 47 percent of cases, depending upon the definition and diagnostic criteria used [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/41,44\">",
"     41,44",
"    </a>",
"    ]. In our practice, we define incomplete bladder emptying as a postvoid residual volume of &gt;150 ml.",
"   </p>",
"   <p>",
"    A slow preoperative urinary flow rate may be a risk factor for voiding dysfunction after surgery. Studies have found that women with a preoperative maximum urinary flow rate &lt;15",
"    <span class=\"nowrap\">",
"     mL/sec",
"    </span>",
"    compared with those with a rate &gt;30",
"    <span class=\"nowrap\">",
"     mL/sec",
"    </span>",
"    had higher rates of postoperative voiding dysfunction (27 to 67 versus 4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Preoperative counseling for patients who undergo urodynamics and have a maximum flow rate of &lt;15",
"    <span class=\"nowrap\">",
"     mL/sec",
"    </span>",
"    may include a discussion of an increased risk of requiring short-term catheterization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22194935\">",
"    <span class=\"h4\">",
"     Postoperative catheter management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various management strategies have been used for post-sling voiding dysfunction, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intermittent self-catheterization &ndash; The patient self-catheterizes after each void and records the postvoid residual in a voiding diary. Catheterization is discontinued when the postvoid residuals are consistently &lt;150 mL.",
"     </li>",
"     <li>",
"      Indwelling bladder catheter &ndash; The bladder catheter is left in place and a voiding trial performed every three to four days until the postvoid residual is &lt;150 mL.",
"     </li>",
"     <li>",
"      Urethral dilation &ndash; A dilator is passed through the urethra and downward traction is exerted on the tape [",
"      <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/63\">",
"       63",
"      </a>",
"      ]. This may loosen the tape enough to relieve the voiding problem.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our practice, we usually start with an indwelling bladder catheter, followed by intermittent self-catheterization. If that fails, then we perform a sling release. Urethral dilation may be considered in the early postoperative period prior to tissue ingrowth into the sling. However, too much traction on the sling theoretically increases the risk of mesh erosion into the urethra.",
"   </p>",
"   <p>",
"    For urinary retention that lasts longer than a few days, clean intermittent self-catheterization is preferable to a long-term indwelling catheter, to avoid the risk of urinary tract infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40697?source=see_link&amp;anchor=H5#H5\">",
"     \"Placement and management of urinary bladder catheters\", section on 'Choice of catheter'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotic prophylaxis is not required for short- or long-term bladder catheter use. Antimicrobial therapy should be reserved for patients with a urinary tract infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40697?source=see_link&amp;anchor=H31#H31\">",
"     \"Placement and management of urinary bladder catheters\", section on 'Prophylactic antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4702658\">",
"    <span class=\"h4\">",
"     Sling release",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of postoperative urinary retention resolve with conservative management. Urinary retention that persists after four to six weeks may require surgical intervention in the form of a sling release [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. In a study of billing codes of over 180,000 women who underwent a midurethral sling procedure between 2001 and 2010, the cumulative rate of sling release performed for the indication of urinary retention was 1.3 percent at nine years postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/66\">",
"     66",
"    </a>",
"    ]. The rate increased from 0.8 percent at six months postoperatively to 1.1 percent at two years, and then generally plateaued.",
"   </p>",
"   <p>",
"    Sling release relieves urinary retention in most women and SUI recurs in some, but not all, women. Studies of 1000 or more procedures have reported persistent voiding dysfunction following 0.6 to 2.0 percent of midurethral sling procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. There are few data regarding the results of sling release. In a retrospective study of 23 women who underwent sling release following TVT: all patients had complete resolution of urinary retention; 14 (61 percent) had complete cure of SUI; 6 (26 percent) had partial improvement in SUI symptoms; and 3 (13 percent) had failure of SUI treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/67\">",
"     67",
"    </a>",
"    ]. Another study of 50 women who had sling release reported that urinary retention did not completely resolve in 4 patients (12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At our institution, we perform sling release in the operating room with local, regional, or general anesthesia, as appropriate. We use the following procedure for sling release:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inject local anesthesia or dilute vasopressin for hydrodissection at the midurethral portion of the vagina.",
"     </li>",
"     <li>",
"      Incise the vaginal mucosa in the midline overlying the sling.",
"     </li>",
"     <li>",
"      Identify the sling. The sling can often be identified with palpation or by transilluminating the urethra with a urethroscope to determine its location.",
"     </li>",
"     <li>",
"      Isolate the entire width of the sling from the urethra; this should be accomplished before any attempt at transection, to ensure that the sling is completely transected. This step is sometimes challenging and requires that an instrument (eg, thin tipped right-angle clamp, nerve hook) is inserted behind the sling. Care is taken during the dissection to isolate only the sling without compromising the urethra. Placement of a bladder catheter before this step is often helpful.",
"     </li>",
"     <li>",
"      Transect the sling completely. After transection, both ends typically retract slightly.",
"     </li>",
"     <li>",
"      Perform urethroscopy to ensure that urethral damage has not occurred and then close the vagina in layers, if possible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4701601\">",
"    <span class=\"h3\">",
"     Urinary urgency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary urge symptoms (eg, urgency, urge incontinence, frequency) develop in some women following retropubic midurethral sling placement. The reported incidence ranges widely from 5.9 percent to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/64,69,70\">",
"     64,69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the immediate postoperative period, transient urge symptoms may result from a pelvic hematoma. The etiology of persistent symptoms is thought to be a combination of mild urinary obstruction and urethral irritation associated with the sling. In one study, 15 of 29 women with post-sling de novo urge symptoms were successfully treated with anticholinergic medications, which are first line therapy for other etiologies of urinary urge symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evaluation and management of urinary urgency symptoms are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4701133\">",
"    <span class=\"h3\">",
"     Other urinary tract complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ureteral injury is rare. As an example, in a survey study that included 12,280 midurethral sling procedures, only two ureteral injuries were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urinary tract fistula is a rare, but serious, complication of midurethral sling placement [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/54,72,73\">",
"     54,72,73",
"    </a>",
"    ]. Isolated cases of vesicovaginal and urethrovaginal fistulas have been reported.",
"   </p>",
"   <p>",
"    Evaluation and management of urinary tract fistulas are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=see_link\">",
"     \"Urogenital tract fistulas in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4700557\">",
"    <span class=\"h2\">",
"     Vascular injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasional vascular injury occurs during retropubic midurethral sling placement, due to the blind passage of the trocars through the highly vascular retropubic space. Injury may involve the paravesical veins, obturator, external iliac, femoral, inferior epigastric or circumflex vessels. Hemorrhage (defined as &gt;500 ml of blood loss)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood transfusion has been reported in approximately 2.5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/44,74\">",
"     44,74",
"    </a>",
"    ]. Excessive bleeding can be managed intraoperatively with direct pressure on the paraurethral or retropubic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Venous injury typically results in a self-limited slowly expanding retropubic hematoma. Hematoma formation may result in symptoms of bladder compression (suprapubic pain, urinary urgency, urinary frequency)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs of significant blood loss (tachycardia, hypotension, anemia, oliguria). Abdominal and bimanual pelvic examination may reveal a palpable mass in the suprapubic or retropubic spaces (this may be either large or small)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ecchymoses in the suprapubic area (bruising may track to the labia). If no signs of hematoma are evident on physical examination, a diagnosis can be made with sonography or computed tomography [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/77\">",
"     77",
"    </a>",
"    ]. One study of 14 women who underwent sonographic evaluation of retropubic hematomas reported that the volume of blood in the hematoma predicted the severity of symptoms: &lt;100 mL (rarely symptomatic); 100 to 200 mL (moderate pain); and &gt;300 mL (severe pain requiring surgical evacuation) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retropubic venous bleeding can often be managed with close observation and conservative management. A study that followed five patients with serial ultrasound noted that it took one to five months for retropubic hematomas to resolve [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute hemodynamic decompensation suggests arterial bleeding and requires invasive measures and supportive care (eg, fluid management, transfusion) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/74\">",
"     74",
"    </a>",
"    ]. Radiographic embolization of arterial vessels associated with the retropubic hemorrhage is the preferred option in a stable patient [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/76\">",
"     76",
"    </a>",
"    ]. Large hematomas may be the result of large vessel damage and may also lead to life-threatening blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/50\">",
"     50",
"    </a>",
"    ]. In an unstable patient, or if radiographic embolization is unavailable, emergent laparotomy is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3907444\">",
"    <span class=\"h2\">",
"     Bowel injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bowel perforation is a rare, but serious, complication of retropubic midurethral sling procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/78\">",
"     78",
"    </a>",
"    ]. There are few data regarding the incidence of this type of injury. A survey of surgeons who had performed a total of over 12,000 TVT procedures reported three bowel perforations [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/71\">",
"     71",
"    </a>",
"    ]. Delayed erosion of the mesh into bowel has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/79\">",
"     79",
"    </a>",
"    ]. From the time of the introduction of the TVT device in the late 1990s through 2004, the United States Food and Drug Association Manufacturer and User Facility Device Experience database had recorded a total of seven deaths associated with the device, six of which were related to bowel injury [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with prior abdominal or pelvic surgery or women who have an abdominal or inguinal hernia appear to have an increased risk of bowel injury during sling placement [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/14,81-84\">",
"     14,81-84",
"    </a>",
"    ]. A transobturator midurethral sling may be preferable for these patients. (See",
"    <a class=\"local\" href=\"#H299273\">",
"     'Contraindications'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16055?source=see_link&amp;anchor=H2822326#H2822326\">",
"     \"Stress urinary incontinence in women: Choosing a type of midurethral sling\", section on 'Transobturator versus retropubic midurethral slings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A measure that has been proposed to prevent bowel injury is to place the patient in steep Trendelenburg position to allow the bowel to shift out of the retropubic area [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bowel perforation is a surgical emergency. Women with severe or persistent abdominal pain following retropubic midurethral sling placement should be evaluated for bowel injury. Pain may be accompanied by fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    feculent or purulent drainage from the abdominal incision sites. Women with suspected bowel injury should undergo imaging with a plain radiograph or computed tomography, and surgical exploration should be expedited, if necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41770?source=see_link&amp;anchor=H17#H17\">",
"     \"Evaluation of the adult with abdominal pain in the emergency department\", section on 'Plain x-rays'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41770?source=see_link&amp;anchor=H19#H19\">",
"     \"Evaluation of the adult with abdominal pain in the emergency department\", section on 'Computed tomography scan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3907598\">",
"    <span class=\"h2\">",
"     Vaginal mesh erosion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesh exposure, also known as erosion, is a common complication when synthetic mesh is used [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. There are few data about the incidence of mesh erosion through the vaginal mucosa following retropubic midurethral sling placement. In one series of 241 women who underwent TVT placement, 0.4 percent experienced vaginal mesh erosion [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/44\">",
"     44",
"    </a>",
"    ]. In a study of billing codes of over 180,000 women who underwent a midurethral sling procedure between 2001 and 2010, the cumulative rate of sling release performed for the indication of mesh erosion was 2.5 percent at nine years postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/66\">",
"     66",
"    </a>",
"    ]. The rate increased from 0.9 percent at six months postoperatively to 2.2 percent at five years, and then generally plateaued.",
"   </p>",
"   <p>",
"    Common clinical presentations of vaginal mesh erosion include visible or palpable tape in the vagina, vaginal discharge, vaginal bleeding, postcoital spotting, dyspareunia, male sexual partner discomfort (dyspareunia), or urinary tract infection. The diagnosis of mesh erosion is made with visual inspection of the vagina.",
"   </p>",
"   <p>",
"    Management for vaginal erosions varies with the extent of the erosion and the severity of symptoms. Initial management is with conservative measures, including vaginal estrogen therapy and avoidance of vaginal insertions (tampons, intercourse) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/86\">",
"     86",
"    </a>",
"    ]. If symptoms persist",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the patient or her partner can feel the sling and find this bothersome, surgical treatments may be offered. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reapproximating the vaginal epithelium (this is only possible if there is sufficient tissue)",
"     </li>",
"     <li>",
"      Excision of the palpable portion of mesh [",
"      <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/86\">",
"       86",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Partial/complete",
"      </span>",
"      removal of the mesh [",
"      <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/58,89\">",
"       58,89",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients should be counseled that removal of all or part of the mesh may result in recurrent SUI. (See",
"    <a class=\"local\" href=\"#H4702658\">",
"     'Sling release'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    Erosion of mesh into the bladder, urethra, or bowel is discussed separately. (See",
"    <a class=\"local\" href=\"#H4700528\">",
"     'Bladder injury'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4701082\">",
"     'Urethral injury'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3907444\">",
"     'Bowel injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3907605\">",
"    <span class=\"h2\">",
"     Pelvic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women develop chronic pelvic pain following retropubic midurethral sling placement (7.5 percent in one series of 241 women) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/44\">",
"     44",
"    </a>",
"    ]. Depending upon the severity and duration, pelvic pain may be treated with expectant management, medical therapy, or pelvic physical therapy. Resolution of symptoms with removal of the mesh via laparoscopy or vaginal and thigh incisions was reported in a prospective study of 32 women who developed pelvic and perineal pain following placement of a midurethral sling [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/90\">",
"     90",
"    </a>",
"    ]. At 10-month follow-up, visual analogue pain scores improved by at least 50 percent in 68 percent of women; 22 percent had recurrent SUI.",
"   </p>",
"   <p>",
"    The evaluation and management of pelvic pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31864?source=see_link\">",
"     \"Evaluation of chronic pelvic pain in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28969?source=see_link\">",
"     \"Treatment of chronic pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postoperative dyspareunia following retropubic midurethral sling placement has not been routinely reported. However, this complication has been reported following transobturator sling procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33401?source=see_link&amp;anchor=H492485#H492485\">",
"     \"Stress urinary incontinence in women: Transobturator midurethral slings\", section on 'Dyspareunia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4701050\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been case reports of necrotizing fasciitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/91\">",
"     91",
"    </a>",
"    ] and ilioinguinal nerve entrapment [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/92,93\">",
"     92,93",
"    </a>",
"    ] following retropubic midurethral sling placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H298266\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2816407\">",
"    <span class=\"h2\">",
"     Postoperative care and instructions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women may experience vaginal, periurethral, or lower abdominal discomfort and pain at incision sites for up to two weeks following the procedure. These symptoms are typically well controlled with oral narcotics or non-steroidal antiinflammatory drugs. Many women also have vaginal spotting for up to two weeks.",
"   </p>",
"   <p>",
"    We counsel patients to call their surgeon if they experience symptoms that may be associated with a serious complication, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Heavy vaginal bleeding",
"     </li>",
"     <li>",
"      Light-headedness",
"     </li>",
"     <li>",
"      Severe or persistent abdominal pain",
"     </li>",
"     <li>",
"      Vomiting or persistent nausea",
"     </li>",
"     <li>",
"      Discharge of clear fluid or blood from the incision sites that is copious or persistent or any amount of purulent or feculent discharge",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who present with these symptoms should be promptly evaluated.",
"   </p>",
"   <p>",
"    Urinary retention may occur even after a successful postoperative voiding trial. Patients who feel a persistent sense of urinary retention or incomplete bladder emptying should have a postvoid residual volume measured and may require catheterization. (See",
"    <a class=\"local\" href=\"#H22194935\">",
"     'Postoperative catheter management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The sling is initially held in place solely by frictional tissue forces, and patients must allow adequate time for tissue in-growth to occur before significant intraabdominal pressure is applied to the mesh. Patients are advised to avoid heavy lifting, actions that increase intraabdominal pressure, or exercise for at least two to four weeks. Ambulation, however, is encouraged. Sexual activity should be avoided until the vaginal epithelium is healed, which takes approximately four to six weeks.",
"   </p>",
"   <p>",
"    The patient may return to work when she feels sufficiently comfortable.",
"   </p>",
"   <p>",
"    We see patients for a routine follow-up visit at four to six weeks. We perform abdominal and vaginal examinations to ensure that the incisions have adequately healed and to check for vaginal mesh erosion. The vaginal sulci are visualized and palpated to confirm that there are no occult extrusions of mesh. We check a postvoid residual volume to assess whether the patient has been adequately emptying her bladder. This can be measured with a bladder ultrasound or catheterization.",
"   </p>",
"   <p>",
"    Patient information regarding care after pelvic surgery can be found separately. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?27/27/28083?source=see_link\">",
"     \"Patient information: Care after gynecologic surgery (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H298966\">",
"    <span class=\"h2\">",
"     Subsequent pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since pelvic support may be disrupted during pregnancy, and particularly following a vaginal birth, most physicians recommend delaying midurethral sling placement until childbearing has been completed.",
"   </p>",
"   <p>",
"    In women who become pregnant following anti-incontinence surgery, the best choice for mode of delivery is uncertain. A review of case reports suggested that vaginal delivery was associated with a higher risk of recurrent incontinence than cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/94\">",
"     94",
"    </a>",
"    ], but a survey of physicians who had performed 3400 retropubic or transobturator midurethral sling procedures reported no difference in incontinence rates (vaginal delivery: 20 percent; cesarean: 13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/95\">",
"     95",
"    </a>",
"    ]. Women of childbearing age who elect surgical treatment should be counseled on the paucity of data regarding the preferred mode of delivery and the risk of recurrent incontinence following delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/94-97\">",
"     94-97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2819228\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimally invasive midurethral slings are widely considered to be the standard of care for women undergoing surgical treatment for SUI [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/30\">",
"     30",
"    </a>",
"    ]. A short-term cure rate (within 12 months postoperatively) of 73 to 82 percent was reported in a meta-analysis of 62 randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/17\">",
"     17",
"    </a>",
"    ]. In the Trial of Midurethral Slings (TOMUS) (n = 597; the largest randomized trial comparing retropubic and transobturator slings to-date), for retropubic slings, the 12-month subjective success rate was 62 percent and the objective cure rate was 78 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/30\">",
"     30",
"    </a>",
"    ]. Patient satisfaction has been reported as over 80 percent at one year postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term data include two prospective cohort studies that followed women for 7 to 11 years after TVT procedures that reported subjective cure rates of 77 to 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/11,99\">",
"     11,99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link&amp;anchor=H17#H17\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\", section on 'Midurethral slings versus other procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for failure of either a retropubic or transobturator sling within one year of placement based upon data from the TOMUS trial included: previous anti-incontinence surgery (2-fold increased risk); urgency symptoms (as measured by a questionnaire score; 2-fold); and maximum Q-tip excursion &lt;30&deg; on preoperative urethral hypermobility testing (1.9-fold) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/49/33562/abstract/100\">",
"     100",
"    </a>",
"    ]. Objective, but not subjective, failure was associated with age (1.5-fold per 10 years). Having concomitant surgery was associated with a lower risk of subjective, but not objective, failure (0.44-fold). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, and answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon. (See",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?22/8/22658?source=see_link\">",
"     \"Patient information: Urinary incontinence (The Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?19/19/19764?source=see_link\">",
"     \"Patient information: Urinary incontinence treatments for women (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25744531\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stress urinary incontinence (SUI) is the involuntary leakage of urine with increased intraabdominal pressure. Midurethral sling placement is the procedure of choice for treatment of SUI in many women. Midurethral slings may be placed either through the retropubic or transobturator spaces. (See",
"      <a class=\"local\" href=\"#H25744271\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Relative contraindications for retropubic midurethral sling placement include future plans for pregnancy and an increased risk of injury to retropubic structures (ie, due to prior surgery or a current hernia that may result in the presence of viscera or major vessels in the retropubic space). (See",
"      <a class=\"local\" href=\"#H299273\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women who are planning primary midurethral retropubic sling placement should undergo preoperative evaluation to confirm the diagnosis of SUI, exclude other etiologies of urinary incontinence, confirm normal bladder emptying, and assess surgical risk. (See",
"      <a class=\"local\" href=\"#H297972\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/58/17319?source=see_link\">",
"       \"Stress urinary incontinence in women: Preoperative evaluation for a primary procedure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend antibiotic prophylaxis for surgical site infection for surgical procedures for treatment of pelvic organ prolapse or stress urinary incontinence that utilize surgical mesh (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H297929\">",
"       'Antibiotic prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women undergoing retropubic midurethral sling placement, we suggest a bottom-to-top rather than top-to-bottom approach for trocar insertion (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2819431\">",
"       'Choosing a type of retropubic sling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest use of local anesthesia with conscious sedation or regional anesthesia rather than general anesthesia for midurethral sling placement (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). General anesthesia may be used if it is preferred by the patient or if it is required for a concomitant procedure. (See",
"      <a class=\"local\" href=\"#H579368\">",
"       'Anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During sling placement, the trocars must be passed along the correct path without deviation to avoid complications. Small deviations of the trocar handle create a magnified deviation of the tip of the trocar, resulting in potential injury to adjacent structures. (See",
"      <a class=\"local\" href=\"#H4700179\">",
"       'Initial trocar insertion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common complications of midurethral retropubic sling placement include bladder perforation, voiding dysfunction, and development of urinary urgency symptoms. Surgeons should be aware of the potential for serious complications, including bowel injury, vascular injury, and urinary tract fistula. (See",
"      <a class=\"local\" href=\"#H25744489\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Voiding dysfunction following sling placement may be treated initially with bladder catheterization or urethral dilation. Persistent symptoms may require sling release, which may result in recurrent SUI. (See",
"      <a class=\"local\" href=\"#H22194935\">",
"       'Postoperative catheter management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4702658\">",
"       'Sling release'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term data show a SUI cure rate of approximately 80 percent following retropubic midurethral sling placement. (See",
"      <a class=\"local\" href=\"#H2819228\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/1\">",
"      Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/2\">",
"      Luber KM. The definition, prevalence, and risk factors for stress urinary incontinence. Rev Urol 2004; 6 Suppl 3:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/3\">",
"      Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/4\">",
"      Suskind AM, Kaufman SR, Dunn RL, et al. Population-based trends in ambulatory surgery for urinary incontinence. Int Urogynecol J 2013; 24:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/5\">",
"      Ulmsten U, Henriksson L, Johnson P, Varhos G. An ambulatory surgical procedure under local anesthesia for treatment of female urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 1996; 7:81.",
"     </a>",
"    </li>",
"    <li>",
"     Walters, MD, Karram, MM. Sling procedures for stress urinary incontinence. In: Urogynecology and Reconstructive Pelvic Surgery, 3rd ed, Mosby Elsevier, Philadelphia 2007. p. 197.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/7\">",
"      Sarlos D, Kuronen M, Schaer GN. How does tension-free vaginal tape correct stress incontinence? investigation by perineal ultrasound. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/8\">",
"      Dietz HP, Wilson PD. The 'iris effect': how two-dimensional and three-dimensional ultrasound can help us understand anti-incontinence procedures. Ultrasound Obstet Gynecol 2004; 23:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/9\">",
"      Majercik S, Tsikitis V, Iannitti DA. Strength of tissue attachment to mesh after ventral hernia repair with synthetic composite mesh in a porcine model. Surg Endosc 2006; 20:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/10\">",
"      Liapis A, Bakas P, Creatsas G. Tension-free vaginal tape in the management of recurrent urodynamic stress incontinence after previous failed midurethral tape. Eur Urol 2009; 55:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/11\">",
"      Liapis A, Bakas P, Creatsas G. Long-term efficacy of tension-free vaginal tape in the management of stress urinary incontinence in women: efficacy at 5- and 7-year follow-up. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/12\">",
"      Rezapour M, Falconer C, Ulmsten U. Tension-Free vaginal tape (TVT) in stress incontinent women with intrinsic sphincter deficiency (ISD)--a long-term follow-up. Int Urogynecol J Pelvic Floor Dysfunct 2001; 12 Suppl 2:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/13\">",
"      Azam U, Frazer MI, Kozman EL, et al. The tension-free vaginal tape procedure in women with previous failed stress incontinence surgery. J Urol 2001; 166:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/14\">",
"      Gurshumov EL, Klapper AS, Sierecki AR. Small bowel perforation in a hernia sac after TVT placement at the time of colpocleisis. Int Urogynecol J 2010; 21:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/15\">",
"      Hoda MR, Wagner S, Greco F, et al. Pelvic organ prolapse management in female kidney transplant recipients. J Urol 2010; 184:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/16\">",
"      McNanley AR, Buchsbaum GM. TVT or TOT? When to avoid retropubic trocar passage. Int Urogynecol J 2010; 21:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/17\">",
"      Ogah J, Cody JD, Rogerson L. Minimally invasive synthetic suburethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev 2009; :CD006375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/18\">",
"      Mallett VT, Brubaker L, Stoddard AM, et al. The expectations of patients who undergo surgery for stress incontinence. Am J Obstet Gynecol 2008; 198:308.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/19\">",
"      Sinha D, Blackwell A, Moran PA. Outcome measures after TVT for mixed urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/20\">",
"      Choe JH, Choo MS, Lee KS. The impact of tension-free vaginal tape on overactive bladder symptoms in women with stress urinary incontinence: significance of detrusor overactivity. J Urol 2008; 179:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/21\">",
"      Madjar S, Frischer Z, Nieder AM, Waltzer WC. Bladder wall abscess following midurethral sling procedure. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/22\">",
"      Lee SY, Kim JY, Park SJ, et al. Bilateral recurrent thigh abscesses for five years after a transobturator tape implantation for stress urinary incontinence. Korean J Urol 2010; 51:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/23\">",
"      DeSouza R, Shapiro A, Westney OL. Adductor brevis myositis following transobturator tape procedure: a case report and review of the literature. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/24\">",
"      Connolly TP. Necrotizing surgical site infection after tension-free vaginal tape. Obstet Gynecol 2004; 104:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/25\">",
"      Sivanesan K, Abdel-Fattah M, Tierney J. Perineal cellulitis and persistent vaginal erosion after transobturator tape (Obtape)--case report and review of the literature. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/26\">",
"      Karsenty G, Boman J, Elzayat E, et al. Severe soft tissue infection of the thigh after vaginal erosion of transobturator tape for stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/27\">",
"      ACOG Committee on Practice Bulletins--Gynecology. ACOG practice bulletin No. 104: antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol 2009; 113:1180.",
"     </a>",
"    </li>",
"    <li>",
"     American Urologic Association: Urologic surgery antimicrobial prophylaxis file://www.auanet.org/content/media/antimicroprop08.pdf (Accessed on August 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/29\">",
"      Ulmsten U, Falconer C, Johnson P, et al. A multicenter study of tension-free vaginal tape (TVT) for surgical treatment of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 1998; 9:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/30\">",
"      Richter HE, Albo ME, Zyczynski HM, et al. Retropubic versus transobturator midurethral slings for stress incontinence. N Engl J Med 2010; 362:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/31\">",
"      Low SJ, Smith KM, Holt EM. Tension free vaginal tape: is the intra-operative cough test necessary? Int Urogynecol J Pelvic Floor Dysfunct 2004; 15:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/32\">",
"      Adamiak A, Milart P, Skorupski P, et al. The efficacy and safety of the tension-free vaginal tape procedure do not depend on the method of analgesia. Eur Urol 2002; 42:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/33\">",
"      Duckett RA, Grapsas P, Eaton M, Basu M. The effect of spinal anaesthesia on urethral function. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/34\">",
"      Duckett JR, Papanikolaou NS, Eaton M. The effect of local anaesthetic infiltration on urethral function during the tension-free vaginal tape (TVT) procedure. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/35\">",
"      Duckett JR, Patil A, Papanikolaou NS. Predicting early voiding dysfunction after tension-free vaginal tape. J Obstet Gynaecol 2008; 28:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/36\">",
"      Koops SE, Bisseling TM, van Brummen HJ, et al. What determines a successful tension-free vaginal tape? A prospective multicenter cohort study: results from The Netherlands TVT database. Am J Obstet Gynecol 2006; 194:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/37\">",
"      Muir TW, Tulikangas PK, Fidela Paraiso M, Walters MD. The relationship of tension-free vaginal tape insertion and the vascular anatomy. Obstet Gynecol 2003; 101:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/38\">",
"      McLennan MT, Melick CF. Bladder perforation during tension-free vaginal tape procedures: analysis of learning curve and risk factors. Obstet Gynecol 2005; 106:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/39\">",
"      Giri SK, Sil D, Narasimhulu G, et al. Management of vaginal extrusion after tension-free vaginal tape procedure for urodynamic stress incontinence. Urology 2007; 69:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/40\">",
"      Pulvino JQ, Duecy EE, Buchsbaum GM, Flynn MK. Comparison of 2 techniques to predict voiding efficiency after inpatient urogynecologic surgery. J Urol 2010; 184:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/41\">",
"      Foster RT Sr, Borawski KM, South MM, et al. A randomized, controlled trial evaluating 2 techniques of postoperative bladder testing after transvaginal surgery. Am J Obstet Gynecol 2007; 197:627.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/42\">",
"      Gold RS, Groutz A, Pauzner D, et al. Bladder perforation during tension-free vaginal tape surgery: does it matter? J Reprod Med 2007; 52:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/43\">",
"      Kristensen I, Eldoma M, Williamson T, et al. Complications of the tension-free vaginal tape procedure for stress urinary incontinence. Int Urogynecol J 2010; 21:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/44\">",
"      Abouassaly R, Steinberg JR, Lemieux M, et al. Complications of tension-free vaginal tape surgery: a multi-institutional review. BJU Int 2004; 94:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/45\">",
"      Dyrkorn OA, Kulseng-Hanssen S, Sandvik L. TVT compared with TVT-O and TOT: results from the Norwegian National Incontinence Registry. Int Urogynecol J 2010; 21:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/46\">",
"      Brubaker L, Norton PA, Albo ME, et al. Adverse events over two years after retropubic or transobturator midurethral sling surgery: findings from the Trial of Midurethral Slings (TOMUS) study. Am J Obstet Gynecol 2011; 205:498.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/47\">",
"      Wang AC. The techniques of trocar insertion and intraoperative urethrocystoscopy in tension-free vaginal taping: an experience of 600 cases. Acta Obstet Gynecol Scand 2004; 83:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/48\">",
"      Bodelsson G, Henriksson L, Osser S, Stjernquist M. Short term complications of the tension free vaginal tape operation for stress urinary incontinence in women. BJOG 2002; 109:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/49\">",
"      Abbas Shobeiri S, Garely AD, Chesson RR, Nolan TE. Recognition of occult bladder injury during the tension-free vaginal tape procedure. Obstet Gynecol 2002; 99:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/50\">",
"      Deng DY, Rutman M, Raz S, Rodriguez LV. Presentation and management of major complications of midurethral slings: Are complications under-reported? Neurourol Urodyn 2007; 26:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/51\">",
"      Mustafa M, Wadie BS. Bladder erosion of tension-free vaginal tape presented as vesical stone; management and review of literature. Int Urol Nephrol 2007; 39:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/52\">",
"      Oh TH, Ryu DS. Transurethral resection of intravesical mesh after midurethral sling procedures. J Endourol 2009; 23:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/53\">",
"      Huwyler M, Springer J, Kessler TM, Burkhard FC. A safe and simple solution for intravesical tension-free vaginal tape erosion: removal by standard transurethral resection. BJU Int 2008; 102:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/54\">",
"      Morton HC, Hilton P. Urethral injury associated with minimally invasive mid-urethral sling procedures for the treatment of stress urinary incontinence: a case series and systematic literature search. BJOG 2009; 116:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/55\">",
"      Karram MM, Segal JL, Vassallo BJ, Kleeman SD. Complications and untoward effects of the tension-free vaginal tape procedure. Obstet Gynecol 2003; 101:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/56\">",
"      Lieb J, Das AK. Urethral erosion of tension-free vaginal tape. Scand J Urol Nephrol 2003; 37:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/57\">",
"      Powers K, Lazarou G, Greston WM. Delayed urethral erosion after tension-free vaginal tape. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/58\">",
"      Blaivas JG, Sandhu J. Urethral reconstruction after erosion of slings in women. Curr Opin Urol 2004; 14:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/59\">",
"      Anger JT, Litwin MS, Wang Q, et al. Complications of sling surgery among female Medicare beneficiaries. Obstet Gynecol 2007; 109:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/60\">",
"      Klutke C, Siegel S, Carlin B, et al. Urinary retention after tension-free vaginal tape procedure: incidence and treatment. Urology 2001; 58:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/61\">",
"      Wheeler TL 2nd, Richter HE, Greer WJ, et al. Predictors of success with postoperative voiding trials after a mid urethral sling procedure. J Urol 2008; 179:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/62\">",
"      Hong B, Park S, Kim HS, Choo MS. Factors predictive of urinary retention after a tension-free vaginal tape procedure for female stress urinary incontinence. J Urol 2003; 170:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/63\">",
"      Glavind K, Glavind E. Treatment of prolonged voiding dysfunction after tension-free vaginal tape procedure. Acta Obstet Gynecol Scand 2007; 86:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/64\">",
"      Nilsson CG, Kuuva N, Falconer C, et al. Long-term results of the tension-free vaginal tape (TVT) procedure for surgical treatment of female stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2001; 12 Suppl 2:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/65\">",
"      Barber MD, Gustilo-Ashby AM, Chen CC, et al. Perioperative complications and adverse events of the MONARC transobturator tape, compared with the tension-free vaginal tape. Am J Obstet Gynecol 2006; 195:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/66\">",
"      Jonsson Funk M, Siddiqui NY, Pate V, et al. Sling revision/removal for mesh erosion and urinary retention: long-term risk and predictors. Am J Obstet Gynecol 2013; 208:73.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/67\">",
"      Rardin CR, Rosenblatt PL, Kohli N, et al. Release of tension-free vaginal tape for the treatment of refractory postoperative voiding dysfunction. Obstet Gynecol 2002; 100:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/68\">",
"      Laurikainen E, Kiilholma P. A nationwide analysis of transvaginal tape release for urinary retention after tension-free vaginal tape procedure. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/69\">",
"      Lim JL, de Cuyper EM, Cornish A, Frazer M. Short-term clinical and quality-of-life outcomes in women treated by the TVT-Secur procedure. Aust N Z J Obstet Gynaecol 2010; 50:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/70\">",
"      Jeffry L, Deval B, Birsan A, et al. Objective and subjective cure rates after tension-free vaginal tape for treatment of urinary incontinence. Urology 2001; 58:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/71\">",
"      Agostini A, Bretelle F, Franchi F, et al. Immediate complications of tension-free vaginal tape (TVT): results of a French survey. Eur J Obstet Gynecol Reprod Biol 2006; 124:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/72\">",
"      Estevez JP, Cosson M, Boukerrou M. An uncommon case of urethrovaginal fistula resulting from tension-free vaginal tape. Int Urogynecol J 2010; 21:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/73\">",
"      Jasaitis Y, Sergent F, Tanneau Y, Marpeau L. [Vesicovaginal fistula after transobturator tape]. Prog Urol 2007; 17:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/74\">",
"      Kobashi KC, Govier FE. Perioperative complications: the first 140 polypropylene pubovaginal slings. J Urol 2003; 170:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/75\">",
"      Walters MD, Tulikangas PK, LaSala C, Muir TW. Vascular injury during tension-free vaginal tape procedure for stress urinary incontinence. Obstet Gynecol 2001; 98:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/76\">",
"      Zorn KC, Daigle S, Belzile F, Tu le M. Embolization of a massive retropubic hemorrhage following a tension-free vaginal tape (TVT) procedure: case report and literature review. Can J Urol 2005; 12:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/77\">",
"      Flock F, Reich A, Muche R, et al. Hemorrhagic complications associated with tension-free vaginal tape procedure. Obstet Gynecol 2004; 104:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/78\">",
"      Huffaker RK, Yandell PM, Shull BL. Tension-free vaginal tape bowel perforation. Int Urogynecol J 2010; 21:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/79\">",
"      Fourie T, Cohen PL. Delayed bowel erosion by tension-free vaginal tape (TVT). Int Urogynecol J Pelvic Floor Dysfunct 2003; 14:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/80\">",
"      Nygaard IE, Heit M. Stress urinary incontinence. Obstet Gynecol 2004; 104:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/81\">",
"      Leboeuf L, Tellez CA, Ead D, Gousse AE. Complication of bowel perforation during insertion of tension-free vaginal tape. J Urol 2003; 170:1310; discussion 1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/82\">",
"      Meschia M, Busacca M, Pifarotti P, De Marinis S. Bowel perforation during insertion of tension-free vaginal tape (TVT). Int Urogynecol J Pelvic Floor Dysfunct 2002; 13:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/83\">",
"      Castillo OA, Bodden E, Olivares RA, Urena RD. Intestinal perforation: an infrequent complication during insertion of tension-free vaginal tape. J Urol 2004; 172:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/84\">",
"      Daneshgari F, Kong W, Swartz M. Complications of mid urethral slings: important outcomes for future clinical trials. J Urol 2008; 180:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/85\">",
"      Rooney KE, Cholhan HJ. Bowel perforation during retropubic sling procedure. Obstet Gynecol 2010; 115:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/86\">",
"      Kobashi KC, Govier FE. Management of vaginal erosion of polypropylene mesh slings. J Urol 2003; 169:2242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/87\">",
"      Mesens T, Aich A, Bhal PS. Late erosions of mid-urethral tapes for stress urinary incontinence--need for long-term follow-up? Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/88\">",
"      Wijffels SA, Elzevier HW, Lycklama a Nijeholt AA. Transurethral mesh resection after urethral erosion of tension-free vaginal tape: report of three cases and review of literature. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/89\">",
"      Rehman J, Chugtai B, Sukkarich T, Khan SA. Extraperitoneal laparoscopic removal of eroded midurethral sling: a new technique. J Endourol 2008; 22:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/90\">",
"      Rigaud J, Pothin P, Labat JJ, et al. Functional results after tape removal for chronic pelvic pain following tension-free vaginal tape or transobturator tape. J Urol 2010; 184:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/91\">",
"      Johnson DW, ElHajj M, OBrien-Best EL, et al. Necrotizing fasciitis after tension-free vaginal tape (TVT) placement. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/92\">",
"      Geis K, Dietl J. Ilioinguinal nerve entrapment after tension-free vaginal tape (TVT) procedure. Int Urogynecol J Pelvic Floor Dysfunct 2002; 13:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/93\">",
"      Vervest HA, Bongers MY, van der Wurff AA. Nerve injury: an exceptional cause of pain after TVT. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/94\">",
"      Groenen R, Vos MC, Willekes C, Vervest HA. Pregnancy and delivery after mid-urethral sling procedures for stress urinary incontinence: case reports and a review of literature. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/95\">",
"      Panel L, Triopon G, Courtieu C, et al. How to advise a woman who wants to get pregnant after a sub-urethral tape placement? Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/96\">",
"      Dainer M, Hall CD, Choe J, Bhatia N. Pregnancy following incontinence surgery. Int Urogynecol J Pelvic Floor Dysfunct 1998; 9:385.",
"     </a>",
"    </li>",
"    <li>",
"     Kohorst, F, et al. Pregnancy and delivery after tension-free vaginal tape (TVT) procedure: literature review and case report. Eur J Obstet Gynecol 2010; :. [Epub ahead of print].",
"    </li>",
"    <li>",
"     Davis, TL, et al. Determinants of patient satisfaction after the tension-free vaginal tape procedure. Am J Obstet Gynecol, 2004; 191:176.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/99\">",
"      Nilsson CG, Palva K, Rezapour M, Falconer C. Eleven years prospective follow-up of the tension-free vaginal tape procedure for treatment of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/49/33562/abstract/100\">",
"      Richter HE, Litman HJ, Lukacz ES, et al. Demographic and clinical predictors of treatment failure one year after midurethral sling surgery. Obstet Gynecol 2011; 117:913.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14217 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.22.229.50-C760863B48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_49_33562=[""].join("\n");
var outline_f32_49_33562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25744531\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25744271\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1168793\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2819310\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25744285\">",
"      SURGICAL CANDIDATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3791434\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3793143\">",
"      - Special considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H299273\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2819431\">",
"      CHOOSING A TYPE OF RETROPUBIC SLING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H297922\">",
"      PREOPERATIVE EVALUATION AND PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H298913\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H297972\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H297929\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H297936\">",
"      Thromboprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25744362\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2816425\">",
"      Operative setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H579368\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H299003\">",
"      Instrumentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H299019\">",
"      Sling placement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4700151\">",
"      - Patient preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4700179\">",
"      - Initial trocar insertion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4700435\">",
"      - Cystourethroscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2451122\">",
"      - Completing the trocar insertion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4700493\">",
"      - Adjusting sling tension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4700982\">",
"      - Closure of incisions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22194879\">",
"      Postoperative voiding trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25744489\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4701067\">",
"      Urinary tract complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4700528\">",
"      - Bladder injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4701082\">",
"      - Urethral injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4701170\">",
"      - Urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4701484\">",
"      - Voiding dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22194935\">",
"      Postoperative catheter management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4702658\">",
"      Sling release",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4701601\">",
"      - Urinary urgency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4701133\">",
"      - Other urinary tract complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4700557\">",
"      Vascular injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3907444\">",
"      Bowel injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3907598\">",
"      Vaginal mesh erosion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3907605\">",
"      Pelvic pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4701050\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H298266\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2816407\">",
"      Postoperative care and instructions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H298966\">",
"      Subsequent pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2819228\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25744531\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/14217\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/14217|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/0/31744\" title=\"figure 1\">",
"      Location of retropubic midurethral sling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/43/32432\" title=\"figure 2\">",
"      Location of transobturator midurethral sling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/42/16034\" title=\"figure 3\">",
"      Sling placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/26/23971\" title=\"figure 4\">",
"      Placement of retropubic midurethral sling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/14217|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?29/32/30208\" title=\"movie 1\">",
"      Midurethral retropubic sling",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=related_link\">",
"      Clinical presentation and diagnosis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31864?source=related_link\">",
"      Evaluation of chronic pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41770?source=related_link\">",
"      Evaluation of the adult with abdominal pain in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=related_link\">",
"      Nerve injury associated with pelvic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=related_link\">",
"      Overview of preoperative evaluation and preparation for gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/27/28083?source=related_link\">",
"      Patient information: Care after gynecologic surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/8/22658?source=related_link\">",
"      Patient information: Urinary incontinence (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/19/19764?source=related_link\">",
"      Patient information: Urinary incontinence treatments for women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1546?source=related_link\">",
"      Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40697?source=related_link\">",
"      Placement and management of urinary bladder catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=related_link\">",
"      Stress urinary incontinence in women: Choosing a primary surgical procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16055?source=related_link\">",
"      Stress urinary incontinence in women: Choosing a type of midurethral sling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44409?source=related_link\">",
"      Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/58/17319?source=related_link\">",
"      Stress urinary incontinence in women: Preoperative evaluation for a primary procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33401?source=related_link\">",
"      Stress urinary incontinence in women: Transobturator midurethral slings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28969?source=related_link\">",
"      Treatment of chronic pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=related_link\">",
"      Urogenital tract fistulas in women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_49_33563="Criteria CIP";
var content_f32_49_33563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F55570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F55570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for critical illness polyneuropathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Major features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Setting of critical illness, particularly if complicated by sepsis, multiorgan failure, and the systemic inflammatory response syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Difficulty weaning from ventilator that is not related to cardiopulmonary causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Possible limb weakness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrophysiologic evidence of axonal motor and sensory polyneuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Features favoring the diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sensory and motor nerve amplitudes &lt;80 percent of the lower limit of normal in two or more nerves on nerve conduction studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absence of conduction block or prolongation of F-waves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Needle EMG with reduced recruitment of normal motor unit potentials (MUPs) (early) followed by fibrillation potentials and reduced recruitment of long-duration, high-amplitude MUPs (after weeks)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absence of a decremental response on repetitive nerve stimulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Supportive features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal cerebrospinal fluid protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal serum creatine kinase",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Bolton, CF. Neuromuscular manifestations of critical illness. Muscle Nerve 2005;32:140.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_49_33563=[""].join("\n");
var outline_f32_49_33563=null;
var title_f32_49_33564="Repeat hepatic resection CRC";
var content_f32_49_33564=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Outcome after repeat hepatic resection for recurrent colorectal metastases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Reference, year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Overall survival",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median survival, months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fong Y; 1994",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        44 percent, 2 year",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nordlinger B;&nbsp;1994",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        33 percent, 3 year",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fernandez-Trigo V;&nbsp;1995",
"       </td>",
"       <td>",
"        170",
"       </td>",
"       <td>",
"        32 percent, 5 year",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adam R; 1997",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        41 percent, 5 year",
"       </td>",
"       <td>",
"        46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yamamoto J; 1999",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        31 percent, 5 year",
"       </td>",
"       <td>",
"        31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Petrowsky H; 2002",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        34 percent, 5 year",
"       </td>",
"       <td>",
"        37",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nagakura S; 2002",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        42 perent, 5 year",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tanaka K; 2004",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        48 percent*, 5 year",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pessaux P; 2006",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        55, 21, 36&bull; percent, 5 year",
"       </td>",
"       <td>",
"        41, 25, 16*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ishiguro S; 2006",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        41 percent, 5 year",
"       </td>",
"       <td>",
"        43 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cunha A; 2007",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        31 percent, 5 year",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jones N; 2012",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        34 percent, 2 year",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Adair RA; 2012",
"       </td>",
"       <td>",
"        &nbsp;195",
"       </td>",
"       <td>",
"        &nbsp;29 percent, 5 year",
"       </td>",
"       <td>",
"        NR&nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NR: not reported.",
"     <br>",
"      * Disease-free survival.",
"      <br>",
"       &bull; Five-year survival and median survival durations reported separately for three groups undergoing second (n = 42), third (n = 11), and fourth (n = 2) hepatectomies.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_49_33564=[""].join("\n");
var outline_f32_49_33564=null;
var title_f32_49_33565="Neurologic examination";
var content_f32_49_33565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F82393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F82393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Organization of the neurologic examination",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            A. Mental status",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1. Level of alertness",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            2. Language",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            a. Fluency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            b. Comprehension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            c. Repetition",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            d. Naming",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            e. Reading",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            f. Writing",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            3. Memory",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            a. Immediate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            b. Short-term",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            c. Long-term",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            i. Recent (including orientation to place and time)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            ii. Remote",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            4. Calculation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            5. Construction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            6. Abstraction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            B. Cranial nerves",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1. Olfaction (CN I)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            2. Vision (CN II)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            a. Visual fields",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            b. Visual acuity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            c. Funduscopic examination",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3. Pupillary light reflex (CNs II, III)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            4. Eye movements (CNs III, IV, VI)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            5. Facial sensation (CN V)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            6. Facial strength",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            a. Muscles of mastication (CN V)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            b. Muscles of facial expression (CN VII)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            7. Hearing and vestibular function (CN VIII)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            8. Palatal movement (CNs IX, X)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            9. Dysarthria (CNs IX, X, XII)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            10. Head rotation (CN XI)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            11. Shoulder elevation (CN XI)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            12. Tongue movements (CN XII)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            C. Motor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1. Gait",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2. Coordination",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3. Involuntary movements",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            4. Pronator drift",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            5. Individual muscles",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            a. Strength",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            b. Bulk",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            c. Tone (resistance to passive manipulation)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            D. Reflexes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1. Tendon reflexes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2. Plantar responses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3. Superficial reflexes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            4. \"Primitive\" reflexes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            E. Sensory",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1. Light touch",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2. Pain/temperature",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3. Joint position sense",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            4. Vibration",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            5. Double simultaneous stimulation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            6. Graphesthesia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            7. Stereognosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Gelb DJ. The Neurologic Examination. In: Introduction to Clinical Neurology. Woburn, MA, Butterworth-Heinemann 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_49_33565=[""].join("\n");
var outline_f32_49_33565=null;
var title_f32_49_33566="Normal kidney lengths age";
var content_f32_49_33566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Sonographic renal length plotted against age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 405px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Rosenbaum D, Korngold E, Littlewood Teele R. Sonographic assessment of renal length in children. Am J Roentgenol 1984; 142:467. Reprinted with permission from the American Journal of Roentgenology.&nbsp;Copyright &copy; 1984 American Roentgen Ray Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_49_33566=[""].join("\n");
var outline_f32_49_33566=null;
var title_f32_49_33567="Pathogenesis of VAP";
var content_f32_49_33567=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 588px\">",
"   <div class=\"ttl\">",
"    Pathogenesis of bacterial hospital-associated and ventilator-associated pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 568px; height: 436px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kollef MH. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit Care Med 2004; 32:1396. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_49_33567=[""].join("\n");
var outline_f32_49_33567=null;
